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The prevalence of Diabetes Mellitus Type 2, also known as non-insulin-
dependent diabetes or adult-onset diabetes, is rising alarmingly. In 1985 
approximately 30 million people worldwide suffered from diabetes. In 2007 
this number had escalated to 246 million and by 2030 it is expected that ~ 438 
million people (7.8% of the adult population) will be affected by diabetes1. At 
present, especially the developed world is coping with the diabetes epidemic, 
the prevalence in the US being 12.3% and in the Netherlands 7.7%, yet the 
developing countries are rapidly catching up1. It is estimated that, in the 
developing countries, the prevalence of diabetes will more than double in the 
years 2000-2030, compared to an increase of merely 50% in the western world2.
Diabetes is a major cause of mortality. According to the WHO, diabetes has 
reached the top 10 of death causes in middle and high income countries3. It is 
predicted that in 2010 almost 4 million deaths will be attributed to diabetes, 
which represents 6.8% of global all-cause mortality4. The mortality risk for 
individuals with diabetes is 2.3 times higher than the risk for people with 
normal glucose homeostasis5. Cardiovascular disease, which is a frequently 
encountered complication of diabetes, is the main reason for the elevated 
mortality risk. Compared to the general population, diabetic people younger 
than 45 years are 10 times more likely to display cardiovascular disease, 
ranging from relatively mild (hypertension and atherosclerosis) to severe 
(stroke and myocardial infarction)6. Approximately 16% of diabetic patients 
suffer from severe cardiovascular incidents leading to hospital admission; this 
risk is ~ 2.3 fold higher than for non-diabetic subjects7,8. In addition, the risk of 
mortality due to cardiovascular disease is 2.6 times higher in diabetic patients5.
Long term diabetes and poor glycemic control also lead to several other 
seriously disabling disorders. Diabetic nephropathy e.g. is one of the major 
causes of end-stage renal failure in the Western world9. Approximately 1.2% 
of diabetic patients develop renal failure, which represents a ~ 4 times higher 
risk than observed for people without diabetes7,8. Also, diabetes is the leading 
cause of new cases of blindness among adults aged 20-74 years10. The risk of 
developing any ophthalmologic complication, including cataract, glaucoma 
and diabetic retinopathy, is ~ 3 times elevated in diabetic versus nondiabetic 
individuals8. And, ~ 50% of diabetic patients develop neuropathy, which might 
manifest as sensory loss, muscle weakness, pain and/or erectile dysfunction10,11.
Aetiology
Type 2 diabetes originates from a complex interplay between genetic 
and environmental factors. The contribution of a genetic component in 






extremely high diabetes prevalence among certain population groups like 
the Pima Indians12,13. Likewise, the high concordance rate of diabetes among 
both monozygotic and dizygotic twins suggests a genetic component to the 
disease14,15. And first-degree relatives from diabetic patients display several 
defects in energy and nutrient metabolism16,17.
Some forms of type 2 diabetes, such as the different types of MODY (Maturity-
Onset Diabetes of the Young), are of monogenic origin, meaning that one gene 
is responsible for the disease18. These forms of diabetes are characterized by a 
single gene mutation, an autosomal dominant inheritance pattern and an early 
onset of the disease. These cases however, represent only about 1-5% of all 
type 2 diabetes cases18. The majority of type 2 diabetes is of polygenic origin, 
meaning that several susceptibility genes additively increase the risk of disease 
onset. The contribution of single susceptibility genes to the diabetes risk is 
generally small; with odds ratios between 1.10 and 1.30. However, if several 
susceptibility loci are present, the risk of developing diabetes may increase 
substantially, as was shown for a Japanese population in which the risk of 
developing diabetes increased ~ 3.7 fold in the presence of a combination of 
7 specific susceptibility loci19. Association studies in large population cohorts 
revealed several susceptibility genes, including PPARγ, TCF7L2, KCNJ11, 
CDKAL1, CDKN2A/CDKN2B, IGF2BP2, SLC30A8 and HHEX19-21.
The contribution of the genetic predisposition is believed to remain stable 
throughout time; therefore it can not explain the recent rapid increase in 
diabetes incidence. Rather, this has been triggered by advances in health care 
and lifestyle changes. The prevalence of obesity, which is a major risk factor for 
diabetes development, has increased considerably the last decennia. In the US, 
the prevalence of adult obesity rose from 13.4% in 1960 to 30.9% in 200022 and 
the number of overweight children aged 6-11 and 12-19 increased from 4% 
and 6% in 1971 to 15.3% and 15.5% respectively in 200023. The rise in diabetes 
incidence may greatly be accounted for by the recent rise in number of obese 
subjects. An objective measure to describe obesity is the body mass index (BMI), 
which is calculated as weight (in kilogram) divided by the square of the height 
(in meters); a BMI of < 18.5 represents underweight, 18.5-25 normal weight, 
25-30 overweight, 30-35 obesity and > 35 morbid obesity. The lifetime risk for 
developing diabetes rises dramatically with increasing BMI. For an 18-year old 
person with normal weight, the risk of developing diabetes was calculated to 
be ~ 18.5%, if this person was morbidly obese though, the risk would increase 
to ~ 72%24. The predisposition of obesity to turn into diabetes is also reflected 
by the observation that in the US ~ 55% of type 2 diabetic patients is obese25.
The change from an active to a sedentary lifestyle, promoted by the 
industrialization, the availability of easy transportation and the introduction of 
computers, television and video games, also independently adds to the elevated 
diabetes prevalence. A prospective cohort study in the US showed that with 
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every additional 2 hours of TV watching daily, the risk of diabetes increases 
with 14% and for every 2 hours/day increase in sitting at work, the risk for 
diabetes rises with 7%26. On the opposite, the impact of physical activity on 
reducing the risk of diabetes development has also firmly been established27-31. 
It is calculated that each 500 kcal increment in energy expenditure per week 
leads a 6% decrease in diabetes risk27. Even in people with impaired glucose 
tolerance, representing a pre-diabetes stage, physical activity is beneficial and 
reduces the risk of overt diabetes with 46%32. Clinical trials in patients with 
overt diabetes also indicate that physical activity, without weight loss, is able to 
improve the diabetic phenotype33-35.
Also, the altered dietary pattern participates in the increased incidence of 
diabetes. With the introduction of highly palatable, energy-dense, food, total 
caloric intake increased and the dietary preferences shifted away from the 
traditionally “healthy” diet, including vegetables, fruits, low-fat dairy products 
and whole grain products, towards the “western type” diet, comprised of red 
and/or processed meat, high fat diary products, refined grain products, fried 
products and sweet beverages. Analyses of the health risk/benefit of both types 
of diets indicated that consumption of the “western type” diet is associated 
with a 28-60% higher risk of developing diabetes, while the “healthy” diet is 
associated with a modestly protective effect of 11-27%36-39.
Finally, improved health care, which dramatically increased life expectancy 
the past decades, accounts for part of the elevated diabetes incidence. Aging is 
associated with an increased prevalence of diabetes; in the US, in the period of 
2005-2006, the prevalence of previously diagnosed diabetes was 2.1% in the 
age group 20-39, 7.9% in the age group 40-59 and 17.6% in the age group 60-
7440. Therefore increased longevity will greatly enlarge the number of diabetes 
patients. It is still a matter of debate whether the increased diabetes risk for 
elderly people is the result of aging per se or the result of age-related alterations 
in lifestyle and body composition. Unhealthy diets, decreased physical activity, 
increased adiposity and an altered fat distribution are all phenomena associated 
with aging and independent risk-factors for the development of diabetes. 
Accordingly, several studies showed an age-related deterioration of insulin 
action, yet in some, the reported differences between young and old individuals 




Plasma glucose levels are maintained within a narrow range of 4-7 mmol/l. 
If glucose levels fall below the threshold of 3 mmol/l, energy supply to the 






glucose for energy and is only equipped with glycogen stores sufficient for a 
few minutes. Therefore, hypoglycemia rapidly leads to functional brain failure, 
seizures and coma. If the hypoglycemia is severe and prolonged it might even 
lead to brain death46. Conversely, elevated glucose levels can damage organs 
leading to macrovascular disease, nephropathy, retinopathy and neuropathy47.
Insulin and glucagon are the key hormones regulating glucose homeostasis. 
Insulin is secreted by pancreatic β-cells in response to a physiological rise in 
glucose levels, e.g. after a meal. The net effect of insulin is to reduce the elevated 
glucose levels by promoting glucose uptake and simultaneously inhibiting 
glucose production. The liver is the main site responsible for the production of 
glucose. It can either convert stored glycogen into glucose or synthesize glucose 
de novo from non-carbohydrate substrates including lactate and amino acids. 
In insulin sensitive tissues like muscle, adipose tissue and also liver, glucose can 
be taken up and subsequently converted into glycerol for storage or oxidized to 
supply energy.
Glucagon is secreted by pancreatic α-cells in response to a reduction in 
blood glucose concentrations, e.g. during fasting. Opposing the action of insulin, 
glucagon increases glucose levels. It promotes the production of glucose by the 
liver, leading to an induction in both the conversion from glycogen to glucose 
and de novo glucose synthesis. Concomitantly glucagon inhibits the synthesis 
of glycogen and the oxidation of glucose in the liver48. During conditions of 
hyperglycemia glucagon production is suppressed by the combined action of 
the elevated glucose levels and the concomitantly raised insulin levels49. Other 
physiological regulators of glucose homeostasis include glucose, which can 
regulate its own disposal and release, catecholamines, cortisol and growth 
hormone.
Pathophysiology
Hyperglycemia is an important hallmark of diabetes and is the direct corollary 
of dysregulation of insulin and glucagon action. Impaired insulin action involves 
both insulin resistance, a reduced ability of tissues to respond to insulin, and 
defects in insulin secretion. In the early development of insulin resistance 
the diminished efficacy of the hormone is overcome by elevated insulin 
production by pancreatic β-cells; hyperinsulinemia therefore is a marker 
for diabetes development. Eventually, β-cells are no longer able to produce 
sufficient amounts of insulin to compensate for the resistance. Consequently, 
the biological function of insulin is undermined and hyperglycemia becomes 
manifest.
Insulin resistance can be demonstrated as a reduction in whole body glucose 
uptake and diminished suppression of glucose production during conditions of 
hyperinsulinemia. Several organ-specific mechanisms are thought to underlie 
the impaired insulin sensitivity.
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Together, muscle, adipose tissue and liver are responsible for glucose 
disposal in response to insulin. As muscle tissue is the major contributor, 
insulin resistance of this tissue will greatly impair the ability of the body to 
remove glucose from the circulation. In response to insulin, GLUT4, the insulin-
responsive transporter mediating the diffusion of glucose across the cell 
membrane, is translocated to the cell membrane. Once glucose has entered the 
cell, it is rapidly phosphorylated in order to maintain a concentration gradient 
for glucose across the cell membrane. In muscle cells from diabetic patients 
both the insulin induced transport of glucose across the cell membrane and 
the subsequent phosphorylation of intracellular glucose are diminished50-52. 
Several alterations in the intracellular signaling pathways downstream of the 
insulin receptor have already been described53-55. Together these might lead to a 
diminished recruitment of GLUT4 from intracellular storage vesicles to the cell 
membrane giving rise to the reduced glucose uptake51. 
Also in adipose tissue from diabetic individuals several defects have been 
noted. Diminished binding of insulin to its receptor in combination with 
a reduced receptor kinase activity greatly impairs the insulin action on 
adipocytes56,57. Concomitantly, both the basal expression of GLUT4 transporters 
on the cell membrane and the insulin stimulated translocation of GLUT4 to 
the surface is decreased in adipocytes from diabetic patients57,58. These latter 
observations might be ascribed to an enhanced turnover of glucose transporters 
and/or a diminished transporter gene expression57,58. 
Glucose uptake by the liver is mainly relevant after a meal, when both 
plasma glucose and insulin concentrations are elevated59. In diabetic patients, 
the capacity of the liver to extract glucose from the circulation under these 
postprandial conditions is compromised60,61 as well as its ability to synthesize 
glycerol62. In contrast to muscle, where glucose transport across the plasma 
membrane is the rate-limiting step for glucose uptake, in liver, phosphorylation 
of glucose, by the enzyme glucokinase, is rate-limiting. Therefore, decreased 
activity of this enzyme, found in diabetic subjects63,64, might be responsible for 
the reduced glucose uptake.
Concomitantly, the role of the liver as main producer of glucose is 
affected. Total, as well as directly measured hepatic, glucose production is 
higher in diabetic patients, both during basal, fasting, conditions60,65-67 and 
hyperinsulinemic, fed, conditions67,68. The direct corollary is fasting and 
postprandial hyperglycemia. The contribution of increased gluconeogenesis to 
the elevated glucose production in diabetic subjects has firmly been established, 
but the contribution of glycogenolysis is still a matter of debate65,66,68. An 
increased ratio of the activity of the enzyme glucose-6-phosphatase to 







Another contributory factor to the pathophysiology of hyperglycemia is 
an elevation in glucagon levels. In type 2 diabetic patients the postprandial 
suppression of glucagon production is impaired69,70 leading to hyperglucagonemia 
and, regarding the nutritional status, an inappropriate stimulation of glucose 
production by the liver71. Possibly, resistance of pancreatic α-cells to the 
inhibitory action of insulin underlies this phenomenon.
Defective insulin secretion, which is, in addition to insulin resistance, an 
obligatory step in the development of type 2 diabetes, is the result of both 
a decrease in β-cell mass and β-cell malfunction. The reduced β-cell mass 
observed in type 2 diabetic patients is presumably the net effect an accelerated 
apoptosis rate in combination with normal β-cell replication and neogenesis72,73. 
Physiological signs of insulin secretion defects include an absence of the first 
phase insulin response74,75, alterations in the pulsatility of insulin secretion76,77 
and an increased proinsulin to insulin ratio78,79. Intracellular defects underlying 
this β-cell malfunction include a reduction in the expression of glucose 
transporters GLUT1 and 2, impaired intracellular glucose processing75 and 
a loss of insulin gene expression80. Damage and death of β-cells may be the 
consequence of hyperglycemia per se, as stated by the glucotoxicity theory. 
Accordingly, it was shown that prolonged hyperglycemia, either in combination 
with high circulating FFA levels or alone, promotes apoptosis and alterations in 
key components of cellular functioning through long-term increases in cellular 
Ca2+ concentrations81 and oxidative stress80. Alternatively, or additionally, 
hyperglycemia may induce defects indirectly by promoting hypersecretion of 
insulin, leading to β-cell exhaustion82. 
Diabetic rodent models
Currently, several different rodent models have been established for diabetes 
research. Although most of these animal models fail to develop overt 
hyperglycemia and diabetes related complications, they do develop a diabetes-
like phenotype characterized by obesity and insulin resistance. Some of these 
rodents models are genetic models; the result of single gene alterations. Three 
frequently used genetic models for diabetes research are the obese Zucker 
rat, the ob/ob mouse and the db/db mouse, all of which are characterized 
by mutations in genes involved in leptin signaling. The hormone leptin, 
predominantly synthesized by adipose tissue, serves as a regulator of long-
term energy balance. Leptin is secreted in proportion to the amount of body fat 
and is therefore able to convey information about peripheral energy reserves. 
The long isoform of the leptin receptor is expressed in several regions of the 
brain, including the hypothalamus, and transmits the ‘anti-obesity’ action of 
leptin on food intake and energy expenditure83. In obese Zucker rats and db/
db mice, respectively, a mutation in, and a deletion of, the leptin receptor were 
General Introduction 15
found84,85, whereas in ob/ob mice a mutation in the leptin gene was discovered86. 
Resistance to the physiological action of leptin, as well as the absence of leptin, 
leads to the development of a diabetogenic phenotype, including hyperphagia, 
reduced energy expenditure, obesity and insulin resistance87-90. 
Another genetic rodent model is the OLETF rat. These rats, presenting 
several of the characteristic features of diabetes, are naturally occurring CCK-
1 receptor knockouts91,92. Cholecystokinin (CCK) is a peptide released from 
the gastrointestinal tract in response to food intake. CCK action is mediated 
by 2 distinct receptors which are both expressed in the periphery as well as 
in the brain. CCK regulates digestive function and promotes satiety. The CCK-1 
receptor is responsible for the latter function93.
Although the animal models described above, displaying spontaneous 
mutations in essential metabolic pathways, have provided us with important 
information concerning energy and nutrient balance, they only represent a 
small portion of the heterogeneous human diabetes population, since only a 
small percentage of diabetes cases are the result of single gene mutations. Diet 
induced obese (DIO) rodents better reflect the complex physiological alterations 
underlying the disease in the majority of obese type 2 diabetic patients. Several 
wild type (wt) rodents, such as the C57BL/6J mice, develop a diabetic phenotype 
after being fed a high fat diet for several weeks94,95. This DIO animal model is often 
used in diabetes research, yet, it is still a heterogeneous group; on average, DIO 
rodents develop a diabetic phenotype, but, there are large differences in the 
adaptation of individual animals to high fat feeding. It was shown that, after 
being maintained on a high fat diet for 9 months, 45% of a group of C57Bl6 
mice became obese and diabetic, 12% remained lean and non diabetic, 12% was 
lean and diabetic and 30% showed an intermediate phenotype96. The insulin 
resistance phenotype of lean diabetic mice resembled more the phenotype of 
lean non-diabetic mice than of obese diabetic mice, so, simplified, the C57Bl6 
mice could be divided into a diet induced obese (DIO), a lean diet resistant (DR) 
and an intermediate group. For experimental purposes wt rodents, while still 
maintained on a chow diet, can be divided into DIO and DR groups according 
to the amount of norepinephrine they excrete97. Alternatively, wt rodents can 
be classified according to their weight gain following several weeks of high fat 
feeding; the rodents with the highest weight gain are designated DIO and those 
with the least weight gain, DR98. 
Considering the heterogeneous response of humans towards the diabetogenic 
western type diets, we believe the DIO/DR rodent model accurately represents 
the human situation and is therefore best suited for analyzing the complex 








Dopamine is the predominant catecholamine neurotransmitter in the 
mammalian central nervous system. It is synthesized in dopamine neurons 
and stored in synaptic vesicles until release. Tyrosine hydroxylase (TH) is the 
rate-limiting enzyme in the conversion of tyrosine into dopamine. Activation 
of dopamine neurons promotes fusion of the synaptic vesicles with the 
neuronal membrane, and dopamine is secreted. Upon release, dopamine binds 
to its receptor, located either on pre- or postsynaptic neurons, and initiates an 
intracellular signaling cascade. Dopamine transporters (DAT) take up dopamine 
from the extracellular fluid, thereby rapidly limiting the activity of secreted 
dopamine. Back in the neuron, dopamine is either transported into synaptic 
vesicles by a vesicular monoamine transporter (VMAT2) to be re-used or it is 
metabolized by monoamine oxidase (MAO) or catechol-O-methyltransferase 
(COMT)99,100.
Dopamine neurons are present in distinct areas of the brain, giving rise 
to three main dopaminergic pathways. The nigrostriatal pathway contains 
dopamine neurons originating in the substantia nigra and projecting to the 
dorsal striatum. Dopaminergic signaling in this pathway controls locomotor 
activity. The mesocorticolimbic pathway consists of dopamine neurons 
projecting from the ventral tegmental area to the ventral striatum, the limbic 
system and the cortex and is involved in emotion, cognition, motivation and 
reward. The dopamine neurons comprising the tuberoinfundibular pathway 
originate in the hypothalamus and project to the pituitary where they control 
hormone secretion and cell survival101,102.
In addition to their role in the tuberoinfundibular pathway, dopamine 
neurons located in the hypothalamus control ingestive behavior. These neurons 
receive signals concerning energy homeostasis and nutrient availability from 
the periphery through afferent nerves, circulating hormones, nutrients and 
small peptide mediators. They integrate the information and relay it to the 
classical food intake-related neurons including NPY/ AGRP producing neurons 
(stimulators of food intake) and POMC producing neurons (inhibitors of food 
intake) to direct energy intake103.
Dopamine receptors
Dopamine action is mediated by 5 distinct receptors which are categorized 
into 2 receptor families based on sequence homology and pharmacological 
characteristics. The D1-like family consists of the dopamine receptors D1 
(DRD1) and D5. Activation of these receptors leads to stimulation of adenylyl 
cyclase and the subsequent production of cyclic AMP. Activation of the D2-like 
family on the contrary, inhibits adenylyl cyclase activity and the concomitant 
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production of cyclic AMP. The receptors DRD2, DRD3 and DRD4 represent the 
D2-like family101. Apart from different functional characteristics, the dopamine 
receptors also differ in spatial expression patterns. DRD1 and DRD2 are the 
most widely expressed receptors; they are found in all brain areas receiving 
dopaminergic innervation. The other dopamine receptors display more 
restricted expression patterns101,102. Although dopamine D1 and D2 receptors 
are present in the same brain areas, they are only occasionally expressed on the 
same neurons101.
Dopamine receptors belonging to the DRD2 family exist both as pre- and 
postsynaptic receptors. Presynaptic receptors, or autoreceptors, which are 
believed to be mainly DRD2 and DRD3, are part of a dopaminergic feedback 
mechanism regulating neuronal activity and neurotransmitter release. 
Accordingly, stimulation of autoreceptors can alter firing rate of the neuron, 
dopamine synthesis and secretion. Postsynaptic receptors, which can be 
either DRD2, DRD3 or DRD4, modulate the action of second order neurons in 
response to dopamine100,101.
Peripheral dopaminergic system
Dopamine receptors are highly expressed in the central nervous system, yet 
they are also present in several peripheral tissues, orchestrating a variety of 
biological functions. In the cardiovascular system, dopamine receptors are 
involved in the regulation of blood pressure. In the heart, up till now, D1, D2 
and D4 dopamine receptors have been described. The role of the individual 
receptors has not yet been defined, but overall, a low concentration of 
dopamine is associated with an increased cardiac output due to improved 
contractility of the heart104-106. All dopamine receptors are expressed in the 
systemic blood vessels where they control vascular resistance by regulating 
vasodilatation107-109.
In the kidney, dopamine, in general, increases renal blood flow and the 
excretion of water and ions such as sodium and calcium. The participation of the 
individual dopamine receptors in this effect is complex and varies depending 
on several factors such as systemic water and sodium balance109,110. Dopamine 
receptors D1, D2, D4 and D5 are also present in the adrenal glands111,112. The D2-
like receptors are known to control aldosterone production, but the function of 
the D1-like receptors hasn’t been clarified yet112-114.
All dopaminergic receptors are expressed in the gastrointestinal tract. The 
dopamine D2 receptor is involved in the inhibition of gastric acid production115 
and gastrointestinal motility116,117. The role of the other dopaminergic receptors 
remains unclear.
Furthermore, all dopamine receptors, except DRD1, are expressed on 
peripheral blood leukocytes118,119. The action of dopamine on immune cells has 






activating resting lymphocytes and inhibiting activated ones120,121.
Recently dopamine receptors were also discovered on pancreatic β-cells. 
The dopamine D2 receptor is clearly involved in the modulation of insulin 
secretion, but the role of the other receptors remains to be elucidated122.
DRD2 and diabetes
DRD2 polymorphisms
Several lines of evidence link the dopaminergic system to obesity, insulin 
resistance and type 2 diabetes in humans and animal models. An important 
indication for a functional relationship between dopamine and metabolic 
disturbances came from epidemiological studies. Several groups have examined 
the association of DRD2 polymorphisms and energy and nutrient metabolism. 
Although in general the impact is small, there is an interaction between DRD2 
variants and energy homeostasis. The polymorphism Ser311Cys, which 
impairs the DRD2 signal transduction pathway123, is associated with a higher 
BMI and lower resting energy expenditure in Pima Indians124,125. The TaqIA1 
allele, resulting in lower DRD2 binding126, is associated with obesity127,128. And, 
a haplotype consisting of 2 SNP’s located in intron 5 and exon 6 of the DRD2 
gene is associated with obesity as well129. Recently, proof for a role of DRD2 in 
the regulation of glucose and insulin metabolism was provided by Guigas et al. 
who showed that, in humans, the rate of glucose stimulated insulin secretion is 
associated with a 4-SNP haplotype (including TaqIA1 SNP) of the DRD2 gene130.
DRD2 neurotransmission
More evidence came from the analysis of the dopaminergic system in obese and 
diabetic animals and humans. The expression of DRD2 is reduced in specific 
brain areas of obese Zucker and OLETF rats compared to lean control rats131-
133. This decreased DRD2 expression is also observed in the striatum of obese 
humans. Moreover, in these individuals the number of DRD2 binding sites is 
inversely related to the body mass index134. Additionally, basal dopamine levels 
are increased in the hypothalamus of obese diabetic rats and the dopamine 
release in response to food intake is exaggerated and longerlasting135-138. A 
higher dopamine concentration was also measured in post mortem brains 
of diabetic patients compared to controls139. The reduction in dopaminergic 
neurotransmission elicited by a decreased DRD2 expression is thought to 
induce a “reward deficiency syndrome”, which might be compensated by 
elevated dopamine release and additionally, or alternatively, by “reward seeking 
behavior”, such as increased food intake140.
DRD2 antagonists
Another indication that dopamine D2 receptors might be involved in energy 
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and nutrient metabolism came from the clinical observation that the use of 
antipsychotic medication is associated with obesity, insulin resistance and 
diabetes. Although numerous different antipsychotic drugs are used in clinic, 
the common denominator of these drugs is their affinity for dopamine D2 
receptors. In general, the newer, second-generation ‘atypical’ antipsychotics 
have a broader range of action and a slightly lower affinity for the D2 receptor 
compared to first-generation ‘typical’ antipsychotics, but they are still (at least 
partial) DRD2 antagonists. In fact, it has been suggested that the clinical efficacy 
of these drugs to alleviate psychotic symptoms depends on the interaction of 
the drugs with dopamine D2 receptors141.
Most antipsychotic drugs induce some degree of weight gain, yet the atypical, 
second generation, drugs clozapine and olanzapine are associated with the most 
severe increase in body weight142-144; in a meta-analysis it was calculated that 
both drugs can induce weight gain of up to 4.5 kg in 10 weeks in schizophrenic 
patients142. Other antipsychotic drugs, such as the typical drug haloperidol, 
induce much less weight gain142,144.
The use of antipsychotic drugs is also linked to the development of 
diabetes143,145. Again, treatment with clozapine or olanzapine is associated 
with the greatest risk of developing diabetes145. One study even showed 
that, in a health care center, 36.6% of patients on clozapine treatment were 
newly diagnosed with diabetes within 5 years after the start of treatment146. 
Although the metabolic side effects of antipsychotic drugs have been observed 
in schizophrenic patients and schizophrenia itself contributes to the increased 
risk of developing diabetes147,148, it is generally accepted that antipsychotics can 
directly affect energy and nutrient metabolism. This is confirmed by studies in 
animal models and healthy humans.
As in schizophrenic patients, weight gain is consistently observed in healthy 
volunteers treated with the antipsychotics olanzapine and risperidone149-153. 
The impact of antipsychotic drugs on glucose metabolism in healthy individuals 
though, is less clear; some studies report a reduction in insulin sensitivity 
following drug treatment149,151,152, whereas others fail to observe an effect 
on insulin sensitivity150,153. In rodents the ability of antipsychotics to induce 
weight gain seems to be gender specific; female rats are sensitive to the weight 
inducing effect of the drugs, whereas in most studies using male rodents, body 
weight is not affected, or even decreased, by drug treatment154-158. The impact of 
antipsychotics on glucose metabolism, however, is consistent in animals. Both 
chronic and acute antipsychotic drug treatment is highly associated with the 
development of glucose intolerance and insulin resistance156,159-164.
Alterations in several pathways might underlie these antipsychotic induced 
metabolic abnormalities. In most animal experiments, antipsychotics induce 
a defect in insulin stimulated glucose uptake during hyperinsulinemia161-164. 






uptake in neuronal cells165. The inability of tissues to appropriately respond to 
insulin stimulation might depend on an antipsychotic induced defect in insulin 
signaling, as is described in muscle cells after incubation with olanzapine166.
In addition, an abnormally high endogenous glucose production during 
hyperinsulinemia is found in several animal models on antipsychotic drug 
treatment159,161,164. The underlying mechanism might be the inability of the liver 
to respond to the inhibitory action of insulin and/or the ability of antipsychotic 
drugs to acutely stimulate the endogenous glucose production, as is shown in 
rats160.
A defect in insulin release might further add up to the metabolic alterations 
induced by antipsychotics. Several studies have reported an antipsychotic drug 
induced reduction in insulin response during hyperglycemia162,163. Accordingly, 
it was found that antipsychotic drugs can directly affect insulin release from 
isolated pancreatic islets167-169.
DRD2 agonists
Considering the impact of the dopaminergic system on energy and nutrient 
metabolism, several groups have examined the efficacy of DRD2 agonists in 
ameliorating the adverse metabolic conditions associated with diabetes. The 
best studied DRD2 agonist in relation to obesity and diabetes is bromocriptine, 
clinically used in the treatment of Parkinson’s disease and hyperprolactinemia. 
In humans, several trials have been performed with this DRD2 agonist. The most 
consistent impact of such treatment in obese individuals is normalization of 
elevated plasma glucose levels170-173. In addition, in several studies, bromocriptine 
treatment diminished basal plasma insulin levels in obese individuals170,173. 
The impact of bromocriptine on body weight though, is inconsistent among 
studies; in some the body weight and fat percentage of subjects decreased 
upon treatment174, while in others body weight remained stable throughout 
the experiment171-173. The impact of bromocriptine on glucose metabolism is 
more consistent; it improves glucose tolerance and insulin sensitivity in obese 
people172,174.
In most animal studies bromocriptine was given in combination with 
the DRD1 agonist SKF38393, as this latter drug enhances the efficacy of 
bromocriptine175,176. Unlike in humans, treatment of obese diabetic animal 
models with the combination of bromocriptine and SKF38393 consistently 
decreases food intake, fat mass and overall body weight175,177-180. Surprisingly, 
the decrease in food intake was only moderately involved in body weight 
reduction, as pair feeding was only able to partly reproduce this effect179,180. 
The impact of enhanced DRD2 stimulation on food intake and body weight 
has also been confirmed with quinpirole, another DRD2 agonistic drug176. 
Furthermore, like in humans, bromocriptine/SKF38393 treatment normalizes 
elevated plasma glucose and insulin levels in obese diabetic animals175,177-180. 
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The underlying mechanism(s) for this improvement is not yet fully elucidated, 
but bromocriptine/SKF38393 treatment reduces the activity of 2 key enzymes 
involved in hepatic gluconeogenesis in obese insulin resistant mice179 and 
glucose production is diminished in bromocriptine treated hamsters181. 
Also, bromocriptine improves glucose tolerance and insulin sensitivity177,182. 
This might be mediated by a restoration of the aberrant β-cell function by 
bromocriptine/SKF38393, resulting in a reduction of the elevated basal insulin 
release, an increase in insulin content and an improved glucose-stimulated 
insulin release178,183,184. 
Injection of bromocriptine directly into the brain of diabetic hamsters, in 
a concentration that does not have an effect when administered systemically, 
also diminishes body weight and improves glucose tolerance and insulin 
sensitivity185; suggesting that (part of) the observed effects of DRD2 stimulation 
on metabolism are mediated by dopamine receptors in the brain.
Outline of this thesis
The dopaminergic system in general and the dopamine receptor D2 specifically 
are functionally linked to diabetes-associated metabolic derangements. Genetic 
variations in the DRD2 gene are associated with altered energy and nutrient 
homeostasis. Inhibition of DRD2 promotes a diabetes-like phenotype, while 
activation of DRD2 restores a normal metabolic profile. Also several components 
of dopaminergic signaling are modified in obese and diabetic humans and 
animals. Despite the established interaction between DRD2 and disturbances 
in the energy and nutrient homeostasis, several questions regarding the exact 
role of DRD2 in the aetiology of diabetes and the mechanism underlying the 
metabolic corollary of DRD2 transmission modulation remain unanswered. 
The research described in this thesis is conducted in order to unravel the 
characteristics of the interplay between the DRD2 and glucose metabolism as 
well as to understand the underlying mechanism(s).
The aim of chapter 2 was to determine the role of the dopaminergic system in 
the aetiology of high fat diet induced obesity and insulin resistance. Therefore, 
glucose metabolism and several indicators of dopaminergic neurotransmission 
were evaluated after 4 weeks of high fat feeding in wt mice and compared to 
mice maintained on a low fat diet.
Calorie restriction is the most effective way to extend lifespan and reduce 
morbidity. As such, it also improves insulin sensitivity and delays the age-
related loss of DRD2 expression in the brain. Considering this, together with 
the role of the dopaminergic system in glucose metabolism, it can be suggested 
that the dopaminergic system is involved in the beneficial impact of calorie 
restriction on insulin action. This hypothesis was addressed in chapter 3. Wt 






access, for 12 weeks. During the entire experiment half of the calorie restricted 
mice also received continuous haloperidol treatment. After the treatment 
period glucose metabolism was evaluated and the hypothalamic DRD2 binding 
was determined. 
In general, high fat feeding induces obesity, insulin resistance and a type 2 
diabetic phenotype in rodents, but there is a large diversity in response within 
single strains of rodents. Based on weight gain, the phenotype of rodents on 
a high fat diet can be characterized as diet induced obese (DIO), intermediate 
or diet resistant (DR). DIO and DR rodents differ in several components of 
the dopaminergic system, even before the onset of obesity. This led to the 
suggestion that variation in dopaminergic neurotransmission participates in 
the development of the divergent DIO and DR phenotypes. Therefore, in chapter 
4 we maintained wt mice on a high fat diet for 10 weeks to classify them as DIO 
and DR. Subsequently we treated DIO and DR mice with, respectively, the DRD2 
agonist bromocriptine and the DRD2 antagonist haloperidol and performed 
indirect calorimetric measurements and characterized glucose metabolism. 
Placebo treated DIO and DR mice served as controls.
Antipsychotic drugs are associated with the development of insulin resistance 
and dyslipidemia. It is, however, still unclear if these drugs directly modify 
glucose and lipid metabolism or if they promote weight gain which may lead to 
the disturbed metabolic profile. Therefore, in chapter 5, the short-term impact 
of the typical antipsychotic drug haloperidol and the atypical drug olanzapine 
were studied in order to unravel the mechanism underlying the deregulation of 
nutrient metabolism. The carbohydrate and lipid metabolism of healthy men 
was evaluated before and after 8 days of antipsychotic drug treatment. 
The DRD2 agonistic drug bromocriptine is highly effective in improving 
glucose metabolism and β-cell function, yet, the underlying mechanism remains 
unclear. In chapter 6 we studied the acute impact of bromocriptine on insulin 
secretion and action in wt mice and the impact on intracellular signaling in INS-
1E cells.
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Obesity is associated with diminished dopaminergic neurotransmission. It 
remains unclear whether this is a cause or a consequence of the obese state. 
We hypothesized that high fat feeding, a well-known trigger of obesity in diet 
sensitive mice, would blunt dopaminergic neurotransmission prior to the 
development of insulin resistance.
We monitored in vivo dopamine release in the dorsomedial region of the 
hypothalamus and determined hypothalamic gene expression patterns of 
dopamine receptors 1 and 2 (DRD1 and 2), tyrosine hydroxylase (TH) and the 
dopamine transporter (DAT) in C57Bl6 mice maintained on a high fat diet for 4 
weeks. Also, a hyperinsulinemic euglycemic clamp was performed to evaluate 
the metabolic status of the mice. Mice maintained on a low fat diet served as 
controls.
The high fat diet did not alter dopamine release in the dorsomedial 
hypothalamus of fed or fasted mice or the dopaminergic response to refeeding. 
Furthermore, gene expression levels of DRD1, DRD2, TH and DAT were not 
affected by high fat feeding. However, the high fat diet did hamper insulin 
action as evidenced by diminished glucose disposal during hyperinsulinemia 
(p<0.05).
We show here that short term high fat feeding does not affect dopaminergic 
neurotransmission in the hypothalamus, whereas it does impair insulin 
action. This suggests that reduced dopaminergic neurotransmission in the 
hypothalamus of obese animal models is due to mechanism(s) that are not 







Dopamine is intimately involved in the regulation of energy balance. Genetically 
engineered dopamine-deficient mice fail to initiate feeding and consequently 
die of starvation, unless L-DOPA, the precursor of dopamine, is provided 
daily1. Conversely, dopamine release in response to food intake induces satiety 
and reward2. Thus, dopamine plays an important dual role in the complex 
physiology driving meal initiation and termination. Moreover, dopaminergic 
neurotransmission profoundly affects glucose and lipid metabolism3.
Dopamine action is mediated by at least 5 distinct G-protein coupled receptor 
subtypes, which are functionally classified into 2 receptor families. Dopamine 
receptor D1 (DRD1) and DRD5 activate adenylyl cyclase in target neurons and 
belong to the D1-like family. The others (DRD2, DRD3 and DRD4) are D2-like 
receptors, which inhibit adenylyl cyclase4.
Drugs that block DRD2 enhance appetite and induce weight gain in animals 
and humans5-8. Conversely, DRD2 agonist drugs reduce body weight, increase 
energy expenditure and improve glycemic control in obese animals and 
individuals9-12. DRD1 agonistic drugs reduce food intake, body weight and 
plasma glucose levels in obese mice10,13. Thus, dopamine impacts on energy 
balance through activation of both DRD1 and DRD2 receptors.
The hypothalamus plays a critical role in the control of food intake 
and metabolism14. Compelling evidence indicates that dopaminergic 
neurotransmission is altered in the hypothalamus of obese animals. Basal and 
feeding evoked dopamine release is exaggerated and longer-lasting in several 
nuclei of the hypothalamus of obese Zucker rats15-17, whereas DRD2 expression 
is reduced in hypothalamic nuclei of obese animal models18,19. Lack of DRD2 
may induce a so called “reward deficiency syndrome”, eliciting exaggerated 
dopamine release in response to large meals to induce reward in the face of 
diminished signal transduction20. The number of DRD2 binding sites is reduced 
in the striatum of obese humans and inversely correlated with body mass 
index21. This supports the view that reward deficiency may be involved in the 
pathogenesis of human obesity.
Dopaminergic neurotransmission has particularly been studied in chronically 
obese animals and humans. Therefore, it remains unclear whether the observed 
changes are a cause or a consequence of the obese state. However, activation 
of DRD2 receptors redresses various pathologic features of obesity12,18, which 
suggests that down regulation of DRD2 may be a primary characteristic. 
Therefore, we hypothesized that high fat (HF) feeding, a well known inducer 
of obesity and insulin resistance in C57Bl6 mice, would reduce DRD2 receptor 
expression and, via the mechanism of reward deficiency, enhance food intake 
and associated dopamine release in the hypothalamus of these mice. To test 
our hypothesis, we monitored in vivo dopamine release in animals maintained 
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on a HF diet for 4 weeks. In addition, we measured gene expression levels 
of the DRD1 and DRD2, tyrosine hydroxylase (TH), the enzyme catalyzing 
the rate-limiting step in dopamine synthesis and the dopamine transporter 
(DAT), which is responsible for presynaptic re-uptake of dopamine. Finally, a 
hyperinsulinemic euglycemic clamp was performed to evaluate the metabolic 
status of the animals. All these parameters were compared to those obtained in 
animals receiving a low fat (LF) control diet.
A relatively short intervention period of 4 weeks was chosen to run ahead of 
overt obesity and/or insulin resistance, as these metabolic features may impact 
on dopaminergic neurotransmission by themselves. Since the hypothalamus 
is a critical player in the control of energy balance and fuel metabolism14, we 
decided to focus on this particular brain area in the current study.
Materials and Methods
Animals
Male 12-week-old C57BL/6J mice (Charles River, Maastricht, The Netherlands) 
were housed in a temperature- and humidity-controlled room on a 12-h light–
dark cycle with free access to food and water, unless mentioned otherwise.
All mice were randomly assigned to a group receiving either a high fat (HF) 
diet (45 energy% of fat derived from palm oil; Research Diet Services, Wijk 
bij Duurstede, The Netherlands) or a low fat (LF) control diet (10 energy% 
fat derived from palm oil; Research Diet Services) for 4 weeks. The exact 
composition and caloric content of both diets is described in table 1.
All animal experiments were performed in accordance with the principles of 
laboratory animal care and regulations of Dutch law on animal welfare, and the 
protocol was approved by the Institutional Ethical Committee on Animal Care 
and Experimentation.
Plasma analysis
Blood samples were drawn from the tail vein before onset of the dietary 
pretreatment and again at the end. Before sampling, mice were fasted for 10 
hours; from 11.00 pm until 9.00 am. Plasma glucose levels were measured 
using a commercially available kit (INstruchemie, Delftzijl, The Netherlands). 
A commercially available ELISA (Mercodia, Uppsala, Sweden) was used to 
measure plasma insulin levels. 
Experiment 1. Effect of diet on in vivo dopamine release in the hypothalamus
Experimental design
Fourteen mice were randomly assigned to a group receiving either a HF diet or 
LF control diet. At the end of the 4-week dietary pretreatment, microdialysis 






Microdialysis started 24 hours after surgery. On the first day, basal dopamine 
output in fed mice was measured. The microdialysis probe was connected to the 
pump and perfusion was started at 8.30 am. After a 2 h stabilization period, 4 
baseline samples were collected at 30 minute intervals. At 11.00 pm, food was 
removed and the mice were fasted. The next day microdialysis was reinitiated at 
08.30 am. After a 2 hour stabilization period, 4 baseline samples were collected 
at 30 minute intervals in fasted mice. Subsequently, food was provided, both 
groups of mice receiving their respective diets, and, while mice had ad libitum 
access to this food, 6 additional samples were collected at 30 minute intervals.
Surgery
Mice were anesthetized using isoflurane (2%, 1000 ml/min O2). Lidocaine was 
used for local anesthesia and fynadine as analgesic. The animals were placed 
Table 1 - Composition and caloric content of the low and high fat diets used.
Low fat diet High fat diet
Ingredients Mass (g/kg) Ingredients Mass (g/kg)
Casein 189.6 Casein 189.6
Cornstarch 298.6 Cornstarch 69.0
Maltodextrin DE10 33.2 Maltodextrin DE10 94.8






Palm oil 19.0 Palm oil 168.2
Soy oil 23.7 Soy oil 23.7
Mineral premix 
S10026
9.5 Mineral premix 
S10026
9.5
Dicalciumphosphate 12.3 Dicalciumphosphate 12.3








9.5 Vitamin premix 
V10001
9.5
L-Cystein 2.8 L-Cystein 2.8
Choline Bitartrate 1.9 Choline Bitartrate 1.9
Energy Content 
(kcal/kg)
3845 Energy Content 
(kcal/kg)
4728
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in a stereotaxic frame (Kopf instruments, CA, USA), and I-shaped probes (PES 
membrane, 1 mm exposed surface; BrainLink, Groningen, The Netherlands) 
were inserted into the dorsomedial region of the hypothalamus. Coordinates 
for the tips of the probes were: posterior (AP) = - 1.5 mm to bregma, lateral 
(L) = 0.6 mm to midline and ventral (V) = - 5.1 mm to dura22. 
Microdialysis procedure
During the experiment, the probes were connected with flexible PEEK tubing 
to a microperfusion pump (Syringe pump UV 8301501, TSE, Bad Homburg, 
Germany) and perfused with artificial cerebrospinal fluid, containing 147 mM 
NaCl, 3.0 mM KCl, 1.2 mM CaCl2, and 1.2 mM MgCl2, at a flow rate of 1.5 µl/min. 
Microdialysis samples were collected at 30 min intervals into mini-vials 
which already contained 15 µl 0.02 M acetic acid. The samples were collected 
by an automated fraction collector (CMA 142), and stored at -80° C awaiting 
analysis. After the experiment, the mice were sacrificed and the brains were 
removed. The brains were incubated for 3 days in a 4% (w/v) solution of 
paraformaldehyde. The position of each probe was histologically verified 
according to the stereotaxic atlas of Paxinos and Franklin22.
Analysis of dopamine
Separation: 
Samples (20 μl) were injected onto the HPLC column by a refrigerated 
microsampler system, consisting of a syringe pump (Gilson, model 402), a multi-
column injector (Gilson, model 233 XL), and a temperature regulator (Gilson, 
model 832). Chromatographic separation was performed on a reverse-phase 
150 x 2.1 mm (3 μm) C18 Thermo BDS Hypersil column (Keystone Scientific). 
The mobile phase (isocratic) consisted of a sodium acetate buffer (4.1 g/l) with 
methanol (2.5 % v/v), Titriplex (EDTA; 150 mg/l), 1-octanesulfonic acid (150 
mg/l), and tetramethylammonium (150 mg/l) and adjusted with glacial acetic 
acid to pH = 4.1. The mobile phase was run through the system at a flow rate of 
0.35 ml/min by an HPLC pump (Shimadzu, model LC-10AD vp). 
Electrochemical detection: 
Dopamine was detected electrochemically using a potentiostate (Antec Leyden, 
model Intro, Zoeterwoude, The Netherlands) fitted with a glassy carbon 
electrode set at +500 mV vs. Ag/AgCl (Antec Leyden). 
Data were analyzed by Chromatography Data System software (Shimadzu, 







Experiment 2. Effect of diet on hypothalamic expression of genes involved in 
dopaminergic neurotransmission
Experimental design
Another twelve mice were randomly assigned to a group receiving either a HF or 
a LF diet. After 4 weeks of dietary intervention, fed mice were sacrificed for the 
analysis of hypothalamic expression patterns of dopaminergic genes. All mice 
were sacrificed between 9.00 and 12.00 am, to minimize effects of circadian 
rhythm. The hypothalamus was rapidly dissected from the brain by making 2 
coronal incisions, one caudal to the optic chiasm and the other rostral to the 
mammillary bodies. The hypothalamus was then isolated from this coronal 
section using the internal capsules as lateral boundaries and the thalamus as 
dorsal boundary. The tissue was immediately frozen in liquid nitrogen and 
stored at -80°C awaiting analysis.
RT-PCR
Total RNA was extracted from the hypothalamus using TRIzol reagent 
(Invitrogen, Breda, The Netherlands) and an additional phenol–chloroform 
(Invitrogen, Breda, The Netherlands) extraction after the phase separation 
step of the TRIzol protocol (C.M.A. Reijnders et al., submitted). Total RNA was 
further purified by treatment with RNase-free DNase (Promega, Leiden, The 
Netherlands) to circumvent DNA contamination. Reverse transcription was 
performed with RevertAid™ First Strand cDNA Synthesis Kit (Fermentas, St. 
Leon-Rot ,Germany).
For RT-PCR commercially available primer sets were used: DRD2 and 
TH (Qiagen, Venlo, The Netherlands), DRD1a, Slc6a3, Rpl13a and Ppia 
(SuperArray, MD, USA). PCR amplification was performed in a total volume of 
25 μl, containing 5 ng of cDNA, 1x primer mix, 1x SYBER Green mix (Qiagen 
or Bio-Rad, Veenendaal, The Netherlands) and RNase free water. The SYBER 
Green mix from Qiagen was used in combination with the DRD2 and TH primer 
sets, whereas the Bio-Rad SYBER Green mix was used in combination with the 
other primer sets. Conditions for the amplification of DRD2 and TH genes were 
15 min at 95°C followed by 45 cycles of 10 sec 95°C, 30 sec 55°C and 30 sec 
72°C. Conditions for the amplification of DRD1a and Slc6a3 were 3 min at 95°C 
followed by 45 cycles of 10 sec 95°C, 30 sec 55°C and 30 sec 72°C. Finally, the 
conditions for the amplification of Rpl13a and Ppia were 3 min at 95°C followed 
by 45 cycles of 10 sec 95°C, 30 sec 60°C and 30 sec 72°C.
Specificity of the amplification reaction was confirmed by analysis of the 
dissociation curve. Each sample was amplified in triplicate. Data was analyzed 
using the IQ5 software (Bio-Rad).
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Gene expression levels in HF mice were expressed relative to gene expression 
levels in LF mice following normalization of the DRD2, DRD1, TH and DAT 
expression levels to those of the reference genes Rpl13a and Ppia. 
Experiment 3. Effect of diet on in vivo insulin resistance
Experimental design
Another thirteen mice were randomly assigned to a group receiving either a HF 
or a LF control diet for 4 weeks. At the end of the dietary intervention, mice were 
subjected to a hyperinsulinemic euglycemic clamp procedure for evaluation of 
in vivo insulin resistance.
Hyperinsulinemic euglycemic clamp
Mice were fasted for 16 hours after food withdrawal at 5.00 pm on the day 
before the clamp. Hyperinsulinemic euglycemic clamp studies started at 9.00 am 
and were performed as described earlier23. During the experiment, mice were 
sedated with a combination of 6.25 mg/kg acepromazine (Alfasan, Woerden, 
The Netherlands), 6.25 mg/kg midazolam (Roche, Mijdrecht, The Netherlands) 
and 0.3125 mg/kg fentanyl (Janssen-Cilag, Tilburg, The Netherlands). First, 
the basal rate of glucose turnover was determined by giving a primed (0.2 
μCi) continuous (0.3 μCi/h) intravenous (i.v.) infusion of D-[U-14C]-glucose 
(37 MBq) (GE Healthcare, Little Chalfont, UK) for 60 minutes. Subsequently, 
insulin (Novo Nordisk, Bagsværd, Denmark) was administered in a primed (4.5 
mU) continuous (6.8 mU/h) i.v. infusion for 90 minutes to attain steady state 
circulating insulin levels of ~4 μg/l. A variable i.v. infusion of a 12.5% D-glucose 
solution was used to maintain euglycemia as determined at 10 min intervals 
via tail bleeding (< 3 µl) (Accu-chek, Sensor Comfort, Roche Diagnostics GmbH, 
Mannheim, Germany). Blood samples (60 µl) were taken during the basal period 
(after 50 and 60 min) and during the hyperinsulinemic period (after 70, 80, and 
90 min) to determine plasma concentrations of glucose, insulin, and 14C-glucose 
specific activities. At the end of the clamp mice were sacrificed.
Analytical procedures
Plasma levels of glucose were determined using a commercially available kit 
(INstruchemie, Delfzijl, The Netherlands). Plasma insulin concentrations were 
measured by a mouse insulin ELISA (Mercodia AB, Uppsala, Sweden). Total 
plasma 14C-glucose was determined in 7.5 µl plasma and in supernatants after 
trichloroacetic acid (20%) precipitation and water evaporation.
Calculations
The rate of glucose disposal (Rd) (µmol/min/kg) was calculated during the basal 
period and under steady-state clamp conditions as the rate of tracer infusion 






The ratio was corrected for body weight. Hepatic glucose production (HGP) 
was calculated as the difference between the tracer-derived rate of glucose 
appearance and the glucose infusion rate. 
Statistical evaluation
Data is presented as mean ± standard error of the mean. Statistical analysis 
was performed using SPSS. Metabolic data or data concerning the basal 
dopamine output and gene expression was analyzed using an independent 
sample t-test. The non-parametric Mann-Whitney test was used to analyze the 
hyperinsulinemic euglycemic clamp data. For the dopamine output in response 
to refeeding, four consecutive fasting microdialysis samples with less than 50% 
variation were taken as baseline and their mean was set at 100%. Treatment 
effects were expressed as percentages of basal level within the same animal. 
For statistical analysis raw dopamine output levels were compared to mean 
fasting baseline values using a two-way ANOVA for repeated measures. The LSD 
method was used as post-hoc test to determine differences at single time points. 
Differences were considered statistically significant when p ≤ 0.05.
Results
Basal metabolic data
Body weight was significantly increased in mice maintained on a HF diet 
compared to mice maintained on a LF diet for 4 weeks (table 2). Fasting plasma 
glucose and insulin levels were not different in HF mice compared to LF mice 
after 4 weeks of dietary intervention.
Basal dopamine output
Mice had fully recovered from anesthesia when microdialysis was started, 
as indicated by complete body weight recovery (weight before vs. 24h after 
surgery; HF mice: 27.7 ± 1.4 vs. 28.0 ± 1.9 g; LF mice: 27.6 ± 1.4 vs. 27.5 ± 1.4 g). 
Table 2 - Weight, fasting plasma glucose and insulin levels measured in mice at the 
start and end of the 4-week dietary intervention.
Before diet After diet
LF group HF group LF group HF group
Weight (g) 24.7 ± 0.60 24.2 ± 0.61 27.3 ± 0.46 29.3 ± 0.51*
Glucose (mM) 6.99 ± 0.57 6.85 ± 0.63 7.53 ± 0.39 8.47 ± 0.42
Insulin (μg/l) 0.47 ± 0.05 0.63 ± 0.12 0.38 ± 0.04 0.44 ± 0.05
Data is measured in 19 HF and 20 LF mice and presented as mean ± SEM
* p< 0.01 vs. LF group after diet
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Basal dopamine levels did not differ between animals maintained on a HF or LF 
diet, neither in fed (fig 1A) nor in fasted state (fig 1B).
Dopamine output in response to refeeding
Dopamine levels rose to approximately 150% of baseline (p = 0.024) within 30 
min after the return of food in both HF and LF mice and decreased to baseline 
again within the next 60 min (fig 2). These findings agree with previous 
observations by others15,16,24, indicating that our experimental procedure 
adequately detects changes in dopamine levels. The dopamine response to 
refeeding was not different between HF and LF mice. 
Expression levels of genes involved in dopaminergic neurotransmission
The hypothalamic expression patterns of DRD2, DRD1, TH and DAT were not 
different in mice maintained on a HF or LF diet (fig 3).
Figure 1 - Basal dopamine output in the dorsomedial region of the hypothalamus of 
fed (A) or fasted (B) mice maintained on a HF vs. LF diet during 4 weeks (n=7 mice per 
group). Value per mouse is the mean of 4 consecutive baseline measurements. Data is 
presented as mean ± SEM.
Figure 2 - Dopamine output in 
the dorsomedial region of the 
hypothalamus in response to 
refeeding after a 13.5-h fast in mice 
maintained on a HF vs. LF diet for 4 
weeks (n=7 mice per group). Data 








Glucose and insulin concentrations measured during basal and hyperinsulinemic 
clamp conditions are shown in table 3. Stimulation of the glucose disposal rate 
by insulin was significantly reduced in HF mice compared to LF mice (fig 4A). In 
contrast, the inhibitory effect of insulin on hepatic glucose production was not 
affected by diet composition (fig 4B).
Table 3 - Plasma glucose and insulin levels measured in mice during the basal and 
hyperinsulinemic conditions of the hyperinsulinemic euglycemic clamp.
Basal Hyperinsulinemia
LF group HF group LF group HF group
Glucose (mM) 5.71 ± 0.31 6.19 ± 0.26 5.78 ± 0.28 6.21 ± 0.42
Insulin (μg/l) 0.29 ± 0.04 0.45 ± 0.11 2.81 ± 0.56 4.03 ± 0.94
Data is measured in 6 HF and 7 LF mice and presented as mean ± SEM.
Figure 3 - Normalized, relative 
expression of DRD2, DRD1, TH, and 
DAT genes in the hypothalamus of mice 
maintained on a HF vs. LF diet during 
4 weeks (n=6 mice per group). Data is 
presented as mean ± SEM.
Figure 4 - Stimulation of glucose disposal (A) and inhibition of glucose production (B) 
during a hyperinsulinemic euglycemic clamp in mice maintained on a HF (n=6 mice) vs. 
LF diet (n=7 mice) for 4 weeks. Data is presented as mean ± SEM.
* p < 0.05 vs. LF diet
A B
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Discussion
In the present work we determined the impact of HF feeding on dopamine 
release and the expression of genes involved in the control of dopaminergic 
neurotransmission in the hypothalamus of diet-susceptible C57Bl6 mice. HF 
feeding, in these animals, recapitulates many of the metabolic and endocrine 
features of human obesity. We hypothesized that a HF diet would diminish the 
expression of DRD2 and thereby trigger a “reward deficiency syndrome” that 
might underlie weight gain and impaired insulin action. However, our results 
do not support this hypothesis. Four weeks of HF (45 energy% fat derived from 
palm oil) or LF (10 energy% fat derived from palm oil) feeding was associated 
with similar dopamine release in the dorsomedial hypothalamus and equivalent 
gene expression levels of DRD1, DRD2, TH and DAT in the whole hypothalamus 
of C57Bl6 mice. Nonetheless, HF feeding hampered insulin action in the current 
experimental context, as evidenced by diminished glucose uptake during the 
hyperinsulinemic euglycemic clamp. Thus, our results argue against the role 
of reduced dopaminergic neurotransmission in the hypothalamus as causal 
intermediate between HF feeding and the pathogenesis of obesity and/or 
insulin resistance in C57Bl6 mice.
A host of papers document a decrease of DRD2 expression and a 
compensatory rise in dopamine levels in the brain of obese animal models 
and humans. OLETF rats, which gradually develop obesity and diabetes as a 
consequence of cholecystokinin (CCK) receptor-1 deficiency, are characterized 
by increased striatal dopamine release25. A loss-of-function mutation in the 
leptin receptor gene, leading to a morbid obesity syndrome and diabetes, is 
associated with a reduction in DRD2 expression and exaggerated dopamine 
levels in the hypothalamus of Zucker rats15,16,19,26. Treatment with the DRD2 
agonist bromocriptine ameliorates the metabolic phenotype of these 
animals27,28. Likewise, DRD2 availability is significantly reduced in the striatum 
of obese humans and inversely correlated with their body mass index21,29,  while 
bromocriptine treatment also ameliorates various metabolic anomalies of 
obese women12.
Virtually all studies evaluating dopaminergic neurotransmission in obesity 
have used chronically obese animal models and human subjects. Therefore, 
current knowledge does not provide an answer to the question whether a 
deficiency in dopaminergic neurotransmission is a primary defect underlying 
obesity syndromes or rather a consequence of the metabolic state. At least 
one study documents a rise in dopaminergic tone in hypothalamic nuclei of 
diet sensitive rats prior to high energy diet exposure, suggesting that elevated 
dopamine levels lead to the development of obesity in these animals30. However, 
our data do not support the hypothesis that HF feeding blunts dopaminergic 






and insulin resistance. In particular, they suggest that diets of quite distinct 
composition in terms of fat and carbohydrate do not, in the short term, impact 
on hypothalamic dopaminergic neurotransmission. Obviously, our data do not 
rule out the possibility that diet composition affects dopaminergic transmission 
in other brain areas. Intermittent (excessive) sugar intake, for example, has 
been shown to increase extracellular dopamine in the mesolimbic system31.
The question then arises whether the metabolic abnormalities associated 
with obesity and insulin resistance could change brain dopaminergic 
neurotransmission to explain the multitude of data documenting reductions 
of dopamine neurotransmission in the brain of obese animals and humans. 
The answer may be yes.  For example, glucose dose-dependently enhances 
dopamine release by PC-12 neuroendocrine cells32, hyperinsulinemia 
combined with hyperglycemia induces exaggerated dopamine release in 
vivo in the nucleus accumbens of rats33, and dopamine release is diminished 
in hippocampal areas of spontaneously hypoinsulinemic diabetic rats34. 
Furthermore, intracerebroventricular administration of insulin increases DAT 
mRNA in the ventral tegmental area of rats35, and insulin enhances dopamine 
uptake in striatal cells and human DAT transfected cells in vitro36,37. Conversely, 
food deprivation, which is accompanied by low circulating insulin levels, blunts 
DAT mRNA expression and activity in the ventral tegmental area of rats38. 
Thus, circulating metabolites and hormones clearly impact on dopaminergic 
neurotransmission, but it remains unclear whether insulin resistance, 
accompanied by hyperinsulinemia and hyperglycemia, affects dopaminergic 
signaling in brain areas involved in the control of food intake and metabolism.
Alternatively, reduction of dopaminergic neurotransmission in obese animal 
models and humans could be due to mechanism(s) that are not directly triggered 
by diet composition or metabolic cues. For example, elevated dopamine levels 
found in OLETF rat might be the consequence of CCK receptor-1 deficiency25,39. 
Reduced DRD2 expression and high dopamine levels in hypothalamic areas 
of Zucker rats15,19 could be a direct corollary of their genetic resistance to the 
inhibitory effect of leptin on dopamine release40-42. In analogy, leptin resistance 
might also be the primary cause of reduced DRD2 binding in obese humans43.
Whatever the biological underpinnings, reduction of central dopaminergic 
tone may modulate neuroendocrine activity so as to impair insulin action5,7,8. In 
a scenario where reduced brain dopamine signal transduction is not caused by 
hyperinsulinemia and/or hyperglycemia, but rather underlies these metabolic 
anomalies, it is easier to understand the undisputable benefits of dopamine 
DRD2 activation for glucose metabolism in various obese animal models and 
humans12,44,45.
It is important to point out that our study did not allow evaluation of 
dopaminergic neurotransmission in individual hypothalamic nuclei. In 
particular, our method of dissecting the hypothalamus for RNA isolation only 
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permitted determination of gene expression levels in the whole hypothalamus. 
Furthermore, the size of the microdialysis probe did not allow determination 
of dopamine levels in one specific nucleus. We chose to position the probe in 
the dorsomedial region of the hypothalamus, as this region contains nuclei 
critical for the control of food intake and metabolism46,47. However, we realize 
that dopamine turnover may be differentially affected by obesity in distinct 
hypothalamic nuclei19,48. Our study does not exclude the possibility that HF 
feeding does impact on dopaminergic neurotransmission in a nucleus specific 
way.
In conclusion, we show here that HF feeding does not affect dopaminergic 
neurotransmission in the hypothalamus of a diet-sensitive mouse strain, even 
though it does impair insulin action. The data suggest that reduced dopaminergic 
neurotransmission in the hypothalamus of obese animal models and humans is 
due to mechanism(s) that are not directly triggered by diet composition.
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Blocking dopamine D2 receptors by 
haloperidol curtails the beneficial impact of 
calorie restriction on the metabolic phenotype 
of high fat diet induced obese mice







Calorie restriction is the most effective way of expanding life-span and 
decreasing morbidity. It improves insulin sensitivity and delays the age-related 
loss of dopamine receptor D2 (DRD2) expression in the brain. Conversely, high 
fat feeding is associated with obesity, insulin resistance and a reduced number 
of DRD2 binding sites. We hypothesized that the metabolic benefit of calorie 
restriction involves preservation of appropriate DRD2 transmission.
The food intake of wild type C57Bl6 male mice was restricted to 60% of ad 
libitum intake while they were treated with the DRD2 antagonist haloperidol 
or placebo using subcutaneously implanted pellets. Mice with ad libitum access 
to food receiving placebo treatment served as controls. All mice received 
high fat food throughout the experiment. After 10 weeks an intraperitoneal 
glucose tolerance test was performed and after 12 weeks a hyperinsulinemic 
euglycemic clamp. Hypothalamic DRD2 binding was also determined after 12 
weeks of treatment.
Calorie restricted (CR) placebo mice were glucose tolerant and insulin 
sensitive compared to ad libitum (AL) fed placebo mice. CR mice treated with 
haloperidol were slightly heavier than placebo treated CR mice. Haloperidol 
completely abolished the beneficial impact of calorie restriction on glucose 
tolerance and partly reduced the insulin sensitivity observed in CR placebo 
mice. The metabolic differences between AL and CR placebo mice were not 
accompanied by alterations in hypothalamic DRD2 binding.
In conclusion, blocking DRD2 curtails the metabolic effects of calorie 
restriction. Although this suggests that the dopaminergic system could be 
involved in the metabolic benefits of calorie restriction, restricted access to 
high fat food does not increase (hypothalamic) DRD2 binding capacity, which 
argues against this inference. 
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Introduction
Calorie restriction is the most effective way to extend lifespan and reduce 
morbidity. The maximal lifespan of rodents can be prolonged up to 60% by 
lifelong calorie restriction1. In mice, carcinogenesis is efficiently decreased 
by calorie restriction2,3 and in humans it is associated with a reduced risk for 
atherosclerosis development4. Calorie restriction is also highly effective in 
reversing insulin resistance, both in humans and rodents5-9. The mechanisms 
responsible for the benefits of calorie restriction on morbidity and mortality are 
not yet fully elucidated. In the context of improving metabolic features though, 
the impact of calorie restriction on the dopaminergic system may be involved. 
In rats, calorie restriction delays the age-related loss of dopamine receptor D2 
(DRD2) and tyrosine hydroxylase expression10-12, while it enhances the affinity 
of DRD2 to ligands13.
The dopaminergic system plays a complex dual role in feeding behaviour 
and profoundly affects glucose and lipid metabolism14-16. Dopamine action 
is mediated by 5 distinct G-protein coupled receptor subtypes, functionally 
classified into 2 receptor families according to their effect on target neurons. 
Activation of dopamine receptor D2, D3 or D4, comprising the D2 family, inhibits 
adenylyl cyclase. Activation of the receptors belonging to the D1 family (DRD1 
and DRD5) stimulates adenylyl cyclase17.
Dopaminergic transmission is altered in obese and insulin resistant animals. 
Basal and feeding evoked dopamine release is exaggerated in several nuclei 
of the hypothalamus of obese Zucker rats18-20, whereas DRD2 expression is 
reduced in hypothalamic nuclei of obese animal models21,22. The number of 
DRD2 binding sites in the striatum of obese humans is reduced and inversely 
correlated with body mass index23.
Modulation of DRD2 activity profoundly affects energy homeostasis. Drugs 
that block DRD2 enhance appetite and induce weight gain in animals and 
humans24-27. Conversely, DRD2 agonist drugs reduce body weight, increase 
energy expenditure and improve glycemic control in obese individuals28-31.
High fat feeding induces obesity, insulin resistance and type 2 diabetes in 
rodents. A reduction in DRD2 transmission due to the high fat diet may be 
involved in this deleterious metabolic profile. We hypothesized that restricting 
access to high fat food would curtail the diet’s effects on glucose metabolism 
by maintaining appropriate hypothalamic DRD2 binding capacity (and thereby 
DRD2 mediated neurotransmission).
To test this hypothesis, wild type C57Bl6 mice were fed a high fat diet, 
either with ad libitum or restricted access. Half of the calorie restricted (CR) 
mice were continuously treated with the DRD2 antagonist haloperidol to 
pharmacologically reduce dopaminergic neurotransmission via this receptor. 






treatment. We speculated that the haloperidol treatment would counteract 
the benefits of calorie restriction on the metabolic phenotype of high fat fed 
mice. A glucose tolerance test was performed after 10 weeks of treatment 
and a hyperinsulinemic euglycemic clamp after 12 weeks. In addition, the 




Fifty-four male C57BL/6J mice (Charles River, Maastricht, The Netherlands), 
10 or 11 weeks old, were individually housed in a temperature- and humidity-
controlled room on a 12-h light–dark cycle (lights on at 7.00 am) with free 
access to water. 
All animal experiments were performed in accordance with the principles 
of laboratory animal care and regulations of Dutch law on animal welfare, and 
the experimental protocol was approved by the Animal Ethics Committee of 
the Leiden University Medical Center.
Experimental design
Mice were randomly assigned to one of the following groups (n=18 mice per 
group): 1) ad libitum access to food combined with placebo treatment, 2) 
restricted access to food combined with placebo treatment and 3) restricted 
access to food combined with haloperidol treatment (1 mg/kg/day). This dose 
was chosen as it is frequently used in rodent experiments and it has proven to 
be effective in several behavioral paradigms32. Chronic administration of this 
dose in mice yields serum concentrations of 8.2 mM, which is comparable to 
the haloperidol concentration in humans occupying 75% of DRD233.
After a run-in period (3 or 7 weeks for the autoradiography and the clamp 
experiment respectively) in which all mice were allowed to get accustomed to 
the high fat (HF) diet (45 energy% of fat derived from palm oil, 35 energy% 
of carbohydrate and 20 energy% of protein; Research Diet Services, Wijk bij 
Duurstede, The Netherlands) and the basal food intake was determined, food 
restriction and drug treatment were started simultaneously. All mice remained 
on the HF diet throughout the study, either with ad libitum or restricted access. 
The CR mice received 60% of the amount of food the AL mice consumed. Food 
intake of the AL mice was measured twice a week. The CR mice received half 
of their daily food in the beginning of the dark phase and the other half in the 
middle of the dark phase.
All mice received treatment by means of subcutaneous implantable pellets 
(Innovative Research of America, Florida, USA), ensuring continuous release 
of the medication. Haloperidol and placebo pellets were implanted under 
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isoflurane anesthesia. Mice were treated for 12 weeks, meanwhile having ad 
libitum or restricted access to the HF food. Non-fasted body weight of AL and CR 
mice was measured weekly.
After 10 weeks of treatment, a group of mice was subjected to an 
intraperitoneal glucose tolerance test and after 12 weeks of treatment the 
body composition of these mice was determined. Subsequently the mice were 
subjected to a hyperinsulinemic euglycemic clamp. Another group of mice 
was sacrificed after 12 weeks of treatment for analysis of hypothalamic DRD2 
binding.
Intraperitoneal Glucose Tolerance Test
Eight mice per group were fasted for 16 hours after food withdrawal at 5.00 
pm. That day, the CR mice received their food at 3.00 pm and if anything was 
left at 5.00 pm, this was discarded. The glucose tolerance test (GTT) started at 
9.00 am the following day. An initial blood sample (t=0) was taken, immediately 
followed by an intraperitoneal injection of 2 g/kg D-glucose, provided as a 20% 
solution. Additional blood samples were taken via tail bleeding at 5, 15, 30, 45, 
60, and 120 minutes after glucose injection for measurement of plasma glucose 
and insulin levels.
DEXAscan
The body composition of 10 mice per group was measured by dual-energy 
X-ray absorptiometry (DEXA) using the Norland pDEXA Sabre X-Ray Bone 
Densitometer (Norland, Hampshire, UK). Before measuring, mice were 
anesthetized with a combination of 6.25 mg/kg acepromazine (Alfasan, 
Woerden, The Netherlands), 6.25 mg/kg midazolam (Roche, Mijdrecht, 
The Netherlands) and 0.3125 mg/kg fentanyl (Janssen-Cilag, Tilburg, The 
Netherlands). Mice were scanned in toto, yet the heads were excluded from 
the analysis due do the inability of the DEXAscan to accurately determine the 
composition of the tissue below the skull.
Hyperinsulinemic euglycemic clamp
Ten mice per group were fasted for 16 hours after food withdrawal at 5.00 pm. 
That day, CR mice received their food at 3.00 pm and if anything was left at 5.00 
pm, this was discarded. Hyperinsulinemic euglycemic clamp studies started at 
9.00 am the following day and were performed as described earlier34. During 
the experiment, mice were anesthetized with a combination of 6.25 mg/kg 
acepromazine (Alfasan, Woerden, The Netherlands), 6.25 mg/kg midazolam 
(Roche, Mijdrecht, The Netherlands) and 0.3125 mg/kg fentanyl (Janssen-
Cilag, Tilburg, The Netherlands). First, the basal rate of glucose turnover was 
determined by giving a primed (0.5 μCi) continuous (0.9 μCi/h) intravenous 






for 60 minutes. Subsequently, insulin (Novo Nordisk, Bagsværd, Denmark) 
was administered in a primed (3.7 mU) continuous (6.1 mU/h) i.v. infusion for 
90 minutes to attain steady-state circulating insulin levels of ~6 ng/ml. Every 
10 min the plasma glucose concentration was determined via tail vein bleeding 
(< 3 µl) (Accu-chek, Sensor Comfort, Roche Diagnostics GmbH, Mannheim, 
Germany) and the i.v. infusion rate of a 12.5% D-glucose solution was adjusted 
to maintain euglycemia. Blood samples (60 µl) were taken during the basal 
period (after 50 and 60 min) and during the hyperinsulinemic period (after 
70, 80, and 90 min) to determine plasma concentrations of glucose, insulin and 
3H-glucose specific activities. At the end of the clamp mice were sacrificed.
Analytical procedures
A commercially available kit was used to determine the plasma concentration 
of glucose (Instruchemie, Delfzijl, The Netherlands). The plasma insulin 
concentration was measured by an ELISA (Crystal Chem Inc., IL, USA). The 
3H-glucose concentration was determined in plasma and in supernatant after 
trichloroacetic acid (20%) precipitation and water evaporation.
Calculations
The rate of glucose uptake (µmol/min/kg) was calculated during the basal 
period and under steady-state hyperinsulinemic conditions as the rate of tracer 
infusion (dpm/min) divided by the plasma-specific activity of 3H-glucose (dpm/
µmol). Endogenous glucose production (µmol/min/kg) was calculated as the 
difference between the tracer-derived rate of glucose uptake and the glucose 
infusion rate. Both glucose uptake and production measures were corrected for 
body weight.
Tissue preparation
Eight mice per group, used for the analysis of hypothalamic DRD2 binding, 
were sacrificed by cervical dislocation between 9.00 and 12.00 am, to minimize 
effects of the circadian rhythm. Brains were rapidly dissected, snap frozen in 
ice-cold isopentane (cooled in ethanol which was placed in dry ice) and stored 
at -80°C until further use.
Sections of 16 μm were cut on a Cryostat (Microm HM 500 M, Adamas 
Instruments, Leersum, The Netherlands) and mounted on Polysine Slides 
(Menzel-Gläser, Braunschweig, Germany). Sections were taken at the level of the 
paraventricular nucleus (PVN) and lateral hypothalamic area (LHA) (Bregma 
-0.70), ventromedial hypothalamus (VMH) (Bregma -1.34) and dorsomedial 
hypothalamus (DMH) and nucleus arcuatus (ARC) (Bregma -1.94) according 
to the brain atlas of Paxinos and Franklin35. Slides were stored at -20°C until 
further use.
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DRD2 autoradiography
Sections were pre-incubated in a 50 mM Tris buffer (pH 7.0), containing 5.7 
mM ascorbic acid, 120 mM NaCl, 5 mM KCl, 1 mM CaCl2 and 1 mM MgCl2, for 60 
min at room temperature. Subsequently, sections were incubated with 0.7 ml of 
the Tris buffer containing 0.1 nM 125I-Iodosulpride (2200 Ci/mmol, 100 μCi/ml; 
Perkin Elmer, Waltham, MA, USA) for 30 min at room temperature. Non-specific 
binding was determined in the presence of 2 μM haloperidol (Sigma-Aldrich, 
St. Louis, MO, USA). After incubation, sections were drained, dipped in distilled 
water (4°C), washed twice in Tris buffer (4°C) for 3 min, dipped in distilled 
water and air-dried. Sections were exposed to a Kodak BioMax MR film (Perkin 
Elmer, Waltham, MA, USA) for 4 weeks.
Analysis of DRD2 binding
The autoradiography films were digitized with an Epson Perfection V350 Photo 
scanner and the grey values on the scans were measured using ImageJ Software 
(NIH, Bethesda, USA). Counterstaining of the sections with Toluidine Blue 
O (Sigma-Aldrich, St. Louis, MO, USA) was performed to visualize individual 
hypothalamic nuclei. Hypothalamic nuclei that were damaged were excluded 
from the analysis. Accordingly, the arcuate nuclei of several mice were excluded. 
Grey values measured in the hypothalamic nuclei were corrected for background 
values.
Statistical analysis
Data is presented as mean ± standard deviation (SD). Statistical analysis was 
conducted using SPSS 16.0 software. A General Linear Model for repeated 
measures was used to analyze the differences in body weight over time, in glucose 
and insulin concentration and glucose infusion rate during the ipGTT and the 
clamp respectively. Only if the overall F-test indicated significant differences 
between the groups, a LSD post-hoc test was used to determine differences 
between specific groups. Analysis of the rest of the data was performed using 
a one-way ANOVA. Only if the overall F-test indicated significant differences 
between the groups, a LSD post-hoc test was used to determine differences 
between specific groups. Differences were considered statistically significant 
when p<0.05.
Results
Body weight and plasma metabolites
Body weight was similar in all groups of mice after the run-in HF diet (AL + 
Placebo: 29.6 ± 3.0 g; CR + Placebo: 30.4 ± 4.2 g; CR + Haloperidol: 30.3 ± 3.6 
g; n=18 mice per group). During the 12 weeks of treatment, AL mice consumed 






received 1.8 ± 0.1 g of HF food daily. During the first few weeks of treatment, 
CR mice lost weight until a new equilibrium was reached and the weight 
remained relatively stable for the rest of the experiment (fig 1). At the end of 
the treatment period, AL mice had a significantly higher body weight compared 
to both CR groups (p<0.001; AL + Placebo: 40.4 ± 2.9 g; CR + Placebo: 22.1 ± 1.2 
g; CR + Haloperidol: 24.7 ± 0.8 g; n=18 mice per group). Haloperidol treatment 
resulted in a slightly, but significantly, higher body weight compared to placebo 
treatment. The difference in body weight between the CR and the AL mice was 
primarily accounted for by fat mass, but lean body mass was also different 
(table 1). The fasting plasma glucose concentration was not different between 
AL and CR placebo mice (table 2), yet the fasting plasma insulin concentration 
was significantly elevated in the AL mice compared to the CR placebo mice 
(table 2). Haloperidol treatment did not affect fasting plasma glucose or insulin 
concentrations in CR mice.
Glucose tolerance
After 10 weeks of treatment mice were subjected to an ipGTT. CR placebo mice 
had significantly lower glucose levels during the ipGTT (fig 2A) and a decreased 
area under the glucose curve (fig 2B) compared to AL mice, indicating improved 
Table 1 - Fasted body weight, lean body mass and fat mass determined by DEXAscan 
analysis of AL and CR mice treated with placebo or haloperidol for 12 weeks.
AL mice CR mice CR mice
Placebo Placebo Haloperidol
Body weight (g) 38.4 ± 3.3 21.2 ± 1.5*** 23.9 ± 0.7***$
Lean body mass (g) 22.09 ± 1.77 18.04 ± 1.48*** 18.94 ± 1.08***
Fat mass (g) 10.68 ± 2.19 0.04 ± 0.13*** 0.29 ± 0.40***
Data is presented as mean ± SD for 9 or 10 mice per group.
*** p<0.001 compared to AL placebo mice
$ p<0.05 compared to CR placebo mice
Figure 1 - Non-fasted body weight of 
AL and CR mice treated with placebo or 
haloperidol during the experiment.
Data is presented as mean ± SD for 18 
mice per group. 
** p<0.01; *** p<0.001
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glucose tolerance. Accordingly, plasma insulin levels and the area under the 
insulin curve were significantly reduced in CR placebo compared to AL mice 
(fig 2C,D). Haloperidol treatment disrupted the glucose tolerance observed 
in CR placebo mice, as indicated by elevated plasma glucose levels and an 
increased area under the glucose curve. Surprisingly though, plasma insulin 
concentrations in CR haloperidol mice were not different from plasma insulin 
concentrations in CR placebo mice.
Insulin sensitivity
After 12 weeks of treatment mice were subjected to a hyperinsulinemic 
euglycemic clamp. The coefficient of variation of the specific activity was 10.5% 
during the basal period and 16.3% during the hyperinsulinemic period of the 
clamp. Basal and hyperinsulinemic plasma glucose and insulin concentrations 
as well as glucose uptake and production levels are shown in table 2. The 
basal glucose turnover was significantly lower in AL mice compared to both 
groups of CR mice (table 2). The glucose infusion rate, necessary to maintain 
Figure 2 - Plasma glucose (A) and insulin (C) concentration during the intraperitoneal 
glucose tolerance test in AL and CR mice treated with placebo (P) or haloperidol (HP) 
for 10 weeks. Area under the glucose (B) and insulin (D) curve.
Data is presented as mean ± SD for 7 or 8 mice per group.










Table 2 - Plasma concentration of glucose and insulin, glucose uptake and 
production during the basal and hyperinsulinemic condition of the hyperinsulinemic 
euglycemic clamp in AL and CR mice treated with placebo or haloperidol for 12 
weeks.
AL mice CR mice CR mice
Clamp condition Placebo Placebo Haloperidol
Glucose (mM) B 5.6 ± 1.3 5.1 ± 1.3 6.5 ± 1.1
HI 5.6 ± 1.6 4.5 ± 1.4 5.1 ± 0.8
Insulin (ng/ml) B 1.5 ± 0.4 1.0 ± 0.2** 1.0 ± 0.3*
HI 5.6 ± 0.6 6.6 ± 1.8 6.8 ± 1.3
Glucose Uptake 
(μmol/min/kg)
B 31.6 ± 7.8 44.4 ± 9.9* 46.5 ± 14.9*
HI 34.5 ± 12.3 96.7 ± 37.7*** 73.4 ± 15.5**
Glucose Production 
(μmol/min/kg)
B 31.6 ± 7.8 44.4 ± 9.9* 46.5 ± 14.9*
HI 17.6 ± 18.8 6.2 ± 11.0 2.9 ± 5.8
B, Basal; HI, Hyperinsulinemia
Data is presented as mean ± SD for 7 or 8 mice per group.
* p<0.05; ** p<0.01; *** p<0.001 compared to AL placebo mice
Figure 3 - Glucose infusion rate (A), 
stimulation of glucose uptake (B) and 
inhibition of glucose production (C) 
during a hyperinsulinemic euglycemic 
clamp in AL and CR mice treated with 
placebo (P) or haloperidol (HP) for 12 
weeks.
Data is presented as mean ± SD for 7 or 8 
mice per group.
* p<0.05; ** p<0.01; *** p<0.001
A
B C
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euglycemia, was significantly increased in CR placebo mice compared to AL 
mice (fig 3A), indicating improved whole-body insulin sensitivity. Haloperidol 
treatment significantly reduced the glucose infusion rate in CR mice, reflecting 
a decrease in insulin sensitivity. The improved insulin sensitivity of CR placebo 
mice compared to the AL mice was reflected by enhanced stimulation of glucose 
uptake (fig 3B) and stronger inhibition of glucose production (fig 3C). The 
decline of insulin sensitivity in CR mice treated with haloperidol was mainly due 
to a decreased ability of insulin to stimulate glucose uptake, whereas insulin’s 
capacity to inhibit glucose production was unaffected (fig 3B,C).
DRD2 binding
After 12 weeks of treatment, DRD2 binding in several hypothalamic nuclei was 
determined. Representative autoradiographs are shown in figure 4. There was 
no difference in DRD2 binding between AL and CR placebo mice in any region of 
the hypothalamus (fig 5). Haloperidol treatment though, significantly increased 
DRD2 binding in all hypothalamic nuclei, except in the DMH.
Discussion
The results presented here demonstrate that restricted access to a high fat diet 
strongly attenuates the diet’s (detrimental) effect on glucose metabolism in 
mice. Simultaneous administration of haloperidol, a DRD2 antagonist, partially 
prevents this effect, suggesting that dopaminergic signalling is involved in 
Figure 4 - Autoradiographs depicting 
DRD2 binding in the hypothalamus of 
representative AL and CR mice, treated 




















the beneficial impact of calorie restriction on glucose metabolism. However, 
restricted access to high fat food did not increase the availability of DRD2 
binding sites in the hypothalamus, which does not support this inference.
Calorie restriction unequivocally reverses the metabolic derangements 
associated with obesity in humans5-7. Likewise, in rats several calorie restriction 
paradigms, ranging from 20% to 45% restriction, improve glucose metabolism 
during aging9,36,37. In addition, 30% or 40% calorie restriction prevents the 
development of diabetic characteristics in genetic rat models8,38,39. In mice, 
40% calorie restriction reduces glucose and insulin concentrations40. Here, we 
extend these findings and show that, in C57Bl6 mice, restricted access to high 
fat food curtails the diet’s impact on glucose metabolism. A high fat diet is well 
Figure 5 - DRD2 binding in the PVN, LHA, 
VMH, DMH and ARC of AL and CR mice 
treated with placebo (P) or haloperidol 
(HP) for 12 weeks. Data is presented as 
mean ± SD for 7 or 8 mice per group.
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known to induce obesity, insulin resistance and a type 2 diabetes-like phenotype 
in rodents. Restricted access to this diabetogenic diet clearly scales down 
these metabolic corollaries, as reflected by improved glucose tolerance and 
insulin sensitivity observed in CR placebo mice compared to AL mice. It seems 
important to note that we are unable to determine whether calorie restriction 
fully abolishes the high fat diet induced disturbance of glucose metabolism, as 
we did not include a low fat fed control group. However, we do show that calorie 
restriction efficiently curtails the metabolic corollaries of high fat feeding. 
Although the beneficial impact of calorie restriction on glucose metabolism 
is unequivocal, the underlying mechanism(s) are still incompletely understood. 
Reduction of body weight and associated changes in ectopic lipid storage 
obviously play a critical role, but some of the metabolic benefits of calorie 
restriction are immediate and occur way before substantial weight loss has 
occurred41. Also, intermittent fasting recapitulates the beneficial impact 
of calorie restriction without altering body weight40,42. Therefore, other 
mechanisms than weight loss per se must contribute as well.
Calorie restriction delays the age-related loss of DRD2 expression and 
enhances the sensitivity of this receptor10-13. The dopaminergic system is 
critically involved in glucose and insulin metabolism. Activation of DRD2 
normalizes elevated plasma glucose and insulin concentrations, improves islet 
function, ameliorates glucose intolerance and enhances insulin sensitivity in 
obese diabetic rodent models and humans28-30,43,44. Conversely, blocking DRD2 
elevates plasma insulin levels and induces insulin resistance45-47. In concert, 
these data suggest that the dopaminergic system may mediate the beneficial 
effects of calorie restriction on metabolism. Specifically, we hypothesized that 
restricting the access to high fat food would prevent any reduction in DRD2 
binding sites associated with high fat feeding. This would ensure appropriate 
hypothalamic DRD2 neurotransmission during restricted intake of the high fat 
diet and thereby curtail the development of high fat diet induced alterations in 
glycemic control.
Indeed, haloperidol partially abolished the beneficial impact of calorie 
restriction on glucose metabolism; compared to CR placebo mice, haloperidol 
treated mice developed both glucose intolerance and insulin resistance. But, 
in contrast to our hypothesis, we found no difference in DRD2 binding in the 
hypothalami of AL and CR placebo mice. We specifically measured DRD2 binding 
in the hypothalamus since this brain region is involved in the modulation of 
glucose and insulin homeostasis48. The lack of impact of CR on DRD2 binding 
is in apparent contrast with the study of Thanos et al., in which an increased 
DRD2 binding was detected in the striatum, cingulate and frontal cortex of CR 
obese Zucker rats compared to AL control rats11. Several differences between 
the study of Thanos et al. and ours might explain the discrepancy. First of 






of calorie restriction is specific for certain regions, e.g. altering DRD2 binding 
in the striatum but not in the hypothalamus. Another difference is the animal 
model used; a diet-induced obese mouse model versus a genetic obese rat 
model. Furthermore, we used a slightly different protocol to measure DRD2 
binding. Yet, we detected elevated DRD2 binding in the hypothalamus of CR 
haloperidol mice, which is consistent with a wealth of literature49-51, indicating 
that our experimental protocol is well suited to accurately determine DRD2 
binding patterns.
The detrimental impact of haloperidol is not constrained to calorie restricted 
mice, the drug affects glucose metabolism of ad libitum fed animals as well. 
Haloperidol acutely induces glucose intolerance in rats52,53. In a previous 
experiment we showed that haloperidol promotes insulin resistance in mice 
after 2 weeks of treatment (De leeuw van Weenen et al., submitted) and 4 weeks 
of haloperidol treatment increases basal insulin levels in rats54. The similar 
impact of haloperidol in calorie restricted and ad libitum fed animals makes 
it difficult to establish the importance of dopaminergic neurotransmission 
in the beneficial effect of calorie restriction. The fact that we were unable to 
detect differences in DRD2 binding between CR and AL mice argues against an 
important role for DRD2 receptors.
Haloperidol might affect glucose homeostasis through several distinct 
mechanisms. First, haloperidol, as well as other antipsychotics, dramatically 
reduces physical activity55-57 and impaired physical activity might directly 
diminish insulin sensitivity. It has consistently been shown that 6-10 days of 
bed rest, representing severe physical inactivity, impairs insulin sensitivity 
in healthy man without affecting body weight58-60. Also in trained volunteers 
refraining from exercise for 10-14 days, representing a milder protocol for 
inactivity, insulin resistance is observed, again without alterations in body 
weight and fat mass61,62. Secondly, haloperidol consistently elevates serum 
concentrations of prolactin63,64 and this is associated with glucose intolerance 
and insulin resistance65,66. Thirdly, haloperidol might, irrespective of its impact 
on physical activity and prolactin levels, acutely reduce insulin sensitivity. 
Several antipsychotic drugs are able to acutely induce insulin resistance57,67-69. 
Although this has not yet been confirmed for haloperidol, the drug does acutely 
impair glucose tolerance52,53. As the glucose intolerance was accompanied by 
elevated insulin levels, defective insulin secretion can not (solely) explain the 
observed glucose intolerance. So, this suggests that haloperidol, like other 
antipsychotic drugs, can acutely alter insulin sensitivity. Finally, haloperidol 
might impair insulin secretion. During the glucose tolerance test, the insulin 
levels were inappropriately low in the face of high glucose levels. This indicates 
defective insulin secretion. Likewise, DRD2 deficient mice are glucose intolerant 
in the face of low circulating insulin levels70. In vitro experiments with islets from 
these mice revealed that the islets were unable to secrete insulin in response to 
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glucose. The pancreata of these mice showed a reduced β-cell mass and insulin 
concentration. Considering these results, Garcia-Tornadu et al. suggested that 
DRD2 activation is essential for β-cell proliferation70. All together this supports 
that chronic inhibition of DRD2 neurotransmission might suppress insulin 
secretion.
Interestingly, in the current experiment, CR haloperidol mice were more 
insulin sensitive than AL mice but equally glucose intolerant. Glucose tolerance 
is the net effect of the production of insulin by pancreatic β-cells and the ability 
of peripheral tissues to respond to insulin by increasing glucose uptake. Insulin 
sensitivity was only modestly decreased in CR haloperidol mice compared to CR 
placebo mice, suggesting that a defect in glucose-stimulated insulin secretion 
was the main cause of the observed glucose intolerance in our experiment.
In summary, calorie restriction strongly limits the deleterious impact of high 
fat feeding on glucose and insulin metabolism in C57Bl6 mice. DRD2 inhibition, 
by means of haloperidol, curtails this effect of calorie restriction, suggesting 
that DRD2 mediated neurotransmission could be involved in the control of 
the metabolic benefits of calorie restriction. However, the fact that restricting 
access to high fat food does not increase hypothalamic DRD2 binding capacity 
does not support this inference.
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Pharmacological modulation of dopamine 
receptor D2 mediated transmission alters the 
metabolic phenotype of diet induced obese 
and diet resistant C57Bl6 mice
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Abstract
High fat feeding induces a variety of obese and lean phenotypes in inbred rodents. 
Compared to Diet Resistant (DR) rodents, Diet Induced Obese (DIO) rodents are 
insulin resistant and have a reduced dopamine receptor D2 (DRD2) mediated 
tone. We hypothesized that this differing dopaminergic tone contributes to the 
distinct metabolic profiles of these animals.
C57Bl6 mice were classified as DIO or DR based on their weight gain during 
10 weeks of high fat feeding. Subsequently DIO mice were treated with the DRD2 
agonist bromocriptine and DR mice with the DRD2 antagonist haloperidol for 
2 weeks.
Compared to DR mice, the body weight of DIO mice was higher and their 
insulin sensitivity decreased. Haloperidol treatment reduced the voluntary 
activity and energy expenditure of DR mice and induced insulin resistance in 
these mice. Conversely, bromocriptine treatment tended to reduce body weight 
and voluntary activity, and reinforce insulin action in DIO mice.
These results show that DRD2 activation partly redirects high fat diet 
induced metabolic anomalies in obesity-prone mice. Conversely, blocking 
DRD2 induces an adverse metabolic profile in mice that are inherently resistant 
to the deleterious effects of high fat food. This suggests that dopaminergic 






Dopamine is intimately involved in the regulation of energy balance. Genetically 
engineered dopamine-deficient mice fail to initiate feeding and consequently 
die of starvation, unless L-DOPA, the precursor of dopamine, is provided 
daily1. Conversely, dopamine release in response to food intake induces satiety 
and reward2. Thus, dopamine plays an important dual role in the complex 
physiology driving meal initiation and termination. Moreover, dopaminergic 
neurotransmission profoundly affects glucose and lipid metabolism3.
Dopamine action is mediated by 5 distinct G-protein coupled receptor 
subtypes, functionally classified into 2 receptor families according to their 
effect on target neurons. Activation of dopamine receptor D2 (DRD2), D3 or D4, 
comprising the D2 family, inhibits adenylyl cyclase. Activation of the receptors 
belonging to the D1 family (DRD1 and DRD5) stimulates adenylyl cyclase4.
Dopaminergic transmission is altered in insulin resistant and obese animals. 
Basal and feeding evoked dopamine release is exaggerated in several nuclei of 
the hypothalamus of obese Zucker rats5-7, whereas DRD2 expression is reduced 
in hypothalamic nuclei of obese animal models8,9. The number of DRD2 binding 
sites in the striatum of obese humans is reduced and inversely correlated with 
body mass index10.
Modulation of DRD2 activity profoundly affects energy homeostasis in 
humans and animals. Drugs that block DRD2 enhance appetite and induce 
weight gain in animals and humans11-14. Conversely, DRD2 agonist drugs reduce 
body weight, increase energy expenditure and improve glycemic control in 
obese animals and individuals15-18. 
High fat feeding induces obesity, insulin resistance and diabetes in rodents. 
However, the amount of weight gained in response to a high fat diet varies 
considerably, even among animals with a genetically identical background19-21. 
Indeed, diet sensitive (diet induced obese, DIO) rodents display several 
alterations in pathways regulating energy homeostasis compared to diet 
resistant (DR) rodents21,22, and DIO and DR rodents differ with respect to 
various components of their dopaminergic system, even before the onset of 
obesity23,24. In particular, DIO mice and rats are characterized by an increased 
expression of dopamine transporter and reduced DRD2 expression23. In view 
of the evidence summarized above, altered DRD2 mediated neurotransmission 
could contribute to the metabolic phenotype of these animals. We hypothesized 
that modulation of dopaminergic transmission in DIO and DR mice with DRD2 
agonist or antagonist drugs would redirect the metabolic phenotypes of these 
mice. We particularly postulated that stimulation of DRD2 would ameliorate 
insulin resistance of DIO C57Bl6 mice, whereas DRD2 antagonism would induce 
insulin resistance in DR animals of the same strain. To address this hypothesis, 
DIO and DR mice were treated with bromocriptine, a DRD2 agonist, or 
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haloperidol, a DRD2 antagonist, respectively. After 1 week of treatment, energy 
metabolism was measured in a Comprehensive Laboratory Animal Monitoring 
System and after 2 weeks a hyperinsulinemic euglycemic clamp was performed 




Seventy-two male C57BL/6J mice (Charles River, Maastricht, The Netherlands), 
11 or 12 weeks old, were housed in a temperature- and humidity-controlled 
room on a 12-h light–dark cycle with free access to food and water, unless 
mentioned otherwise.
All animal experiments were performed in accordance with the principles 
of laboratory animal care and regulations of Dutch law on animal welfare, and 
the experimental protocol was approved by the Animal Ethics Committee of the 
Leiden University Medical Center.
Experimental design
All mice were maintained on a high fat diet (45 energy% of fat derived from 
palm oil, 35 energy% of carbohydrate and 20 energy% of protein; Research 
Diet Services, Wijk bij Duurstede, The Netherlands). After 10 weeks of high fat 
feeding, the 24 mice with the highest weight gain were classified as DIO mice 
and the 24 mice with the lowest weight gain were classified as DR mice. The 24 
mice with intermediate weight gain were not further used in this study.
DIO and DR mice were randomly divided into a placebo and treatment group. 
DR treated mice received haloperidol (1 mg/kg/day), DIO treated mice received 
bromocriptine (10 mg/kg/day) and DIO and DR placebo mice received placebo 
treatment. Subcutaneous implantable haloperidol, bromocriptine and placebo 
pellets (Innovative Research of America, Florida, USA), ensuring continuous 
release of the medication were used. Pellets were implanted under isoflurane 
anesthesia. Mice were treated for 2 weeks, meanwhile maintained on the high 
fat diet.
Measurement of energy metabolism
Mice were subjected to indirect calorimetric measurements for a period of 3 
consecutive days using a Comprehensive Laboratory Animal Monitoring System 
(CLAMS; Columbus Instruments, Ohio, USA). Due to a limited number of cages, 
eight mice per group were measured. Mice were allowed to acclimatize to the 
cages for a period of 14 hours prior to the start of the experiment. Measurements 
started at 7.00 am and continued for 72 hours. The CLAMS system enables 






and metabolic gas exchange. Oxygen consumption (VO2) and carbon dioxide 
production rates (VCO2) were measured at 7 minute intervals. The respiratory 
exchange rate (RER), as a measure for metabolic substrate choice, was calculated 
using the following formula:
RER = VCO2/VO2
Carbohydrate and fat oxidation rates were calculated from VO2 and VCO2 using 
the following formulas25:
Carbohydrate oxidation (kcal/h) = ((4.585*VCO2)-(3.226*VO2))*4/1000
Fat oxidation (kcal/h) = ((1.695*VO2)-(1.701*VCO2))*9/1000
VO2 and VCO2 are in ml/h.
Total energy expenditure was calculated as the sum of carbohydrate and fat 
oxidation. Activity was monitored by infrared beam breaks across the x- and 
y-axis. All energy metabolism data was calculated separately for day and night 
time.
DEXAscan
Body composition was measured by dual-energy X-ray absorptiometry (DEXA) 
using the Norland pDEXA Sabre X-Ray Bone Densitometer (Norland, Hampshire, 
UK). Before measuring, mice were anesthetized with a combination of 6.25 mg/
kg acepromazine (Alfasan, Woerden, The Netherlands), 6.25 mg/kg midazolam 
(Roche, Mijdrecht, The Netherlands) and 0.3125 mg/kg fentanyl (Janssen-Cilag, 
Tilburg, The Netherlands).
Hyperinsulinemic euglycemic clamp
Prior to the experiment, mice were fasted for 16 hours after food withdrawal 
at 5.00 pm. Hyperinsulinemic euglycemic clamp studies started at 9.00 am 
and were performed as described earlier26. During the experiment, mice 
were anesthetized with a combination of 6.25 mg/kg acepromazine (Alfasan, 
Woerden, The Netherlands), 6.25 mg/kg midazolam (Roche, Mijdrecht, 
The Netherlands) and 0.3125 mg/kg fentanyl (Janssen-Cilag, Tilburg, The 
Netherlands). First, the basal rate of glycerol turnover was determined by 
giving a primed (0.6 μCi) continuous (0.9 μCi/h) intravenous (i.v.) infusion 
of [1-(3)-3H]-Glycerol (GE Healthcare, Little Chalfont, UK) for 60 minutes. 
Subsequently, insulin (Novo Nordisk, Bagsværd, Denmark) was administered 
in a primed (4.5 mU) continuous (6.8 mU/h) i.v. infusion for 90 minutes to attain 
a steady state circulating insulin concentration of ~6 μg/l.
Every 10 min the plasma glucose concentration was determined via tail 
vein bleeding (< 3 µl) (Accu-chek, Sensor Comfort, Roche Diagnostics GmbH, 
Mannheim, Germany) and accordingly the i.v. infusion rate of a 12.5% D-glucose 
solution was adjusted to maintain euglycemia. Blood samples (60 µl) were taken 
during the basal period (at 50 and 60 min) and during the hyperinsulinemic 
period (at 70, 80, and 90 min) to determine plasma concentrations of glucose, 
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insulin, Non-Esterified Fatty Acids (NEFA), free glycerol and 3H-Glycerol specific 
activities. At the end of the clamp mice were sacrificed.
Analytical procedures
Commercially available kits were used to determine the plasma concentration 
of glucose (Instruchemie, Delfzijl, The Netherlands), NEFA (Wako, Nuess, 
Germany) and free glycerol (Sigma, MO, USA). The plasma insulin concentration 
was measured by an ELISA (Mercodia AB, Uppsala, Sweden). Total plasma 
3H-Glycerol was determined in plasma and in supernatant after trichloroacetic 
acid (20%) precipitation and water evaporation.
Calculations
The turnover rate of glycerol (µmol/min/kg) was calculated during the basal 
period and under steady-state hyperinsulinemic conditions as the rate of tracer 
infusion (dpm/min) divided by the plasma-specific activity of 3H-Glycerol 
(dpm/µmol). The turnover rates were corrected for body weight.
Statistical analysis
Data is presented as mean ± standard deviation. Statistical analysis was 
performed using SPSS. A one-way ANOVA was used for analysis of the data. If 
significant differences were found, the LSD method was applied as post-hoc 
test to determine differences between 2 groups. Statistical differences are 
only shown when apparent between DIO and DR placebo groups, between DIO 
placebo and bromocriptine groups or between DR placebo and haloperidol 
groups. Differences were considered statistically significant when p<0.05.
Results
Body weight and basal plasma metabolites
Mice were designated DIO or DR according to their weight gain following a 
10-week high fat diet. By definition, DIO mice had a significantly higher body 
weight compared to DR mice after this dietary pre-treatment (35.4±1.5 vs. 
30.6±1.9; p<0.001), which was completely accounted for by a difference in fat 
mass (fig 1B). Lean body mass did not differ (not shown). Two weeks of placebo 
treatment did not alter the difference in body weight between DIO and DR mice 
(fig 1A). Two weeks of bromocriptine treatment tended to induce weight loss in 
DIO mice (primarily fat mass, fig 1B), although the effect did not reach statistical 
significance. Haloperidol did not impact on the body weight of DR mice.
The fasting plasma glucose concentration was not different between 
placebo treated DIO and DR mice (fig 2A), whereas the fasting plasma insulin 
concentration was significantly elevated in DIO mice (fig 2B). Haloperidol 
significantly increased fasting plasma glucose and insulin concentrations in 






unchanged upon bromocriptine treatment. The fasting plasma NEFA 
concentration didn’t differ between the groups (fig 2C).
Figure 2 - Fasting plasma glucose (A), 
insulin (B) and NEFA (C) concentrations 
in DIO and DR mice after treatment with 
bromocriptine (BC), haloperidol (HP) or 
placebo (P) for 2 weeks. Data is presented 
as mean ± SD for 9 or 10 mice per group.




Figure 1 - Body weight (A) and fat mass (B) of DIO and DR mice after treatment with 
bromocriptine (BC), haloperidol (HP) or placebo (P) for 2 weeks. Data is presented as 
mean ± SD for 12 (A) or 10 (B) mice per group.
** p<0.01, *** p<0.001
A B
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Energy metabolism
After 1 week of treatment, whole body energy metabolism of mice was assessed 
with a Comprehensive Laboratory Animal Monitoring System using indirect 
calorimetry. Individual food intake, activity and respiratory gas exchange was 
monitored for 3 consecutive days. Cumulative food intake (fig 3A), voluntary 
activity (fig 3B,C), energy expenditure (fig 3D) as well as the carbohydrate 
oxidation rate (data not shown) did not differ between placebo treated DIO and 
DR mice. The diurnal fat oxidation rate tended to be higher in DIO mice, but this 
failed to reach statistical significance (fig 3E). Diurnal and nocturnal voluntary 
Figure 3 - Cumulative food intake (A), 
mean nocturnal (B) and diurnal x-axis 
activity (C), mean nocturnal energy 
expenditure (D) and mean diurnal fat 
oxidation rate (E) in DIO and DR mice 
after treatment with bromocriptine (BC), 
haloperidol (HP) or placebo (P) for 1 
week. Data is presented as mean ± SD for 
7 or 8 mice per group.










activity in DR mice was dramatically reduced by haloperidol (fig 3B,C), and this 
was accompanied by a reduction in whole body nocturnal energy expenditure 
(fig 3D). The impact of haloperidol on fat (fig 3E) and carbohydrate oxidation 
(data not shown) did not reach statistical significance. Food intake was not 
affected by haloperidol treatment (fig 3A). The diurnal voluntary activity 
tended to be lower in DIO mice receiving bromocriptine, but this also failed to 
reach statistical significance (fig 3C). Furthermore, bromocriptine treatment 
had no significant effect on food intake (fig 3A), energy expenditure (fig 3D), fat 
oxidation (fig 3E) or carbohydrate oxidation (data not shown).
Insulin action
After 2 weeks of treatment, mice were subjected to a hyperinsulinemic euglycemic 
clamp. Basal and hyperinsulinemic plasma glucose, insulin, free glycerol and 
NEFA concentrations are shown in table 1. The plasma NEFA concentration was 
reduced to the same extent in all groups during hyperinsulinemia.
The glucose infusion rate necessary to maintain euglycemia was significantly 
higher in DR compared to DIO mice (fig 4), which indicates that DIO mice were 
insulin resistant compared to DR animals. Haloperidol significantly diminished 
the glucose infusion rate in DR mice, reflecting a deterioration of insulin action, 
whereas bromocriptine tended to increase glucose infusion required to maintain 
euglycemia in DIO mice (indicating improved insulin action). The capacity of 
insulin to inhibit glycerol turnover was not different between DR and DIO mice 
and it was not affected by either drug (data not shown).
Table 1 - Plasma glucose, insulin, free glycerol and NEFA concentrations during the 
basal and hyperinsulinemic conditions of the hyperinsulinemic euglycemic clamp in 
DIO and DR mice after treatment with bromocriptine, haloperidol or placebo for 2 
weeks.
DIO mice DR mice
Clamp condition Placebo Bromocriptine Placebo Haloperidol
Glucose 
(mM)
B 5.9 ± 0.6 5.3 ± 1.1 5.0 ± 0.6 6.7 ± 1.7
HI 5.4 ± 0.7 5.6 ± 0.6 6.0 ± 0.7 4.8 ± 1.1
Insulin 
(μg/l)
B 2.4 ± 0.3 2.0 ± 0.8 1.6 ± 0.5 2.6 ± 0.7
HI 6.8 ± 1.9 7.2 ± 1.4 6.7 ± 1.3 7.1 ± 0.6
Free Glycerol 
(mM)
B 0.1 ± 0.1 0.1 ± 0.1 0.2 ± 0.1 0.2 ± 0.1
HI 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0
NEFA 
(mM)
B 1.0 ± 0.2 1.1 ± 0.3 1.1 ± 0.2 1.0 ± 0.3
HI 0.5 ± 0.1 0.5 ± 0.1 0.5 ± 0.2 0.5 ± 0.1
B, Basal; HI, Hyperinsulinemia
Data is measured in 9 or 10 mice per group and presented as mean ± SD.
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Discussion
The results presented here demonstrate that pharmacological modulation of 
dopaminergic transmission by a DRD2 agonist or antagonist can partly redirect 
the divergent metabolic phenotypes of DIO and DR mice. In particular, blocking 
dopaminergic transmission by means of haloperidol induces insulin resistance 
of glucose metabolism in DR mice. Conversely, activation of dopaminergic 
neurotransmission by bromocriptine tends to ameliorate insulin resistance 
in DIO animals. These data suggest that DRD2 mediated neurotransmission is 
involved in the control of glucose and insulin metabolism.
Although they have a genetically identical background, individual C57Bl6 
mice show distinct susceptibility to develop obesity and insulin resistance 
when maintained on a high fat diet. We classified mice as DIO or DR based on 
the amount of weight gained during 10 weeks of high fat feeding. DIO mice were 
insulin resistant compared to DR mice, as evidenced by higher fasting plasma 
insulin levels and a lower glucose infusion rate required to maintain euglycemia 
during insulin infusion. These findings are in accordance with other rodent 
studies19-21,24,27. Remarkably, there was no measurable difference in food intake, 
energy expenditure or voluntary physical activity in DIO compared to DR mice.
DIO mice have significantly lower DRD2 expression levels in certain brain 
areas compared to DR mice23. Also, dopamine turnover is reduced in hypothalamic 
nuclei of DIO rats even before the onset of obesity24 and the hypothalamus is 
intimately involved in the control of glucose and lipid metabolism28,29. Since 
pharmacological activation of DRD2 ameliorates insulin resistance in various 
obese animal models17,30, we hypothesized that modulation of DRD2 mediated 
neurotransmission could reverse the metabolic phenotypes of DIO and DR 
mice. In keeping with this hypothesis, blocking DRD2 by haloperidol induced 
insulin resistance in DR mice, whereas activation of DRD2 by bromocriptine 
tended to improve insulin sensitivity in DIO mice. In concert, these data suggest 
that DRD2 activation is involved in the control of glucose metabolism and that 
reduced dopaminergic transmission via DRD2 contributes to the metabolic 
Figure 4 - Glucose infusion rate during 
a hyperinsulinemic euglycemic clamp in 
DIO and DR mice after treatment with 
bromocriptine (BC), haloperidol (HP) or 
placebo (P) for 2 weeks. Data is presented 
as mean ± SD for 9 or 10 mice per group.






phenotype (insulin resistance) of obese animals.
However, we can not exclude the possibility that the observed effects of 
bromocriptine and haloperidol are (partly) mediated by receptors other than 
DRD2. Haloperidol is also known to have a high affinity for DRD3, DRD4 and 
adrenergic α1 receptors31 and bromocriptine also possesses high affinity 
for DRD3, the serotonergic 5-HT1A and 1D receptors and the adrenergic α1 
and α2 receptors32. Each of these receptors might participate in the impact 
of haloperidol and/or bromocriptine on energy and nutrient homeostasis. 
Adrenergic receptors (AR) are involved in the control of energy expenditure 
and glucose metabolism. Stimulation of α2-AR reduces spontaneous physical 
activity33 and impairs insulin secretion34-36. Accordingly, overexpression of 
α2A-AR is associated with glucose intolerance37. Stimulation of α1-AR, on the 
other hand, has a positive impact on glucose homeostasis by promoting glucose 
uptake by adipose and muscle tissue38-40 and absence of the α1B-AR leads to 
hyperinsulinemia and insulin resistance41. Acute stimulation of the 5-HT1A 
receptor increases food intake42,43, reduces plasma insulin levels and induces 
a concomitant rise in plasma glucose levels44,45. As far as we know, the specific 
impact of DRD3, DRD4 and 5-HT1D receptors on the regulation of energy and 
nutrient homeostasis is still unknown. Thus, the effects of bromocriptine and 
haloperidol we observe here may be the ultimate result of modulation of various 
of these receptor activities. 
The fact that haloperidol induced insulin resistance is consistent with 
literature reporting an increased incidence of diabetes among individuals 
treated with haloperidol46. Interestingly, treatment with haloperidol is not 
associated with (massive) weight gain in humans47, which also fits with our data 
and suggests that the drug hampers insulin action via mechanistic routes other 
than obesity. First, haloperidol dramatically reduced physical activity of DR mice. 
This is in agreement with a wealth of data from other animal experiments48,49. 
Diminished locomotor activity hampers insulin action in muscle50,51. Second, a 
major (side) effect of haloperidol treatment is elevation of prolactin levels52,53 
which may contribute to the induction of glucose intolerance and insulin 
resistance54,55. Third, haloperidol may alter glucose metabolism by modifying 
plasma levels of peptide hormones. The data documenting effects of haloperidol 
on leptin levels are inconsistent; increased56 as well as unchanged leptin levels 
in response to haloperidol treatment have been reported57,58. But, haloperidol 
seems to increase plasma ghrelin levels, while leaving levels of adiponectin, 
resistin and visfatin unaffected56. Both leptin and ghrelin may impact on 
insulin sensitivity directly59,60. Fourth, haloperidol may diminish glucose 
induced insulin secretion by blocking D2 receptors on pancreatic β-cells61,62, 
which leads to (postprandial) hyperglycemia. In the long run, hyperglycemia 
diminishes insulin action through “toxic” effects on insulin sensitive tissues63. 
Fifth, blockade of central DRD2 may induce insulin resistance via modulation 
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of autonomic nervous output to peripheral tissues (including muscle, adipose 
tissue and liver)64.
Bromocriptine treatment tended to improve insulin sensitivity of glucose 
metabolism in DIO animals, but its effect on glucose infusion rate did not reach 
statistical significance. It is important to note that the route of bromocriptine 
administration we used here may have diminished the efficacy of the drug. 
Indeed, it has been shown that subcutaneous, compared to intraperitoneal, 
administration of the drug limits its metabolic impact65. The tendency 
we observed though, is in line with data obtained in diet induced obese 
hamsters66, and genetically engineered obese mice67. In accordance, short term 
administration of bromocriptine ameliorates various metabolic anomalies 
in obese humans without affecting body weight18 and longer term treatment 
improves glycemic control and serum lipid profiles in patients with type 2 
diabetes68. In addition, DRD2 agonists improve glucose and lipid metabolism 
in patients with hyperprolactinemia69,70 and acromegaly71-73. Although DRD2 
agonists generally benefit nutrient metabolism, the use of these drugs is 
sometimes associated with the development of impulse control disorders, 
including binge and compulsive eating, in patients with Parkinson’s disease, 
which may lead to excessive weight gain and insulin resistance74,75.
The effects of bromocriptine on metabolism may be mediated by 
central dopamine receptors, as is suggested by Luo et al.17 who showed that 
intracerebroventricular administration of low dose bromocriptine during 
14 days improves insulin sensitivity in obese, insulin resistant, hamsters. 
However, peripheral receptors might also be involved. We previously reported 
that bromocriptine acutely impairs insulin secretion by stimulating the α2-AR 
on β-cells36. To explain that (sub)chronic bromocriptine treatment improves 
glucose metabolism15,66,76, we hypothesized that suppression of insulin secretion 
induces β-cell ‘rest’, which might allow β-cells to replenish insulin stores, 
thereby enhancing the secretory capacity in the long run77,78. It might also 
increase the number of organ specific insulin receptors leading to improved 
insulin sensitivity79,80. In addition, bromocriptine may alter glucose metabolism 
via modulation of circulating peptide levels. In obese women bromocriptine 
reduces leptin concentrations81; the biological relevance of this for the results 
reported by us is questionable however, as leptin improves insulin sensitivity59. 
The impact of bromocriptine on other regulatory peptide hormones remains to 
be determined.
In summary, activation of DRD2 tends to ameliorate the metabolic profile 
of DIO mice, whereas antagonism of these receptors induces insulin resistance 
in DR mice. In concert with previous findings by other groups indicating that 
dopaminergic (DRD2 mediated) neurotransmission is reduced in the brain of 
DIO mice, our data suggest that DRD2 mediated dopaminergic mechanisms 
may be involved in the development of the divergent metabolic phenotypes in 
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Effects of olanzapine and haloperidol on the 
metabolic status of healthy men
Journal of Clinical Endocrinology and Metabolism 
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Abstract
Background: A large body of evidence suggests that antipsychotic drugs cause 
body weight gain and type 2 diabetes mellitus, and atypical (new generation) 
drugs appear to be most harmful. The aim of this study was to determine the 
effect of short-term olanzapine (atypical antipsychotic drug) and haloperidol 
(conventional antipsychotic drug) treatment on glucose and lipid metabolism.
Research Design and Methods: Healthy normal weight men were treated 
with olanzapine (10 mg/day, n=7) or haloperidol (3 mg/day, n=7) for 8 days. 
Endogenous glucose production, whole body glucose disposal (by 6,6 2H2-
glucose dilution), lipolysis (by 2H5-glycerol dilution) and substrate oxidation 
rates (by indirect calorimetry) were measured before and after intervention in 
basal and hyperinsulinemic condition.
Results: Olanzapine hampered insulin-mediated glucose disposal (by 1.3 
mg/kg/min), while haloperidol did not have a significant effect. Endogenous 
glucose production was not affected by either drug. Also, the glycerol rate 
of appearance (a measure of lipolysis rate) was not affected by either drug. 
Olanzapine, but not haloperidol, blunted the insulin-induced decline of 
plasma free fatty acid and triglyceride concentrations. Fasting free fatty acid 
concentrations declined during olanzapine treatment, while they did not during 
treatment with haloperidol.
Conclusions: Short-term treatment with olanzapine reduces fasting plasma 
free fatty acid concentrations and hampers insulin action on glucose disposal in 
healthy men, whereas haloperidol has less clear effects. Moreover, olanzapine, 
but not haloperidol, blunts the insulin-induced decline of plasma free fatty acid 
and triglyceride concentrations. Notably, these effects come about without a 







Typical antipsychotic drugs (AP) have been the cornerstone of the medical 
management of patients with schizophrenia for a long time. The advent of 
atypical AP drugs has brought clear benefits for schizophrenic patients, as 
these compounds have less extrapyramidal side effects and ameliorate negative 
symptoms1. However, a large body of evidence suggests that the use of these 
drugs is associated with obesity2,3 and diabetes mellitus4. Several studies have 
looked at the metabolic effects of AP drugs in non-diabetic schizophrenic 
patients. The results consistently show that these drugs induce (euglycemic) 
hyperinsulinemia and impaired glucose tolerance5,6. Treatment with atypical AP 
drugs appears to be more harmful for glucose/lipid metabolism than treatment 
with conventional AP drugs5,7.
As obesity is a major risk factor for insulin resistance and type 2 diabetes8, it is 
tempting to postulate that weight gain induced by atypical AP drugs is primarily 
responsible for their unfavourable impact on these pathologies. However, this 
does not appear to be the case in studies evaluating this possibility2,9. Moreover, 
in a review of case reports, diabetes often developed after a short treatment 
period, in some cases without significant weight gain10. The metabolic profile 
often improved upon drug discontinuation, while re-challenge with the same 
drug resulted in recurrence of hyperglycemia10. Thus, AP drugs may act directly 
to induce insulin resistance and diabetes. Atypical AP drugs antagonize a broad 
range of monoamine neurotransmitter receptors. In addition to their relatively 
week affinity for dopamine D2 receptors, they have a strong affinity for 
serotonin 5-HT2, histamine H1, α1 adrenergic, and muscarinic M3 receptors, 
while typical AP drugs particularly antagonize dopamine D2 receptors. Indeed, 
various neurotransmitters whose signals are blocked by atypical but not typical 
AP drugs, are involved in the control of glucose metabolism11-15, which could 
mechanistically explain direct actions of olanzapine on insulin sensitivity.
We hypothesized that short-term treatment with AP drugs induces insulin 
resistance through a mechanistic route that is independent of weight gain and 
that atypical drugs exert stronger effects than typical compounds in this respect. 
To evaluate this hypothesis, we treated healthy non-obese men with olanzapine 
(atypical AP) or haloperidol (typical AP) for 8 days, and studied the impact 
of these interventions on glucose and lipid metabolism by hyperinsulinemic 
euglycemic clamp, isotope dilution technology and indirect calorimetry.
Subjects and Methods
Subjects
Fourteen healthy men between 20 and 40 years were recruited through 
advertisements in local newspapers. Subjects were required to have a normal 
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weight, normal fasting plasma glucose concentration (<6.0 mmol/l) and normal 
physical examination. Subjects who had ever used antipsychotic medication, 
and subjects who where currently smoking or using medication affecting the 
central nervous system were excluded. Subjects who dropped out (because of 
side effects) were replaced by other volunteers. All subjects provided written 
informed consent after the study procedures and possible adverse effects of the 
treatment had been explained. The protocol was approved by the medical ethics 
committee of the Leiden University Medical Center.
Clinical protocol
Subjects underwent a hyperinsulinemic euglycemic clamp at baseline and on 
the last day (day 8) of treatment with either olanzapine (10 mg once daily) or 
haloperidol (3 mg once daily). The drugs were taken at 8.00 am. The drug doses 
prescribed are in the low range of doses used for the treatment of patients 
with schizophrenia. On both study days, substrate oxidation was measured 
by indirect calorimetry (Oxycon ß; Jaeger Toennies, Breda, The Netherlands) 
in basal (after a 10 hr overnight fast) and hyperinsulinemic conditions. Body 
fat percentage was determined by bioelectrical impedance analysis (Bodystat® 
1500, Bodystat Limited, Dougles, Isle of Man, UK). Body mass index (weight/
length2) and waist/hip circumference were measured according to WHO 
recommendations. The subjects were asked to refrain from vigorous physical 
exercise for one week before each clamp. When the study drug was not tolerated, 
treatment was discontinued. Food intake was not monitored.
Hyperinsulinemic euglycemic clamp
[6,6-2H2]-glucose was infused in the basal state and during a hyperinsulinemic 
euglycemic clamp to determine the effect of insulin on peripheral glucose 
disposal and endogenous glucose production. Lipolysis was monitored by a 
primed continuous infusion of [2H5]-glycerol. At 7.30 am, after an overnight (10 
h) fast, subjects were admitted to the clinical research unit and asked to lie down 
in a semi-recumbent position. An i.v. catheter was placed in an antecubital vein 
for infusions. Another catheter was placed in the contra-lateral hand for blood 
sampling. This hand was placed in a heated box (60°C) to obtain arterialised 
venous blood samples.
The subjects were asked to take their last drug dose at 8.00 am. Thereafter, 
basal blood samples for glucose, insulin, FFA, lipid spectrum and background 
isotope enrichment of [6,6-2H2]-glucose and [2H5]-glycerol were taken. At 
t=0, a primed (26.4 μmol/kg) continuous (0.33 μmol/kg/min) infusion of 
[6,6-2H2]-glucose (enrichment 99.9%; Cambridge Isotopes, Cambridge, MA, 
USA) was started and continued throughout the clamp (4 h) to monitor glucose 
metabolism. At 9.00 am (t=60), a primed (1.6 μmol/kg) continuous (0.11 μmol/






throughout the clamp (3 h) to monitor lipolysis.
At t=90-120 min, 4 blood samples were taken with 10 minute intervals for 
determination of plasma glucose, insulin, glycerol, and enrichment of [6,6-2H2]-
glucose and [2H5]-glycerol. Subsequently (t=120), a primed continuous (40 mU/
m2/min) infusion of insulin (Actrapid, Novo Nordisk Pharma BV, Alphen aan de 
Rijn, The Netherlands) was started. Insulin was infused for 2 h. Blood glucose 
concentrations were measured every 5 minutes, and a variable infusion of 20% 
glucose (enriched with 3% [6,6-2H2]-glucose) was adjusted to maintain a stable 
blood glucose concentration (~5.0 mmol/l). By the end of the hyperinsulinemic 
clamp (t=210-240), blood was drawn every 10 minutes for determination of 
plasma glucose, insulin, glycerol, and enrichment of [6,6-2H2]-glucose and 
[2H5]-glycerol. Indirect calorimetry was performed for determination of resting 
energy expenditure, respiratory quotient (RQ), glucose and fat oxidation in 
basal condition (t=60-90) and during hyperinsulinemia (t=180-210).
Assays
Each tube, except the serum tubes, was immediately chilled on ice. Samples 
were centrifuged at 4000 rpm at 4° C for 20 min. Subsequently, plasma was 
divided into separate aliquots and frozen at –80° C until assays were performed.
Serum glucose, total cholesterol (TC) and HDL-cholesterol were measured 
in the laboratory for Clinical Chemistry at the Leiden University Medical Center, 
using a fully automated Hitachi Modular P800 system. LDL-cholesterol was 
measured with COBAS INTEGRA 800 (Roche Diagnostics, Mannheim, Germany).
Serum insulin was measured by immuno-radiometric assay (INS-IRMA; 
BioSource Europe S.A., Nivelles, Belgium) and serum glucagon was measured 
by radioimmunoassay (RIA; Medgenix, Fleurus, Belgium). Serum prolactin 
(PRL) concentrations were measured with a sensitive time-resolved 
fluoroimmunoassay with a detection limit of 0.04 µg/l (Delfia, Wallac Oy, Turku, 
Finland).
Plasma levels of free fatty acids (FFA) and triglycerides (TG) were determined 
using commercially available kits (Wako Pure Chemical Industries, Osaka, Japan 
and Roche Diagnostics).
Glucose and [6,6-2H2]-glucose enrichment as well as glycerol and [2H5]-
glycerol enrichment were determined in a single analytical run, using gas 
chromatography coupled to mass spectrometry (Hewlett-Packard, Palo Alto, 
CA, USA) as previously described16,17.
Calculations
In isotopic steady state condition, the rate of glucose disappearance (Rd) equals 
the rate of glucose appearance (Ra). Ra, which represents endogenous glucose 
production (EGP), was calculated by dividing the [6,6-2H2]-glucose infusion 
rate (mg/min) by the steady state plasma [6,6-2H2]-glucose tracer/tracee ratio. 
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During insulin infusion, Rd was calculated by adding the rate of exogenous 
glucose infusion to the Ra. The Ra of glycerol was calculated by dividing the 
[2H5]-glycerol infusion rate (μmol/min) by the steady-state plasma [2H5]-glycerol 
tracer/tracee ratio. Total lipid and carbohydrate oxidation rates were calculated 
as previously described18. Data are expressed per kilogram body weight.
Statistical analysis
The study was powered to detect a difference in glucose infusion rate before and 
after treatment with either drug. Eight subjects per group allowed detection of 
a 30% difference with 80% power at a 2-sided significance level of 0.05. Data 
is presented as mean ± standard error of the mean. Data were logarithmically 
transformed when appropriate. Comparisons were made within groups with 
two-tailed dependent Student’s t-test. To compare the effect of olanzapine 
and haloperidol treatment (between groups) an independent Student’s t-test 
was used; the difference of the values before and after each intervention was 
compared. When the distribution of data was not normal after logarithmic 
transformation they were analysed using non-parametric Wilcoxon signed-
rank test. Significance level was set at 0.05. All analyses were performed using 
SPSS for Windows, version 12.0 (SPSS Inc, Chicago, IL, USA).
Results
Subjects, anthropometric measures and plasma metabolites
Fourteen subjects were included in the study. Four subjects discontinued 
haloperidol treatment: 1 subject because of a vasovagal reaction when basal 
blood samples where taken at the first study day; 3 subjects because of the 
occurrence of side effects. Of those subjects, 2 subjects had acute dystonia, 
which was treated with anticholinergic drugs (Akineton® i.m.) and 1 subject 
discontinued treatment because of restlessness. All of these subjects were 
replaced by other volunteers. None of the subjects using olanzapine had major 
side effects. Five were somewhat drowsy during the first day of treatment only. 
The father of one subject in the haloperidol group was of Mediterranean origin 
(ethnicity may have impact on insulin sensitivity); all other subjects were of 
Caucasian origin. In the haloperidol group one subject had a father with type 
2 diabetes and in the olanzapine group one subject had a second degree family 
member with type 2 diabetes.
Table 1 summarizes anthropometric measurements and biochemical 
parameters in fasting condition on day 0 and day 8 in both groups. Baseline 
characteristics, including risk factors for insulin resistance (i.e. anthropometrics, 
ethnicity, family history of type 2 diabetes, fasting insulin and glucose levels), 
did not differ between the treatment groups. Body weight and waist-hip ratio 






slightly during treatment with haloperidol. Fasting plasma insulin and glucose 
levels did not change during treatment in either group. FFA concentrations 
significantly declined during olanzapine treatment (p=0.03). This effect did not 
differ significantly from the effect of haloperidol treatment. Serum glucagon 
concentrations were significantly elevated by olanzapine treatment, but the 
difference with the effect of haloperidol did not reach statistical significance. 
Plasma prolactin concentrations were increased during treatment in both 
groups (olanzapine p=0.002 and haloperidol p=0.01), which indicates that the 
drugs were properly taken.
Endogenous glucose production and whole body glucose disposal
Basal condition
Serum glucose and insulin concentrations in basal condition did not change 
in response to either treatment (table 1). Accordingly, endogenous glucose 
production was not affected by olanzapine or haloperidol (table 2 and figure 1).
Table 1 - Subject characteristics; before and after treatment with olanzapine or 
haloperidol.
Olanzapine (n=7) Haloperidol (n=7)
 Day 0 Day 8 Day 0 Day 8
Age (yr) 25.7 ± 1.3 23.7 ± 1.3
Body weight (kg) 76.7 ± 3.4 77.4 ± 3.3 76.8 ± 2.2 76.6 ± 2.2
BMI (kg/m2) 22.3 ± 0.7 22.5 ± 0.6 22.9 ± 0.8 22.8 ± 0.9
WHR 0.82± 0.02 0.83 ± 0.02 0.79 ± 0.02 0.80 ± 0.02
Fat (%) 9.1 ± 0.7 9.3 ± 1.2 10.6 ± 1.3 8.9 ± 1.5*
Glucose (mmol/l) 4.9 ± 0.2 5.1 ± 0.2 5.1 ± 0.1 4.9 ± 0.1
Insulin (mU/l) 10.2 ± 1.2 11.5 ± 1.9 8.3 ± 0.8 7.6 ± 0.6
Glucagon (pg/ml) 54.3 ± 4.7 68.5 ± 6.6* 50.9 ± 5.2 53.9 ± 4.3
Prolactin (μg/l) 9.0 ± 1.9 16.3 ± 3.1** 8.8 ± 1.5 15.2 ± 1.9*
TG (mmol/l) 1.22 ± 0.20 1.33 ± 0.18 1.16 ± 0.12 1.32 ± 0.30
FFA (mmol/l) 0.58 ± 0.10 0.43 ± 0.10* 0.51 ± 0.08 0.53 ± 0.08
Total cholesterol 
(mmol/l)
4.3 ± 0.3 4.2 ± 0.2 3.8 ± 0.3 3.9 ± 0.2
BMI, body mass index; FFA, free fatty acids; TG, triglycerides; WHR, waist hip ratio. 
Values are expressed as mean ± SEM.
* p < 0.05, ** p < 0.01 vs baseline
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Hyperinsulinemic euglycemic clamp
Data on glucose metabolism during insulin infusion is shown in table 2. Serum 
glucose concentrations were clamped at similar levels on both study days. Also, 
plasma insulin concentrations during insulin infusion were in the postprandial 
range and similar on both days (table 2). Background enrichment of 6.6-2H2 
glucose (% of total glucose) was similar on both study occasions (olanzapine 
day 0: 1.33 x 10-2 ± 0.07 x10-2, day 8: 1.29 x 10-2 ± 0.04 x 10-2; haloperidol day 0: 
1.31 x 10-2 ± 0.02 x 10-2, day 8: 1.32 x 10-2 ± 0.03 x 10-2).
The glucose infusion rate (GIR) required to maintain euglycemia during 
hyperinsulinemia was reduced after olanzapine treatment (figure 1). Although 
haloperidol did not affect the GIR to a significant extent, the magnitude of its 
effect did not differ significantly from that of olanzapine. The capacity of insulin 
to suppress endogenous glucose production (EGP) was not affected by either 
treatment (figure 1). Glucose disposal during hyperinsulinemia was significantly 
blunted by olanzapine treatment (figure 1). Again, although haloperidol did not 
affect glucose disposal to a significant extent, the magnitude of its effect did not 
differ significantly from that of olanzapine.
Lipid metabolism
Basal condition
In fasting condition plasma FFA concentrations significantly decreased during 
olanzapine treatment, and this effect did not differ from that of haloperidol 
despite the fact that haloperidol’s impact did not reach statistical significance. 
Fasting TG concentrations (table 1) and basal glycerol Ra (table 2) were not 
affected by either drug.
Figure 1 - GIR, EGP basal (B), EGP hyperinsulinemia (HI) and glucose disposal (Rd) 
before and after 8-d treatment with olanzapine and haloperidol. Values are expressed 
as mean ± SD, n=7 per group.
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Hyperinsulinemic euglycemic clamp.
Data on lipid metabolism during insulin infusion is shown in table 2. Insulin 
significantly suppressed the glycerol Ra in the haloperidol treated group 
(p=0.028 on day 0 and p=0.018 on day 8) , but not in the olanzapine treated 
group (p=0.071 on day 0 and p=0.379 on day 8). During hyperinsulinemia, the 
decline of circulating FFA and TG levels, expressed as percentage of basal value, 
was significantly blunted by olanzapine, whereas the decline of circulating FFA 
and TG was not affected by treatment with haloperidol. Thus, the propensity of 
olanzapine to blunt the decline of circulating FFA and TG by hyperinsulinemia 
differed significantly from the effect of haloperidol.
Glucose and lipid oxidation rate
Table 3 provides an overview of the effects of both drugs on substrate oxidation. 
Resting energy expenditure, RQ, and lipid and glucose oxidation rate were not 
affected by either drug.
Discussion
To establish the early effects of antipsychotic drugs on glucose and lipid 
metabolism, we treated healthy young men with 10 mg olanzapine or 3 mg 
Table 3 - Fuel oxidation before and after treatment with olanzapine or haloperidol.
Olanzapine (n=7) Haloperidol (n=7)
Day 0 Day 8 Day 0 Day 8
RQ
B 0.83 ± 0.015 0.87 ± 0.026 0.82 ± 0.011 0.83 ± 0.012
HI 0.86 ± 0.020 0.92 ± 0.034 0.86 ± 0.018 0.86 ± 0.017
Glucose oxidation (mg/kg/min)
B 1.92 ± 0.25 2.62 ± 0.52 1.85 ± 0.18 2.07 ± 0.18
HI 2.92 ± 0.37 3.60 ± 0.68 2.63 ± 0.28 2.87 ± 0.28
Lipid oxidation (mg/kg/min)
B 1.04 ± 0.09 0.76 ± 0.14 1.06 ± 0.07 1.04 ± 0.09
HI 0.83 ± 0.11 0.48 ± 0.20 0.94 ± 0.12 0.93 ± 0.14
REE (kcal/day)
B 1344.3 ± 36.4 1351.7 ± 79.9 1303.9 ± 35.3 1341.8 ± 26.6
HI 1382.7 ± 38.3 1457.1 ± 64.9 1430.6 ± 54.0 1493.1 ± 56.1
B, basal; HI, hyperinsulinemia; RQ, respiratory quotient; REE, resting energy 





haloperidol once daily for only 8 days. Olanzapine significantly reduced the 
glucose infusion rate required to maintain euglycemia during insulin infusion, 
indicating that the drug induces whole body insulin resistance. Specifically, 
olanzapine reduced insulin mediated glucose disposal, whereas it did not affect 
insulin’s capacity to suppress EGP. These effects did not differ from those of 
haloperidol to a significant extent, although the glucose infusion rate and 
disposal during haloperidol treatment were not significantly different from 
baseline. Olanzapine also curtailed the decline of circulating FFA and TG during 
hyperinsulinemia, whereas it did not affect the glycerol rate of appearance or 
the ability of insulin to inhibit this measure of the rate of lipolysis. Notably, 
these metabolic effects occurred without a measurable effect on body weight or 
body fat mass, although the waist circumference increased slightly in response 
to olanzapine treatment. In clear contrast, haloperidol did not affect the insulin-
induced decline of FFA and TG concentrations.
Effects on glucose metabolism
These data indicate that olanzapine hampers insulin action on glucose disposal, 
while the effect of haloperidol was less clear. This inference is consistent with 
data from large epidemiological studies19-21, showing that patients treated with 
atypical antipsychotic drugs are more likely to develop diabetes mellitus than 
patients treated with typical AP drugs. Also in line with our data, Newcomer 
et al7 reported that schizophrenic patients treated with olanzapine are more 
insulin resistant than patients treated with typical AP drugs, as estimated by i.v. 
glucose tolerance test. Relatively few studies have looked at the metabolic effects 
of AP drugs in healthy subjects. Sowell et al22 assessed meal tolerance and insulin 
sensitivity, using a 2-step hyperinsulinemic euglycemic clamp and a mixed meal 
tolerance test (MMTT), in normal subjects after 3 weeks of olanzapine (10 mg/
day; n=22), risperidone (4 mg/day; n=14) or placebo (n=19) treatment. The 
glucose infusion rate required to maintain euglycemia during hyperinsulinemia 
was not affected by either treatment, suggesting that the drugs did not impact 
on insulin action. However, treatment with olanzapine significantly increased 
fasting insulin and glucose levels, while treatment with risperidone or placebo 
did not. Also, there was a significant increase of the glucose area under the 
plasma concentration curve in response to the MMTT in the group treated 
with olanzapine. These data are quite difficult to reconcile. Moreover, glucose 
disposal and EGP were not determined in this study. In full agreement with our 
data, 10 days of olanzapine treatment was recently reported to decrease the 
glucose infusion rate required to maintain euglycemia in healthy men23. EGP 
and glucose disposal were not determined in this study.
The (sub)acute nature of the inhibitory impact of olanzapine treatment on 
glucose disposal is consistent with clinical data indicating that atypical AP drugs 
can induce hyperglycemia within a couple of weeks, before significant weight 
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gain has occurred10. Moreover, it corroborates papers reporting that proximate 
measures of insulin resistance do not correlate with BMI in schizophrenic 
patients treated with atypical AP drugs2,9. Also, Dwyer et al.24 reported that 
atypical AP drugs acutely (<3 h) induce hyperglycemia in mice, while typical 
AP drugs do not. The ability of these medications to induce hyperglycemia 
in vivo was tightly correlated with their effect on glucose transport in 
pheochromocytoma (PC12) cells in vitro24. However, PC12 cells do not express 
the GLUT4 transporter, which is abundant in muscle and responsive to insulin25, 
and the concentration of drugs required to block glucose uptake in these cell 
systems is generally very high26. Thus, although clozapine and fluphenazine 
were shown to also block glucose transport in a rat muscle cell line in vitro27, the 
relevance of these findings for the mechanistic explanation of our data remains 
uncertain.
Alternatively, our observations may be explained by the distinct receptor 
affinity profiles of olanzapine and haloperidol. Haloperidol particularly 
antagonizes dopamine D2 receptors, whereas olanzapine also blocks serotonin 
5-HT2, histamine H1, α1 adrenergic, and muscarinic M3 receptors28. Activation 
of all of these receptor (sub)types, including the dopamine D2 receptor29, 
generally inhibits food intake, reduces body weight and/or enhances insulin 
secretion30-33. Notably, various receptors blocked by olanzapine appear to 
be directly (i.e. independent of their effects on body weight) involved in the 
regulation of glucose metabolism. Indeed, imipramine induces hyperglycemia 
in mice by blocking 5-HT2 receptors14, and a single dose of ketanserin, a 5-HT2A 
receptor antagonist, impairs insulin action on glucose metabolism in healthy 
humans12. Blocking H1 receptors in cardiac muscle tissue impairs glucose 
uptake15, whereas, in apparent contradiction, activation of H1 receptors in the 
brain acutely elevates plasma glucose levels34. Thus, the H1 receptor has multiple, 
apparently opposite roles in the control of glucose metabolism. Activation of 
dopamine D2 receptors ameliorates insulin resistance in obese women through 
a mechanism that is independent of body weight13 and D2 receptor binding 
sites are reduced in the brain of obese animal models and humans29. Finally, a1-
adrenergic receptor knock out mice are glucose intolerant11 and a1-adrenergic 
receptors stimulate glucose uptake in muscle cells35. Thus, antagonism of either 
one of these receptors, alone or in combination, by olanzapine may hamper 
insulin action and explain our findings.
Effects on lipid metabolism
Neither drug affected insulin’s capacity to suppress lipolysis. Olanzapine, but 
not haloperidol decreased FFA concentrations in fasting condition (although 
group differences did not reach statistical significance). Moreover, it curtailed 
the decline of circulating FFA and TG concentrations during hyperinsulinemia, 






our findings, olanzapine was shown to reduce FFA concentration in a recent 
comprehensive evaluation of lipid changes in schizophrenia36. The cause of 
these changes in lipid metabolism remains to be established. We speculate that 
olanzapine inhibits lipoprotein lipase (LPL) activity in muscles and impairs 
the stimulatory action of insulin on LPL in adipose tissue. LPL hydrolyses the 
triacylglycerol component of circulating lipoprotein particles, chylomicrons 
and very low density lipoprotein, to provide FFA for tissue utilisation. In fasting 
condition, LPL is active in muscle and inhibited in adipose tissue, whereas 
(postprandial) hyperinsulinemia stimulates LPL in adipose tissue and inhibits 
LPL activity in muscle37,38. Reduced LPL activity in muscle may therefore reduce 
plasma FFA concentrations and impair fatty acid oxidation in fasting condition. 
Reduced LPL activity in adipose tissue would explain the blunted decline of 
plasma FFA and TG during hyperinsulinemia. Inhibition of LPL activity could 
either result from direct effects of the drug or be secondary to its effect on 
circulating prolactin levels. Hyperprolactinemia has been reported to inhibit 
LPL activity in adipose tissue in humans39 and rodents40.
In aggregate, these data suggest that olanzapine impairs insulin action on 
glucose and lipid disposal in muscle and adipose tissue, whereas it does not affect 
insulin’s capacity to inhibit glucose production or lipolysis. Notably, these are 
early metabolic effects of olanzapine, which occur without a measurable change 
of body fat mass. Our findings may explain the property of olanzapine to induce 
dyslipidemia and diabetes mellitus in the long term. Short term haloperidol 
treatment does not appear to affect lipid metabolism, which corroborates the 
notion that typical antipsychotic drugs are less harmful in a metabolic context.
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The dopamine receptor D2 agonist 
bromocriptine inhibits glucose-stimulated 
insulin secretion by direct activation of the 
α2-adrenergic receptors in beta cells
Biochemical Pharmacology 2010; 79: 1827-1836









Treatment with the dopamine receptor D2 (DRD2) agonist bromocriptine 
improves metabolic features in obese patients with type 2 diabetes by a still 
unknown mechanism. In the present study, we investigated the acute effect of 
bromocriptine and its underlying mechanism(s) on insulin secretion both in 
vivo and in vitro.
For this purpose, C57Bl6 mice were subjected to an intraperitoneal glucose 
tolerance test (ipGTT) and a hyperglycemic (HG) clamp 60 min after a single 
injection of bromocriptine or placebo. The effects of bromocriptine on glucose-
stimulated insulin secretion (GSIS), cell membrane potential and intracellular 
cAMP levels were also determined in INS-1E beta cells.
We report here that bromocriptine increased glucose levels during the 
ipGTT in vivo, an effect associated with a dose-dependent decrease in GSIS. 
During the HG clamp, bromocriptine reduced both first-phase and second-
phase insulin response. This inhibitory effect was also observed in INS-1E 
beta cells, in which therapeutic concentrations of bromocriptine (0.5-50 
nM) decreased GSIS. Mechanistically, neither cellular energy state nor cell 
membrane depolarization was affected by bromocriptine, whereas intracellular 
cAMP levels were significantly reduced, suggesting involvement of G-protein-
coupled receptors. Surprisingly, the DRD2 antagonist domperidone did 
not counteract the effect of bromocriptine on GSIS, whereas yohimbine, an 
antagonist of the α2-adrenergic receptor, completely abolished bromocriptine-
induced inhibition of GSIS.
In conclusion, acute administration of bromocriptine inhibits GSIS by a 
DRD2-independent mechanism involving direct activation of the pancreatic α2-
adrenergic receptors. We suggest that treatment with bromocriptine promotes 
beta cells rest, thereby preventing long-lasting hypersecretion of insulin and 







Type 2 diabetes, which is often associated with obesity and dyslipidemia, is 
characterized by insulin resistance, glucose intolerance and a progressive 
deterioration of beta cell mass and function1. The central and peripheral 
dopaminergic system is involved in the regulation of whole-body fuel and 
energy homeostasis2,3. Besides its role in the control of complex processes 
driving feeding behavior, dopaminergic neurotransmission affects both glucose 
and lipid metabolism. Alterations of this central regulatory pathway have 
been reported in insulin-resistant rodent models4-6 and patients with type 2 
diabetes7,8.
Dopamine action is mediated by 5 distinct G-protein coupled receptor 
subtypes belonging to 2 receptor families according to their effect on target 
neurons. Activation of dopamine receptors D2, D3 or D4, classified as the D2 
family, inhibits adenylyl cyclase activity and cyclic AMP (cAMP) synthesis9. 
By contrast, activation of the receptors belonging to the D1 family (DRD1 and 
DRD5) leads to stimulation of adenylyl cyclase and cAMP generation9.
Modulation of DRD2 activity profoundly affects energy homeostasis. Indeed, 
antipsychotic drugs antagonizing DRD2 enhance appetite and body weight gain 
in both animals10 and humans11. Conversely, the DRD2 agonist bromocriptine, a 
semi-synthetic ergot alkaloid used in the treatment of Parkinson’s disease and 
hyperprolactinemia, exerts opposite beneficial effects on energy homeostasis. 
For instance, prolonged administration of bromocriptine normalizes elevated 
plasma glucose and insulin concentrations and improves both glucose tolerance 
and insulin sensitivity in obese insulin-resistant rodents12,13 and humans14,15. 
Furthermore, long-term treatment with bromocriptine improves pancreatic 
beta cell function and increases the islet insulin content in obese insulin-
resistant mice12,16,17. However, the underlying mechanism(s) associated with 
these beneficial effects remains poorly understood. Interestingly, it has been 
recently demonstrated that all dopaminergic receptor subtypes are widely 
expressed on pancreatic beta cells, suggesting that at least some of the metabolic 
effects of bromocriptine could result from direct interaction with DRD2 on beta 
cells18. Accordingly, dopamine, as well as several synthetic analogues and the 
DRD2 agonist quinpirole, inhibit insulin secretion in beta cell lines and isolated 
islets from rodents18-20.
Here, we hypothesized that one of the early steps involved in the beneficial 
effects of  bromocriptine on glucose homeostasis could be linked to modulation 
of insulin secretion following direct activation of DRD2 in pancreatic beta cells. 
To address this issue, the acute effect of bromocriptine on insulin secretion was 
investigated by means of a glucose tolerance test and hyperglycemic clamp in 
C57Bl6 mice and the underlying molecular mechanism(s) was studied in INS-
1E beta cells.
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Materials and methods
Chemicals
Bromocriptine (2-Bromo-α-ergocryptine methanesulfonate salt), domperidone, 
yohimbine, hGLP-1 7-36 amide and 3-isobutyl-1-methylxanthine (IBMX) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). For the in vivo experiments, 
bromocriptine was dissolved in water containing 5% (v/v) DMSO. Domperidone 
was dissolved in water containing 5% (v/v) DMSO and acidified with HCl until 
pH 4. Water containing 5% (v/v) DMSO was used as placebo for both drugs.
Animals
Twelve-week-old male C57BL/6J mice (Charles River, Maastricht, The 
Netherlands) were housed in a temperature- and humidity-controlled room 
on a 12-h light–dark cycle with free access to standard laboratory chow (RM3; 
Special Diets Services, Witham, UK) and water. All animal experiments were 
performed in accordance with the principles of laboratory animal care and the 
regulations of Dutch law on animal welfare, and the experimental protocol was 
approved by the Animal Ethics Committee of the Leiden University Medical 
Center.
Experimental design
For determination of the acute effects of bromocriptine on glucose and 
insulin homeostasis, mice were randomly assigned to groups receiving either 
bromocriptine (10 or 25 mg/kg BW12,21) or placebo. They were first subjected 
to an intraperitoneal glucose tolerance test (ipGTT) and subsequently, after a 
wash-out period of 2 weeks, to a hyperglycemic clamp (HG clamp). One hour 
before the start of the experiments (t=-60 min), a baseline blood sample was 
taken, immediately followed by an i.p. injection of either bromocriptine or 
placebo. At t=0 min the ipGTT or the HG clamp was started, as described below. 
The blood samples taken at t=-60 min and t=0 min were used to determine the 
basal effect of bromocriptine on plasma glucose and insulin levels.
Another group of mice was used to determine the impact of the DRD2 
antagonist domperidone on bromocriptine-induced metabolic effects. The 
design of these experiments was similar to the one described above, except 
that domperidone (5 mg/kg BW22,23) or placebo was injected 30 min before 
bromocriptine administration (t=-90 min).
Intraperitoneal Glucose Tolerance Test
Nine mice per group were fasted for 16 hours after food withdrawal at 5.00 pm. 
At 9.00 am the next day, mice were injected with the drugs as described above 
and subjected to an ipGTT. This procedure began with the collection of a blood 






provided as a 20% solution in PBS. Additional blood samples (30 μl) were 
taken via tail bleeding at 5, 15, 30, 45, 60, and 120 min after glucose injection 
for measurement of plasma glucose and insulin concentrations.
Hyperglycemic clamp
Eleven mice per group were fasted for 16 hours after food withdrawal at 5.00 pm. 
At 9.00 am the next day, mice were injected with the drugs as described above 
and then subjected to a HG clamp. During the clamp, mice were anesthetized 
with a combination of 6.25 mg/kg acepromazine (Alfasan, Woerden, The 
Netherlands), 6.25 mg/kg midazolam (Roche, Mijdrecht, The Netherlands) and 
0.3125 mg/kg fentanyl (Janssen-Cilag, Tilburg, The Netherlands). An initial 
blood sample (t=0 min) was taken, immediately followed by a primed (30 or 20 
mg for placebo and bromocriptine groups, respectively), continuous (10 mg/h) 
intravenous (i.v.) infusion of a 20% D-Glucose solution. To maintain a steady state 
blood glucose concentration of ~20 mM, the continuous glucose infusion rate 
was adjusted according to the glucose concentration measured via tail bleeding 
(Accu-chek, Sensor Comfort, Roche Diagnostics GmbH, Mannheim, Germany) at 
1, 5, 20, 35, 50, 70 and 90 min after the glucose bolus. Blood samples (30 μl) for 
the measurement of plasma glucose and insulin concentrations were taken at 
1, 5, 20, 50, 70 and 90 min after the start of the clamp. The blood sampling at 
90 min was immediately followed by an i.v. injection of 2.1 mmol/kg L-arginine 
(Sigma-Aldrich), in order to assess maximal insulin secretion. Two additional 
blood samples were taken at 5 and 20 min after the injection.
Analytical procedures
Plasma insulin and glucose concentrations were measured using commercially 
available kits (Insulin: Crystal Chem Inc., Downers Grove, IL, USA; Glucose: 
Instruchemie, Delfzijl, The Netherlands).
INS-1E cells
The rat insulinoma-derived INS-1E cell line was used as a well differentiated 
beta cell clone24 and cultured in a humidified atmosphere containing 5% CO2 in 
RPMI 1640 medium (Invitrogen, Breda, The Netherlands) supplemented with 
10 mM Hepes, 5% (v/v) heat-inactivated fetal calf serum, 2 mM glutamine, 1 mM 
sodium pyruvate, 50 µM 2-mercaptoethanol, 100 units/ml penicillin and 100 
mg/ml streptomycin (Invitrogen, Breda, The Netherlands). The maintenance 
culture was split once a week by gentle trypsinization, and 3x106 cells were 
seeded in 75-cm2 Falcon bottles (BD Biosciences, Breda, The Netherlands) with 
20 ml complete medium. For experiments, INS-1E cells were seeded at 2x105 
cells/1 ml in Falcon 24-well plates (insulin secretion, cell membrane potential 
and cAMP determination) or 9x105 cells/2 ml in Falcon 6-well plates (Western 
blot) and used 4 days later, with one medium change on day 3.
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Insulin secretion
Insulin secretion in response to glucose or other secretagogues was measured 
in INS-1E cells between passages 53-67. Before the experiments, cells were 
maintained for 2 h in glucose-free culture medium. The cells were then washed 
twice and pre-incubated for 30 min at 37°C in glucose-free Krebs-Ringer 
bicarbonate HEPES buffer (KRBH: 135 mM NaCl, 3.6 mM KCl, 5 mM NaHCO3, 
0.5 mM NaH2PO4, 0.5 mM MgCl2, 1.5 mM CaCl2, 0.1% BSA and 10 mM HEPES, pH 
7.4) in the presence or absence of various drugs, as indicated. Next, cells were 
washed once with glucose-free KRBH and incubated for 30 min in KRBH with 
or without various drugs and secretagogues, as indicated. Then, plates were 
placed on ice and the supernatants were collected for determination of insulin 
secretion. Cellular insulin content was measured in acid-ethanol extracts24. 
Insulin concentrations were measured after appropriate dilution (1/20 and 
1/400 for supernatant and acid-ethanol extract, respectively) using a rat/
mouse ELISA kit (Millipore, Nuclilab, Ede, The Netherlands). 
Cell membrane potential and cAMP levels 
Cell membrane potential was monitored in INS-1E cells using 100 nM of the 
fluorescent probe bis-oxonol (bis-(1,3-diethylthiobarbituric acid)trimethine 
oxonol) (Molecular Probes, Leiden, The Netherlands) in a temperature-controlled 
(37°C) plate reader fluorimeter with excitation and emission wavelengths of 
544 and 590 nm, respectively18. For cAMP measurements, INS-1E cells were 
incubated in the same conditions as for GSIS experiments, but in the presence 
of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX, 1 
mM). At the end of incubation, cells were lysed following the manufacturer’s 
instructions and cAMP levels were determined using an enzyme immunoassay 
kit (Amersham Biosciences, Roosendaal, The Netherlands).
Western blot analysis
INS-1E cells were incubated in the same conditions as for GSIS experiments. 
At the end of incubation, cells were washed once in PBS and then lysed in 400 
ml of a buffer containing 10% (w/v) glycerol, 3% (w/v) SDS and 100 mM Tris-
HCl (pH 6.8). The homogenates were immediately boiled for 5 min and then 
centrifugated (13.200 rpm; 2 min). Protein content of the supernatant was 
determined using a bicinchoninic acid protein assay kit (Pierce, Rockford, IL, 
USA). Proteins (10 mg) were separated by SDS-PAGE followed by transfer to 
a PVDF membrane. Membranes were blocked for 1 h at room temperature in 
TBST buffer (10 mM Tris-HCl (pH 7.4), 150 mM NaCl, and 0.1% (v/v) Tween 
20 containing 5% (w/v) fat free milk) and incubated overnight with primary 
antibodies (all from Cell Signalling, Danvers, MA, USA). Blots were then washed 
in TBST buffer and incubated with horseradish peroxidase (HRP)-conjugated 






developed using enhanced chemiluminescence and quantified by densitometry 
analysis using Image J software (NIH, Bethesda, MD, USA).
Statistical analysis
Data is presented as mean ± SEM. Statistical analysis was conducted with 
SPSS 16.0 software. The basal effect of treatment on glucose and insulin 
concentrations was analyzed with a univariate General Linear Model, with 
pre-injection values as a covariate. Analysis of the remaining in vivo data 
was performed using a one-way ANOVA. Only if the overall F-test indicated 
significant differences between the groups, a Bonferroni post-hoc test was used 
to determine differences between specific groups. Statistical analysis of most 
of the in vitro data was performed using a two-tailed unpaired Student’s t-test. 
The membrane potential data was analyzed with a General Linear Model for 
repeated measures. Differences were considered statistically significant when 
p<0.05.
Results
Acute effects of bromocriptine on glucose tolerance and insulin secretion in 
mice
To investigate the effects of bromocriptine on glucose homeostasis, overnight-
fasted C57Bl6 mice received a single i.p. injection of the drug (10 or 25 mg/kg 
BW) or placebo and were subjected to an ipGTT one hour later. As shown in 
table 1, bromocriptine induced a dose-dependent rise in basal plasma glucose 
levels. During the ipGTT, plasma glucose and insulin levels were determined 
at different time points and their respective areas under the curve (AUC) were 
calculated (fig 1). Glucose levels were significantly elevated by bromocriptine 
(fig 1A,B; +48% and +50% for AUC glucose at 10 and 25 mg/kg BW, respectively; 
Table 1 - Plasma glucose and insulin levels in fasted mice before and 60 min after a 
single i.p. injection of bromocriptine or placebo.
Glucose (mM) Insulin (ng/ml)
Before 
injection




60 min after 
injection
Placebo 3.3 ± 0.2 4.2 ± 0.2 0.16 ± 0.04 0.19 ± 0.05
Bromocriptine 
10 mg/kg 3.9 ± 0.2 5.1 ± 0.3 0.13 ± 0.03 0.17 ± 0.05
Bromocriptine 
25 mg/kg 3.7 ± 0.3 5.8 ± 0.2** 0.13 ± 0.04 0.27 ± 0.06
Data is expressed as mean ± SEM, n=8-9 mice per group.
** p<0.01 vs placebo
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p<0.01), indicating impaired glucose tolerance. Concomitantly, bromocriptine 
delayed and reduced the rise in plasma insulin levels after the glucose challenge 
(fig 1C). Total insulin release, calculated as AUC, was thus decreased by 
bromocriptine (fig 1D; -19% (NS) and -58% (p<0.05) at 10 and 25 mg/kg BW, 
respectively).
To further assess the effect of bromocriptine on glucose-stimulated insulin 
secretion (GSIS), we performed a hyperglycemic (HG) clamp in similar conditions, 
i.e. one hour after i.p. administration of bromocriptine or placebo in overnight-
fasted C57Bl6 mice. Plasma glucose levels were successfully clamped at 20 
mM in both placebo and bromocriptine-injected mice (fig 2A). We confirmed 
that bromocriptine strongly affected GSIS (fig 2B). Indeed, insulin release was 
significantly and dose-dependently decreased during both first-phase (fig 2D; 
-58% (p=0.064) and -79% (p<0.01) for AUC insulin at 10 and 25 mg/kg BW, 
respectively) and second-phase GSIS (fig 2E; -51% and -70% for AUC insulin 
Figure 1 - Effects of acute injection of bromocriptine on plasma glucose and 
insulin kinetics in mice during an intraperitoneal glucose tolerance test.
An ipGTT was performed in overnight fasted C57Bl6 male mice one hour after a single 
i.p. injection of bromocriptine (10 or 25 mg/kg BW) or placebo. The glucose (A) and 
insulin (C) levels were measured and their respective areas under the curve (AUC) were 
calculated (B,D). Data is expressed as mean ± SEM, n=8-9 mice per group.









Figure 2 - Effects of acute injection of bromocriptine on glucose and arginine-
induced insulin secretion in mice subjected to a hyperglycemic clamp.
A HG clamp (~20 mM) was performed in overnight fasted C57Bl6 male mice one hour 
after a single i.p. injection of bromocriptine (10 or 25 mg/kg BW) or placebo. The 
glucose (A) and insulin (B) levels were measured at different time points during 90 min 
and the areas under the curve (AUC) corresponding to the first (D, from 0 to 5 min) and 
second phase (E, from 5 to 90 min) of insulin secretion were calculated. At t=90 min, an 
i.v. bolus of arginine (2.1 mmol/kg BW) was administered to the mice and both insulin 
levels (C) and AUC (F) were determined during the next 20 min. Data is expressed as 
mean ± SEM, n=8-9 mice per group.
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at 10 and 25 mg/kg BW, respectively; p<0.001). Consistent with reduced GSIS, 
insulin secretion in response to arginine was still present but decreased in 
bromocriptine-injected mice (fig 2C,F).
Figure 3 - Effects of bromocriptine on insulin secretion in INS-1E cells.
The insulin secretion in response to glucose and non-nutrient secretagogues was 
determined over a 30-min stimulation period in INS-1E cells pre-incubated for 30 min 
with various concentrations of bromocriptine (BC) or vehicle (0.05% (v/v) DMSO; 
black bars). (A) Dose-response effect of BC on insulin secretion in response to basal 
(2.5 mM) and stimulatory (20 mM) glucose concentrations. (B) Effect of BC (5 nM; 
open bars) on insulin secretion in presence of 2.5 mM glucose and 30 mM KCl or 250 
μM tolbutamide. Data is expressed as mean ± SEM, n=3-4 independent experiments 
performed in triplicate.
* p<0.05 vs 2.5 mM glucose; $ p<0.05 vs control-vehicle
Figure 4 - Effects of bromocriptine on AMPK activity, cell membrane potential and 
intracellular cAMP levels in INS-1E cells.
Various metabolic parameters were determined at low (2.5 mM) and stimulatory (20 
mM) glucose concentrations in INS-1E cells treated for 30 min with bromocriptine (BC, 
5 nM; open bars) or vehicle (0.05% (v/v) DMSO; black bars). (A) The phosphorylation 
state of AMPK was assessed by Western blot using anti-phospho-Thr172 antibody. Total 
AMPK was used as loading control. The quantitative results are expressed in arbitrary 
units as a ratio over the control-basal glucose group. (B) Cell membrane potential was 
monitored before and after successive addition of glucose (20 mM) and KCl (30 mM) in 
INS-1E cells treated from t=0 with BC (5 nM) or vehicle. (C) Intracellular cAMP levels 
were determined in the same conditions as in panel A except for the additional presence 
of 1 mM of the phosphodiesterase inhibitor IBMX. (D) The phosphorylation states of 
the PKA-downstream targets ERK1/2 and CREB were assessed by Western blot using 
anti-phospho-Thr202/Tyr204 and anti-phospho-Ser133 antibodies, respectively. Total 
ERK1/2 and CREB were used as loading controls. The quantitative results are expressed 
in arbitrary units as a ratio over the control-basal glucose group. Data is expressed as 
mean ± SEM, n=3-5 independent experiments.







Effects of bromocriptine on insulin secretion in response to glucose and 
non-nutrient secretagogues in INS-1E cells
To elucidate the underlying molecular mechanism(s), we used the insulinoma-
derived INS-1E cell line. The cells were pre-treated for 30 min with increasing 
concentrations of bromocriptine (from 0.5 to 500 nM) or vehicle (DMSO) before 
determination of insulin secretion over a 30-min stimulatory period with low 
(2.5 mM) or high (20 mM) glucose concentration. Figure 3A shows that addition 
of high glucose induced a 4.5-fold increase in insulin secretion in vehicle-treated 
INS-1E cells (p<0.05), in line with previous results obtained with this beta cell 
line18,24. Bromocriptine treatment did neither change cellular insulin content 
(data not shown) nor basal insulin secretion, but it dose-dependently inhibited 
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1E cells, insulin secretion was also stimulated by non-nutrient secretagogues 
eliciting cell membrane depolarization, such as KCl or tolbutamide, leading to a 
2.2-fold (p<0.05) and 1.5-fold (p<0.05) increase in insulin release, respectively 
(fig 3B). Bromocriptine also inhibited insulin secretion in these conditions 
(fig 3B; -34% and -26% in KCl- and tolbutamide-stimulated cells, respectively; 
p<0.05), suggesting that its inhibitory action is located at a step distal to ATP-
sensitive potassium (KATP) channels and cell membrane depolarization.
Effects of bromocriptine on ATP level, cell membrane potential and cAMP 
generation in INS-1E cells
We assessed the effects of bromocriptine on basal and glucose-induced changes 
in cellular energy state, membrane depolarization and cyclic AMP (cAMP) levels 
in INS-1E cells. The AMP-activated protein kinase (AMPK) acts as a cellular fuel 
gauge and is activated in response to a drop in ATP levels or increase in AMP/ATP 
ratio25. As shown in figure 4A, challenging the cells with 20 mM glucose, which 
results in increased intracellular ATP levels, is associated with a significant 
decrease in AMPK activation, i.e. phosphorylation on its Thr172 residue. 
Bromocriptine did not change the AMPK phosphorylation state in both basal 
and glucose-stimulated conditions (fig 4A), suggesting that inhibition of GSIS 
by the drug is not mediated by impairment in glucose-induced mitochondrial 
ATP generation. In line with our results showing that the inhibitory effect of 
bromocriptine is still present when insulin secretion is triggered by KCl and 
tolbutamide (see above), we confirmed that the drug did not affect glucose- 
and KCl-induced cellular membrane depolarization measured using bis-oxonol 
fluorescence (fig 4B).
Because cAMP is a key player in the amplifying pathway involved in insulin 
secretion by beta cells26, we also measured intracellular cAMP levels in INS-1E 
cells. As expected, upon a 30-min stimulatory period with 20 mM glucose in the 
presence of the phosphodiesterase inhibitor IBMX, intracellular cAMP levels 
were increased compared to 2.5 mM glucose (fig 4C; 28±3 vs 43±4 fmol/mg 
protein, respectively; p<0.05). Bromocriptine at 5 nM significantly decreased 
cAMP levels at both 2.5 and 20 mM glucose (fig 4C; -33% and -29% respectively; 
p<0.05). Accordingly, the phosphorylation state of two of the main cAMP-
dependent protein kinase (PKA) downstream protein targets, CREB-Ser133 
and ERK1/2-Thr202/Tyr204, were also significantly reduced by bromocriptine 
(fig 4D) in a dose-dependent manner (supplementary fig 1).
Effects of bromocriptine on GLP-1-stimulated insulin secretion in INS-1E 
cells
GLP-1 is among the most effective agents potentiating glucose-dependent 
insulin secretion in beta cells. It exerts its stimulatory effect via an increase in 






of adenylyl cyclase27. As expected, GLP-1 increased intracellular cAMP content 
and phosphorylation of CREB and ERK1/2, leading to amplified GSIS (fig 5A-C). 
In this condition, addition of bromocriptine reduced GLP-1-induced increase 
in cAMP level and GSIS, suggesting that the drug could interact with some 
G-protein-coupled receptors inhibiting adenylyl cyclase activity, such as DRD228.
Vehicle hGLP-1





Figure 5 - Effects of bromocriptine on insulin secretion and intracellular cAMP 
levels in INS-1E cells pre-treated with GLP-1.
The insulin secretion was determined in INS-1E cells pre-incubated with hGLP-1 7-36 
amide (10 nM) or vehicle (KRBH buffer) for 30 min and subsequently challenged 
with glucose (20 mM) for 30 min in the presence of bromocriptine (BC, 5 nM; open 
bars) or vehicle (0.05% (v/v) DMSO; control, black bars). (A) Effects of BC (5 nM) 
on glucose-induced insulin secretion in basal (vehicle) and GLP-1-stimulated INS-1E 
cells. (B) Intracellular cAMP levels were determined in the same conditions except 
for the additional presence of 1 mM IBMX. (C) The phosphorylation states of the PKA-
downstream targets ERK1/2 and CREB were assessed by Western blot as described in 
figure 4D. Data is expressed as mean ± SEM, n=3 independent experiments performed 
in duplicate. * p<0.05 vs vehicle; $ p<0.05 vs control
A B
C
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Effects of the DRD2 antagonist domperidone on bromocriptine-induced 
inhibition of GSIS in mice and INS-1E cells
We therefore tested whether the in vivo effects of bromocriptine on glucose 
tolerance and insulin secretion could be prevented by administration of the 
peripheral DRD2 antagonist domperidone in C57Bl6 mice. Pre-treatment with 
domperidone did not prevent the rise in basal plasma glucose levels induced 
by bromocriptine (table 2). During the ipGTT, domperidone did neither affect 
the bromocriptine-induced impairment of glucose disposal (fig 6A,C) nor its 
inhibitory effect on glucose-stimulated insulin response (fig 6B,D). In addition, 
domperidone did not prevent the bromocriptine-induced decrease in first- and 
second-phase GSIS during the HG clamp (fig 6E-H).
Figure 6 - Effects of the DRD2 antagonist domperidone on bromocriptine-induced 
alterations of glucose tolerance and insulin secretion in mice.
An ipGTT was performed in overnight fasted C57Bl6 male mice pre-treated for 30 min 
with domperidone (i.p., DP, 5 mg/kg BW) or placebo one hour after a single i.p. injection 
of bromocriptine (BC, 10 mg/kg BW) or placebo. The glucose (A) and insulin (B) levels 
were measured and their respective areas under the curve (AUC) were calculated (C,D). 
A HG clamp (~20 mM) was performed in the same conditions. The glucose (E) and 
insulin (F) levels were measured at different time points during 90 min and the areas 
under the curve (AUC) corresponding to the first (G, from 0 to 5 min) and second phase 
(H, from 5 to 90 min) of insulin secretion were calculated. Data is expressed as mean ± 
SEM, n=6-9 mice per group.
* p<0.05, ** p<0.01; *** p<0.001 vs placebo and $ p<0.05; $$ p<0.01; $$$ p<0.001 vs 
domperidone
Table 2 - Plasma glucose and insulin levels before and 60 min after a single i.p. 
injection of bromocriptine or placebo in fasted mice pre-treated with or without 
domperidone.
Glucose (mM) Insulin (ng/ml)
Before 
injection




60 min after 
injection
Placebo 4.9 ± 0.3 5.0 ± 0.2 0.08 ± 0.01 0.10 ± 0.00 
Bromocriptine
10 mg/kg 4.8 ± 0.2 6.3 ± 0.2*** 0.13 ± 0.02 0.22 ± 0.06 
Domperidone
5 mg/kg 5.0 ± 0.3 5.0 ± 0.3 0.09 ± 0.01 0.16 ± 0.02 
Domperidone + 
Bromocriptine 4.8 ± 0.3 6.1 ± 0.3** $$ 0.10 ± 0.01 0.19 ± 0.01 
Data is expressed as mean ± SEM, n=9 mice per group
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Accordingly, we found that domperidone only modestly rescued the inhibitory 
effect of bromocriptine on GSIS in INS-1E cells whatever the antagonist 
concentrations used (-41% for bromocriptine alone vs -29% and -33% when pre-
treated with 10 and 25 nM domperidone, respectively; p<0.05; supplementary 
fig 2), suggesting that a DRD2-independent signaling pathway(s) plays a more 
prominent role. Since it has been suggested that bromocriptine, in addition to its 
D2-dopaminergic activity, can stimulate the G-protein-coupled α2-adrenergic 
receptors (α2-AR)29, we investigated the effect of yohimbine, a selective α2-AR 
antagonist, on cAMP levels and GSIS in INS-1E cells. Interestingly, yohimbine 
completely prevented the bromocriptine-induced decrease in intracellular 
cAMP levels and GSIS (fig 7). Taken together, our results indicate that the major 
effect of bromocriptine on insulin secretion results from modulation of the α2-
AR rather than direct activation of the pancreatic DRD2.
Figure 7 - Effects of the α2-adrenergic receptor antagonist yohimbine on 
bromocriptine-induced decrease in intracellular cAMP levels and insulin 
secretion in INS-1E cells.
The insulin secretion was determined in INS-1E cells pre-incubated with the α2-
adrenergic receptor antagonist yohimbine (1 μM) or vehicle (KRHB buffer) for 30 
min and subsequently challenged with glucose (20 mM) for 30 min in the presence of 
bromocriptine (BC, 5 nM; open bars) or vehicle (0.05% (v/v) DMSO; black bars). (A) 
Effects of BC (5 nM) on glucose-induced insulin secretion in vehicle- and yohimbine-
treated INS-1E cells. (B) Intracellular cAMP levels were determined in the same 
conditions except for the additional presence of 1 mM IBMX. Data is expressed as mean 
± SEM, n=3 independent experiments.








Here we report for the first time that a single administration of the DRD2 agonist 
bromocriptine inhibits GSIS in C57Bl6 mice at concentrations in the range of 
those used for chronic treatment in rodents12,16,17,21. This acute effect was also 
observed in INS-1E beta cells at therapeutic plasma concentrations, suggesting 
that bromocriptine affects insulin secretion through a direct effect on pancreatic 
beta cells. We further demonstrated that the underlying molecular mechanism 
of bromocriptine is not mediated by DRD2 activation but rather by modulation 
of the α2-AR.
A single i.p. injection of bromocriptine acutely elevated fasting plasma 
glucose levels in mice. This is in agreement with several other studies reporting 
that short-term administration of L-DOPA, dopamine or dopamine agonists 
induces hyperglycemia in rodents30-33. The exact underlying mechanism remains 
unknown, although stimulation of glycogenolysis and/or gluconeogenesis 
through modulation of the sympatho-adrenal axis might be involved19,32.
We also found that administration of bromocriptine acutely impairs glucose 
tolerance. This finding is in apparent contradiction with the improvements 
of fasting plasma glucose and insulin levels, glucose tolerance and insulin 
sensitivity observed in obese insulin-resistant animals and humans treated 
with bromocriptine12,14,34. However, this discrepancy might be explained by 
the difference between single/acute and multiple/chronic treatment and also 
possibly by the use of healthy/lean C57Bl6 mice instead of insulin-resistant/
obese animals in the present study. It is interesting to note that the pancreatic 
KATP activator diazoxide, which also decreases insulin secretion, also exerts 
opposite effects on glucose tolerance in lean and obese Zucker rats35. Whether 
acute administration of bromocriptine differentially affects glucose tolerance 
and insulin secretion in rodent models of insulin resistance and obesity requires 
further investigation.
Our most striking finding is the clear demonstration that bromocriptine 
acutely inhibits GSIS in both mice and INS-1E beta cells. This confirms previous 
in vitro reports showing a negative impact of dopamine and several dopaminergic 
agonists on insulin secretion18,20,36. GSIS from beta cells is primarily controlled by 
metabolism-secretion coupling26. Following an increase in its circulating levels, 
glucose rapidly equilibrates across the plasma membrane due to the presence of 
GLUT2 and is phosphorylated by glucokinase to enter the glycolysis pathway. 
Subsequently, mitochondrial metabolism generates ATP, which promotes the 
closure of KATP channels and, as a consequence, depolarization of the plasma 
membrane. This leads to intracellular calcium (Ca2+) influx through voltage-
gated Ca2+ channels resulting in increased free cytosolic Ca2+ levels, which 
ultimately triggers insulin exocytosis26. Although this triggering pathway is 
essential for GSIS, activation of additional metabolic signals involved in the so-
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called amplifying pathway, are also required to fully stimulate insulin secretion26.
Interestingly, it has been shown that all dopamine receptor subtypes, including 
DRD2, are expressed in rat, mouse, and human islets as well as in INS-1E cells18. 
In addition to the early demonstration that dopamine inhibits GSIS in various 
cellular models18,20, a role for dopaminergic receptors in the regulation of insulin 
secretion was supported by a recent large-scale compound screening showing 
that a substantial number of dopaminergic agonists and antagonists were able 
to modulate GSIS37. Furthermore, the siRNA-mediated knockdown of DRD2 in 
INS-832/13 beta cells enhances GSIS, which is consistent with the involvement 
of this receptor in the negative regulation of insulin secretion37. In the present 
study, we showed that the inhibition of GSIS by bromocriptine is apparently 
not the consequence of an impaired triggering signal since neither intracellular 
energy state nor glucose- and KCl-induced cell membrane depolarization are 
affected in INS-1E cells. In contrast, bromocriptine significantly decreases 
intracellular cAMP levels, affecting one of the main metabolic amplifying 
pathways involved in GSIS, suggesting that activation of G-protein-coupled DRD2 
receptors could mediate its effect. However, pre-treatment with domperidone, 
a peripheral DRD2 antagonist which does not cross the blood brain barrier38, 
did not prevent the inhibition of insulin secretion or the impairment of glucose 
tolerance induced by bromocriptine in vivo. Although we can not exclude that 
part of the bromocriptine-induced inhibition of GSIS is mediated by a DRD2-
dependent central effect in vivo, the experiments performed in INS-1E cells 
confirmed that domperidone only marginally prevented inhibition of GSIS, 
pointing to a DRD2-independent mechanism.
Our in vitro results provide clear evidence that activation of G-protein-
coupled adrenergic receptors primarily accounts for the inhibition of GSIS by 
bromocriptine since yohimbine, a α2-AR antagonist, completely prevented its 
action. Interestingly, activation of α2-AR has already been shown to inhibit 
insulin secretion by a still incompletely understood effect on the exocytosis 
machinery39 following receptor-coupled inhibition of adenylyl cyclase and 
decrease in cAMP synthesis36,40-43. However, this effect on cAMP-mediated 
pathways seems to be ascribed to selective activation of the α2A-, but not 
α2C-AR, in isolated islets44, suggesting that part of the inhibition of GSIS by 
bromocriptine could also be mediated by cAMP/PKA-independent effects 
through α2C-AR activation. Further studies in receptor-specific α2-AR knock-
out mice would be crucial to clarify this point.
Strikingly, overexpression of α2-AR results in impaired insulin secretion 
and glucose intolerance45,46, whereas α2-AR knockout mice display higher basal 
insulin levels and improved glucose tolerance47. Finally, an α2-AR-mediated 
inhibition of GSIS by bromocriptine is further supported by in vitro binding 
studies showing that the drug exhibited high affinity for α2-AR48 and that 






It is also tempting to speculate that the reduction of blood pressure observed 
in patients treated with bromocriptine could be ascribed to its peripheral α2-
adrenergic action15.
Although counter intuitive, the ability of bromocriptine to acutely suppress 
insulin secretion might be at the basis of its beneficial effect on glucose 
homeostasis observed after long-term treatment in obese insulin resistant 
rodents and humans13,15,34. Indeed, it has been suggested that the progressive 
deterioration of beta cell mass and function in patients with type 2 diabetes 
might not only be the consequence of hyperglycemia per se, but could also be 
due to the compensatory insulin secretion itself. Thus, inhibition of GSIS could 
avoid long-lasting insulin hypersecretion and therefore prevent subsequent 
development of insulin resistance and beta cell failure50,51. Accordingly, it has 
been shown that chronic increase of insulin release using tolbutamide impairs 
GSIS in insulin sensitive rats52, whereas long-term pharmacological inhibition 
of insulin secretion improves beta cell glucose responsiveness in hyperglycemic 
rats53 and patients with type 2 diabetes54,55. While several mechanisms have 
been proposed to explain the beneficial impact of beta cell rest on glucose 
homeostasis50,51, future studies will have to clarify this point.
In conclusion, we report here that acute administration of bromocriptine 
inhibits insulin secretion both in vivo and in vitro mainly by a DRD2-
independent mechanism involving direct activation of the pancreatic α2-AR. 
Taking into account that long-term treatment with bromocriptine has been 
shown to improve glucose homeostasis in patients with type 2 diabetes, we 
suggest that inhibition of GSIS by the drug could be one of its early effects, 
preventing long-lasting hypersecretion of insulin and subsequent beta cell 
failure.
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Supplementary Figure 2 - Effects of the dopamine D2 receptor antagonist 
domperidone on bromocriptine-induced inhibition of insulin secretion in INS-1E 
cells.
The insulin secretion was determined in INS-1E cells pre-incubated with the dopamine 
D2 receptor antagonist domperidone (DP, 10 or 25 nM) or vehicle (0.05% (v/v) DMSO) 
for 30 min and subsequently challenged with glucose (20 mM) for 30 min in the presence 
of bromocriptine (BC, 5 nM; open bars) or vehicle (0.05% (v/v) DMSO; black bars). Data 
is expressed as mean ± SEM, n=3 independent experiments.
* p<0.05 vs vehicle; $ p<0.05 vs control
Supplementary Figure 1 - Dose-dependent effects of bromocriptine on 
phosphorylation state of PKA-downstream targets in INS-1E cells.
The phosphorylation states of the PKA-downstream protein targets ERK1/2 and CREB 
were assessed by Western blot in INS-1E cells treated for 30 min with increasing 
concentrations of bromocriptine (grey bars) or vehicle (0.05% (v/v) DMSO; black 
bars) in presence of 20 mM glucose. Actin was used as loading control. The quantitative 
results are expressed in arbitrary units as a ratio over the control-vehicle glucose group. 
Data is expressed as mean ± SEM, n=3 independent experiments.
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The dopaminergic system controls a multitude of physiological functions, 
ranging from motor activity to hormone secretion and feelings of reward. 
Previously, it has also been implicated in glucose and insulin metabolism. 
Disruption of the glucose and insulin metabolism leads to insulin resistance 
and diabetes mellitus type 2. During the initial stages of diabetes development, 
insulin resistance will be compensated by an elevated pancreatic insulin 
production. When this compensatory mechanism fails, plasma glucose levels 
will rise and overt diabetes will develop.
A multitude of literature has firmly established the impact of modified 
dopaminergic transmission on glucose and insulin metabolism, yet several 
questions still remain unanswered. With the research described in this thesis, 
we sought to answer 2 main questions: is the altered dopamine signaling 
causally related to the development of diabetes? And, what is the mechanism 
underlying the ability of dopaminergic drugs to modify glucose metabolism? 
Knowledge of the developmental mechanisms of diabetes will hopefully assist 
in reducing morbidity and mortality by preventing the onset of diabetes as well 
as improving treatment.
In this chapter the major conclusions and implications of our findings are 
discussed in light of current knowledge.
Pharmacological modification of the dopaminergic system
To unravel the underlying mechanisms we examined the impact of DRD2 
activation and inhibition on nutrient and energy metabolism. Inhibition of 
DRD2 by means of haloperidol and olanzapine induced glucose intolerance and 
insulin resistance (chapters 3-5) and activation of dopamine D2 receptors by 
means of bromocriptine led to improved insulin sensitivity (chapter 4). Although 
the results presented here show that activation and inhibition of dopamine D2 
receptors lead to opposite metabolic profiles, the underlying mechanisms are 
distinct.
We showed in chapter 4 that subchronic treatment with bromocriptine 
leads to a reduction in body weight and fat mass, which is consistent with other 
experiments in rodents and humans1-3. The mechanism responsible for the 
decrease in body weight and fat mass is still unknown. The most straightforward 
explanation would be a reduction in energy intake and/or increase in energy 
expenditure, but, neither of these mechanisms occurred in our experiments. 
In accordance with our findings, Cincotta et al. showed that hamsters on 
bromocriptine treatment lost body weight and fat mass without alterations in 
food intake and energy expenditure4. Also, mice treated with bromocriptine 
displayed a significantly greater weight loss than pair fed mice5,6. Therefore, 
one must conclude that bromocriptine modifies adiposity and body weight via 






As obesity and the associated increase in fat mass represent a significant  risk 
factor for the development of insulin resistance7, and loss of  body fat and weight 
improves insulin sensitivity8,9, the impact of bromocriptine on body weight and 
adiposity might participate in its positive effect on insulin sensitivity. However, 
several studies in humans show that bromocriptine beneficially alters the 
diabetic phenotype without implicating body weight and fat mass10,11, indicating 
that alterations in adiposity are not necessarily involved in the positive action of 
the drug on glucose and insulin metabolism.
Bromocriptine also controls insulin secretion; in chapter 6 the drug 
acutely inhibits glucose-stimulated insulin secretion, which results in glucose 
intolerance. In agreement with this, mice injected with the DRD2 agonist 
cabergoline also acutely displayed glucose intolerance12. One can assume that 
suppression of insulin secretion leads to a diabetes-like phenotype. Initially, 
this assumption is true, as mice acutely develop glucose intolerance; however, 
in apparent contrast, we also showed that bromocriptine treatment for 2 weeks 
improved insulin sensitivity (chapter 4). This is in accordance with a wealth of 
literature showing that (sub)chronic bromocriptine treatment improves insulin 
secretion, glucose tolerance and insulin resistance in humans and animals1,2,10,13. 
To explain the discrepancy between acute and chronic treatment, we propose 
that bromocriptine promotes β-cell ‘rest’, leading to short-term deterioration 
and long-term improvement of glucose metabolism.
Beta-cell dysfunction is crucial in the development of diabetes; insulin 
resistance only progresses to overt diabetes when β-cells fail to secrete sufficient 
amounts of insulin to overcome whole body insulin resistance. This malfunction 
of β-cells is the corollary of an increased rate of apoptosis and changes in the 
intracellular pathway controlling insulin secretion. It has been hypothesized 
that the high glucose levels, fundamental in diabetes, might be, indirectly, 
responsible for β-cell degeneration by promoting insulin hypersecretion and 
consequently β-cell exhaustion and death14,15. Indeed, pharmacologically 
increasing insulin release for 48 h subsequently decreased insulin secretion in 
rats16. Accordingly, suppression of insulin secretion, preventing hypersecretion 
and death, might in the long-term, improve β-cell function. This concept has 
been verified in several experiments. Treatment of diabetic rats with the insulin 
secretion inhibitor diazoxide enhanced the diminished glucose-stimulated 
insulin response17. And, short-term treatment of diabetic patients with insulin 
secretion inhibitors attenuated the defective insulin release characteristic for 
type 2 diabetes18,19. Two mechanisms might explain the long-term beneficial 
impact of the initially deleterious impact of the suppression of insulin secretion: 
1) inhibition of insulin secretion increases β-cell insulin stores, thereby 
enhancing the secretory capacity17,20, and 2) inhibition of insulin secretion 
increases the number of organ specific insulin receptors leading to improved 
insulin sensitivity21,22.
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Finally, bromocriptine might also directly improve insulin sensitivity. In 
chapter 4 we showed that 2 weeks of bromocriptine treatment reduced insulin 
resistance. However, as up till now, no studies examining the acute impact of 
the drug on insulin action have been performed, it remains to be determined 
whether bromocriptine directly modulates insulin action or indirectly via its 
effect on insulin secretion21,22.
The disruption of insulin action by inhibition of dopamine D2 receptors is 
achieved via other mechanistic routes than the improvement of insulin action 
by stimulation of D2 receptors. However, like bromocriptine, haloperidol 
treatment also participates in body weight regulation; although after 
subchronic treatment (2 weeks) body weight was not affected (chapter 4), after 
chronic treatment (12 weeks) body weight of treated mice was significantly 
increased compared to control mice (chapter 3). Keeping in mind that, due 
to the experimental setup of the latter study, food intake of haloperidol and 
control mice was identical, obviously the impact of haloperidol on weight is 
independent of alterations in food intake. In accordance with our findings, 
Pouzet et al. reported that an increased food efficiency, indicating an enhanced 
ability of food to increase body weight, was responsible for haloperidol induced 
weight gain23. In our experiments, mice treated with haloperidol for 1 week 
displayed a tremendous reduction in physical activity (chapter 4); in fact, this 
is a common phenomenon in rodents treated with antipsychotic drugs24-26. This 
reduced activity and concomitant reduction in energy expenditure might well 
account for the enhanced food efficiency and the body weight gain induced by 
the drug. If haloperidol indeed induces weight gain as we propose, an intriguing 
question is why we did not observe an increased body weight in mice treated 
with haloperidol for 2 weeks (chapter 4). Two explanations can be thought 
of: 1) the treatment period was too short to reveal differences in body weight. 
This would be in line with the chronic experiment in which alterations in body 
weight were not observed before the third week of treatment, or 2) haloperidol 
may have slightly, albeit not significantly, reduced food intake in the 2-week 
experiment, thereby preventing weight gain.
Besides its possible deleterious impact on insulin sensitivity via the 
development of obesity7, the reduction in physical activity might also directly 
affect insulin sensitivity, independent of weight gain. It has consistently been 
shown that 6-10 days of bed rest, representing severe physical inactivity, 
impairs insulin sensitivity in healthy man without affecting body weight27-29. 
Also in trained volunteers refraining from exercise for 10-14 days, representing 
a milder protocol for inactivity, insulin resistance is observed, again without 
alterations in body weight and fat mass30,31. Typically, this inactivity induced 
insulin resistance is restricted to tissues responsible for glucose-uptake, as 
glucose production remains adequately suppressed by insulin27,28,32. It has been 






induced impairment of glucose uptake31, but more research is warranted to 
confirm this.
In addition, haloperidol, and other DRD2 antagonists, might directly affect 
insulin sensitivity, independent of their impact on physical activity and body 
weight gain. In fact, it is known that several antipsychotic drugs, other than 
haloperidol, are able to acutely induce insulin resistance26,33-35. This insulin 
resistance seems to involve both glucose uptake and glucose production33-35, 
although the acute impact of antipsychotic medication on glucose production 
is not always observed26. Interestingly, the antipsychotic drug induced inability 
of tissues to take up glucose during hyperinsulinemia seems largely confined 
to muscle tissue, as glucose clearance by adipose tissue is even enhanced26. 
Even though the direct impact on insulin sensitivity has not yet been confirmed 
for haloperidol, the drug does acutely impair glucose tolerance36,37. This 
implies that haloperidol is able to reduce insulin secretion and/or promote 
insulin resistance. As the glucose intolerance was accompanied by elevated 
insulin levels36, defective insulin secretion can not (solely) explain the glucose 
intolerance. This provides evidence that haloperidol, like other antipsychotics 
is able to acutely decrease insulin sensitivity.
Finally, haloperidol might also impair insulin secretion; after 10 weeks of 
treatment, haloperidol and control mice had, despite significantly increased 
glucose levels in the former, similar insulin levels during a glucose tolerance test 
(chapter 3). This indicates an insulin secretion malfunction. Likewise, the low 
basal insulin levels in the face of elevated basal glucose levels observed in these 
mice after 12 weeks of drug treatment, confirm the hypothesis that β-cells are 
unable to produce sufficient amounts of insulin. These findings are in accordance 
with studies in DRD2 deficient mice, which also show inappropriately low 
insulin levels during an i.p. glucose tolerance test12. In vitro experiments with 
isolated islets from these mice showed that glucose was unable to stimulate 
insulin secretion from these islets compared to islets from wt mice. Further 
examination of the pancreata of DRD2 deficient mice revealed a reduced β-cell 
mass and insulin concentration12. According to these results it is conceivable 
that in our chronically treated haloperidol mice, the malfunctioning insulin 
secretion is due to a reduced β-cell mass and/or intracellular β-cell defects. The 
mechanism underlying the deregulation of β-cell function has not been resolved 
yet, but it has been suggested that DRD2 activation is essential for β-cell 
proliferation12. Consequently, chronically blocking DRD2 could reduce β-cell 
proliferation and eventually lead to a diminished β-cell mass. Alternatively, one 
might speculated that, in analogy with the hypothesized impact of bromocriptine 
on insulin secretion, haloperidol may initially promote glucose-stimulated 
insulin secretion, which may lead to insulin hypersecretion and consequently to 
β-cell damage and death. Several papers document a reduced responsiveness 
of β-cells towards insulin secretagogues following prolonged stimulation of 
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insulin secretion16,38, confirming the last part of the hypothesis. The initial part 
though, the acute effect of haloperidol on insulin secretion, remains to be verified 
as the literature on this subject is controversial. In an in vitro study by Best 
et al. haloperidol induced a depolarization of β-cell membrane potential and, 
although this might be expected to enhance insulin secretion, such effect could 
not be detected39. Two other studies reported a diminished and an unaltered 
insulin secretory response of β-cells following incubation with haloperidol40,41.
All together, we have provided evidence that modulation of glucose 
homeostasis by activation or inhibition of dopamine D2 receptors is achieved 
via different mechanistic routes. Presumably, bromocriptine mainly improves 
glucose metabolism by suppressing insulin secretion which, paradoxically, 
leads to enhanced insulin action. Weight reduction, as a result of bromocriptine 
treatment, might additionally improve insulin sensitivity, but it is not a 
prerequisite for the beneficial impact of the drug. Haloperidol, on the other 
hand, most likely disrupts physiological glucose metabolism by reducing 
physical activity, which, directly, or via weight gain, reduces insulin sensitivity. 
In addition, the drug probably also directly promotes insulin resistance and 
gradually impairs insulin secretion.
Dopaminergic system and the aetiology of diabetes
With the experiments described in this thesis, we also wanted to gain more 
insight into the role of dopaminergic neurotransmission in the course of 
diabetes development. Several cross-sectional studies suggest that alterations 
in dopaminergic neurotransmission are involved in the pathogenesis of type 
2 diabetes. In obese humans and insulin resistant animals the expression 
of dopamine D2 receptors in certain brain areas is reduced42-45. In obese 
humans the decrease in dopamine D2 receptors is even inversely related 
with BMI42. And, in brains of diabetic patients and type 2 diabetic animal 
models, increased dopamine levels are measured46-48. As cross-sectional 
research does not provide details about the cause-effect relationship, two 
hypotheses, based on the observations above, can be postulated: 1) altered 
dopaminergic neurotransmission is the cause of metabolic derangements or 
2) altered dopaminergic neurotransmission is the consequence of metabolic 
derangements.
Considering the indisputable positive impact of DRD2 activation on glucose 
and insulin metabolism and the detrimental effect of blocking DRD2, described 
in chapters 3-5 and discussed above, the first hypothesis is more likely. This 
hypothesis requires that components involved in dopaminergic signaling are 
altered prior to the initiation of metabolic derangements. Genetic variations 
of dopaminergic genes may be responsible for the initial alterations. This is 
supported by the observed association between DRD2 polymorphisms which 






However, as diabetes is also associated with obesity7, reduced physical activity55, 
aging56, an altered dietary pattern57-60 and the use of antipsychotics61,62, we 
proposed that the initial modifications in dopaminergic activity might also 
be triggered by nutritional, environmental, pharmaceutical or physiological 
factors.
In chapter 2 we examined the hypothesis that high fat feeding, which is a 
well-recognized trigger for the development of a diabetes-like phenotype in 
rodents, induces these metabolic anomalies via modifications in dopaminergic 
neurotransmission. In contrast to our hypothesis, though, wt C57Bl6 mice, 
maintained on a high fat diet for 4 weeks, were insulin resistant compared 
to control mice without detectable alterations of dopaminergic features. 
Consequently, we concluded that the reduced dopaminergic neurotransmission 
observed in obese humans and animals is not due to dietary factors. There are 
several ways to explain the discrepancy between the literature, showing an 
altered dopaminergic phenotype in obese animals and humans and the absence 
of dopaminergic alterations in our experiment.
We hypothesized that nutritional cues will diminish dopaminergic action, 
thereby inducing insulin resistance, but, we did not consider the existence of 
dopaminergic gene variations that might be present in our mice. However, these 
polymorphisms could alter dopaminergic action, which might set the stage for 
high fat diet induced insulin resistance. This is supported by the finding that 
body weight gain in schizophrenic patients on antipsychotic drug treatment 
is associated with certain DRD2 gene variations63,64. Also, compared to diet-
resistant rats, rats prone to become obese on a high fat diet already display 
alterations in dopamine metabolism when still maintained on a regular low 
fat diet65,66. In addition, already prior to the onset of food intake and body 
weight alterations, the expression of DRD2 in the striatum of obese Zucker 
rats is reduced compared to lean Zucker rats67. These observations strongly 
suggest that genetic variations in dopaminergic parameters determine the 
susceptibility of individuals to develop an unfavorable metabolic phenotype 
in response to pharmacological or nutritional cues. One may even speculate 
that these dopaminergic variations are a prerequisite for the development 
of metabolic alterations. This genetic predisposition might explain why only 
some rodents develop massive weight gain on a high fat diet (DIO; Diet Induced 
Obese) and others remain relatively lean (DR; Diet Resistant)68-70.
If this theory is true, it is understandable that we found metabolic, but not 
dopaminergic, differences between the mice maintained on a high vs. low fat 
diet. Rodents prone to become obese (DIO prone) or remain lean (DR prone) 
on a high fat already have a different dopaminergic profile when still on the 
control diet65,66. This suggests that, in a random population of rodents, various 
dopaminergic phenotypes are present. We showed in chapter 4 that some 
C57Bl6 mice become more obese and insulin resistant on a high fat diet than 
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others, so it is possible that the C57Bl6 mice in our experiment initially already 
have different dopaminergic phenotypes. We believe this might be true. As we 
divided our mice in chapter 2 randomly into a high and low fat group, both 
groups could have contained mice with a ‘normal’ dopaminergic phenotype as 
well as mice with a, genetically-determined, ‘deterimental’ phenotype. It goes 
without saying that if both phenotypes were equally represented in both the 
high and low fat group, there would be, on average, no measurable difference in 
dopaminergic parameters between these groups. The corollary of the presence 
of these different dopaminergic profiles in the high fat group should have been 
the development of different degrees of weight gain and insulin resistance. 
Unfortunately, due to the small sample size, we were unable to divide the high 
fat mice into DIO and DR mice according to their dopaminergic and metabolic 
phenotype. So, obviously, more research is warranted to confirm this hypothesis.
If, however, the first assumption that dopaminergic neurotransmission 
is the cause of metabolic derangements is incorrect, is it then possible that 
dopaminergic alterations are the consequence of changes in the hormonal 
environment in diabetic individuals? In other words, is it possible that in our 
experiment dopaminergic alterations would have developed after insulin 
resistance was established? This might be true. Hyperglycemia, a hallmark of 
diabetes, promotes elevated brain dopamine levels71-73. NPY, which’s levels are 
elevated in obese and diabetic individuals74, stimulates dopamine output75. 
PYY (3-36) suppresses dopamine release76 and its levels are reduced in obese 
subjects77. Leptin also reduces dopamine output78,79 while chronic obesity 
is characterized by a resistance to the actions of this hormone80. In apparent 
contrast, insulin acutely increases dopamine uptake by promoting the surface 
expression of the dopamine transporter81 and chronic insulin stimulation 
upregulates dopamine transporter mRNA82. In conclusion, these results 
indicate that disturbances of several internal regulators of energy balance 
might account for the alterations in dopaminergic neurotransmission observed 
in obese diabetic animals and humans. Yet, the physiological role and relevance 
of these processes in the course of obesity and diabetes development remain to 
be determined.
All together, we presented evidence that alterations in dopaminergic signaling 
may be either cause or consequence of the diabetic phenotype. Polymorphisms 
in dopaminergic genes may determine the susceptibility of a subject to develop 
obesity and diabetes in response to nutritional of pharmacological cues. On the 
other hand, diabetes-associated disturbances of hormone levels, or action, may 
promote alterations in dopamine homeostasis.
Humans versus rodents
Interestingly, in our experiments we observed a discrepancy between the 






modify glucose and insulin metabolism (chapter 5) whereas in mice haloperidol 
clearly induced glucose intolerance and insulin resistance (chapter 3 and 4). 
Several explanations can be thought of: 1) different dose, 2) different mode of 
administration, 3) different treatment period and 4) species-specific sensitivity 
to the effect of haloperidol.
First, the difference in dose; in mice we used 1 mg/kg/day, whereas the human 
volunteers were treated with 3 mg haloperidol per day, which corresponds 
to 0.04 mg/kg/day given the average weight of the subjects (~75 kg). When 
comparing drug doses between humans and rodents, though, one must take 
into account that the metabolism of drugs in rodents is faster than in humans, 
resulting in a, in general, 4 - 6 times shorter half-life of drugs in rodents83. So 
for rodents, the dose comparable to the one used in humans would be 0.16 - 
0.24 mg/kg/day. The dose given to the human volunteers is in the low range 
of doses prescribed to schizophrenic patients, whereas the dose given to 
the mice is in the high range of doses used to treat schizophrenia. Possibly, 
this difference in medication dose can explain the dissimilarities in efficacy 
of haloperidol in mice and man. Experiments performed in rodents using a 
low dose of haloperidol (0.25 mg/kg/day), equivalent to the dose used in our 
human study, showed no impact of the drug on glucose metabolism after 7 
and 28 days of daily injections, although, interestingly, glucose intolerance was 
observed 1 hour after the first injection36.
Another variable in these studies is the mode of drug administration 
which might further affect the plasma levels of the drug. In our experiments 
mice received haloperidol through subcutaneous implanted pellets, while 
human individuals received haloperidol tablets. Two issues regarding the 
mode of administration are relevant in this discussion: the frequency of 
drug administration (continuous vs. once daily) and the route of drug entry 
(subcutaneous vs. oral). As described above, the half-life of drugs in rodents 
is considerably shorter than in humans. Specifically, in humans, the half-life 
of haloperidol is 12-36 hours; in rodents, the half-life is only approximately 
1.5 h83. According to these figures, in humans a ‘single administration a day’ 
regiment is sufficient to achieve a relatively stable plasma concentration of 
haloperidol and level of DRD2 receptor occupancy throughout the day. The 
short half-life of haloperidol in mice though, imposes that the drug should be 
administered approximately 8 times a day in order to achieve a similar stable 
drug concentration and receptor occupancy. The most practical way to ensure 
stable plasma haloperidol concentrations in mice is to use pellets or minipumps 
continuously releasing the drug. So, most likely, the frequency of drug delivery 
does not explain the discrepant impact of haloperidol in humans and mice, but 
the route of drug delivery may. Compared to subcutaneous drug administration, 
which we used in our mice experiments, the efficacy of orally administered 
drugs is limited by the so-called ‘first pass effect’. Orally ingested drugs are 
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absorbed by the gastrointestinal tract and are transported, via the portal vein, 
to the liver before entering the systemic circulation. The liver metabolizes part 
of the drug, in case of haloperidol, into inactive compounds, thereby limiting the 
bioavailability of the drug. So, the oral delivery route may have further amplified 
the impact of the different doses used in the human and mice studies.
Another variable was the treatment period; the volunteers were treated for 
8 days (chapter 5), while the mice were treated for 14 days (chapter 4) or 12 
weeks (chapter 3). One can propose that 8 days of treatment is too short for 
metabolic alterations to emerge, yet, this is most likely not true. Haloperidol 
already induces glucose intolerance as soon as 1 hour after injection in mice36. 
This strongly suggests that 8 days of haloperidol treatment should suffice to 
uncover the metabolic consequences of treatment if any were present.
Finally, a species-specific sensitivity should also be considered. The existence 
of such species-dependent sensitivity to antipsychotic drugs is perhaps 
best illustrated by the effect of those drugs on weight gain. In contrast to the 
human situation where both males and females develop obesity in response 
to antipsychotic drug treatment, in rats, only females seem to be susceptible 
for the weight inducing ability of these drugs23,84. Up till now, only one group, 
using a specific treatment protocol, has been able to induce obesity in male rats 
in response to olanzapine85. Also the impact of haloperidol on weight gain is 
different in rats and humans; low concentrations of haloperidol already trigger 
body weight gain in female rats23, while this drug is associated with no, or very 
limited weight gain in the humans86,87. This discrepant body weight regulation 
in response to antipsychotic drugs suggests that glucose metabolism might also 
be differentially affected in humans and rodents, but to confirm this, thorough 
dose-response experiments should be performed in both species.
In conclusion, the absence of metabolic consequences in haloperidol 
treated humans in spite of the insulin resistance observed in mice treated with 
haloperidol is most likely due to a combination of factors: the bioavailability of 
the drug, determined by the drug dose and the route of administration, together 
with the species-specific sensitivity to the drug.
Conclusion
With the experiments described in this thesis we attempted to unravel the 
intricate relationship between diabetes and DRD2 mediated dopaminergic 
transmission. We provided evidence that although both DRD2 agonistic and 
DRD2 antagonistic drugs affect glucose metabolism, the mechanistic routes 
are distinct. Unlike bromocriptine, which beneficially affects insulin action by, 
paradoxically, suppressing insulin secretion, haloperidol disturbs insulin action 
by diminishing physical activity and directly disrupting insulin sensitivity.
We also discussed that dopaminergic dysfunction might be cause or 






genes, leading to diminished dopaminergic transmission, may predispose 
individuals to develop a diabetes-like phenotype in response to physiological 
or pharmacological cues. Alternatively, dopaminergic transmission may be 
disturbed by diabetes-induced alterations in the hormone profile.
Although caution is warranted when extrapolating the results of drug 
experiments obtained in animals to humans, especially with regard to the dose-
effect relationship, we believe the general mechanisms we observed in these 
animals are also applicable to humans.
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The dopaminergic system controls a multitude of physiological functions, 
ranging from motor activity to hormone secretion and feelings of reward. 
Previously, the dopaminergic system has also been implicated in glucose and 
insulin metabolism. Blood glucose levels are maintained within a narrow range 
to prevent glucose toxicity and, in the meantime, provide the necessary fuel 
for glucose-dependent tissues like the brain. Insulin is one of the key players 
mediating glucose control. Diabetes mellitus type 2 is characterized by insulin 
resistance and impaired insulin secretion. During the initial stages of diabetes 
development, insulin secretion is increased to maintain insulin action in spite 
of insulin resistance. When β-cells are no longer able to produce sufficient 
amounts of insulin to overcome the resistance, blood glucose levels rise and 
overt diabetes is established. This will, if left untreated, lead to significant 
morbidity and mortality.
Extensive literature links the dopaminergic system, and more specifically 
the dopamine receptor D2, to insulin resistance and diabetes. Polymorphisms 
of the DRD2 gene are associated with alterations in energy and nutrient 
metabolism. DRD2 antagonists induce weight gain and diabetes whereas DRD2 
agonistic drugs improve glucose and insulin homeostasis. Also, dopaminergic 
neurotransmission is altered in obese and diabetic humans and animal models. 
Despite the evidence, many aspects of the functional relationship between 
diabetes and the dopaminergic system remain unclear. In this thesis we sought 
to unravel the characteristics of the interplay between dopamine D2 receptors 
and glucose metabolism as well as to understand the underlying mechanism(s).
In our studies we used wild type C57Bl6 mice. When maintained on a high 
fat diet for several weeks, these mice develop obesity, insulin resistance and a 
metabolic phenotype closely resembling type 2 diabetes in humans. Therefore, 
this mouse strain is a valuable animal model to study the development 
of diabetes. We also used the INS-1E cell line, which is derived from a rat 
insulinoma. Physiological β-cell functions are preserved in this cell line, making 
it a valuable model to study insulin secretion in vitro.
High fat feeding induces obesity and insulin resistance. Given the fact that 
obesity is associated with reduced DRD2 expression and increased dopamine 
release, we reasoned that high fat feeding could alter dopaminergic transmission 
and via this route stimulate weight gain and insulin resistance. Therefore, in 
chapter 2 we examined the role of the dopaminergic system in the aetiology 
of high fat diet induced obesity and the deregulation of glucose metabolism. Wt 
C57Bl6 mice were maintained on a high fat diet for 4 weeks. The high fat feeding 
increased body weight of these mice and reduced insulin sensitivity. Despite 






release in fed or fasted mice. Also, hypothalamic expression of dopamine 
receptors D1 and D2, dopamine transporter and tyrosine hydroxylase genes 
was not affected by high fat feeding. So, as high fat diet-induced metabolic 
corollaries are independent of changes in parameters of dopaminergic activity, 
we concluded that the alterations in dopaminergic parameters observed in 
obese animal models and humans are probably due to mechanisms other than 
dietary composition.
Calorie restriction is the most effective way of increasing life-span and decreasing 
morbidity. It improves insulin sensitivity and delays the age-related loss of 
DRD2 expression. Obesity and insulin resistance is associated with a reduction 
in DRD2 binding sites. Blocking DRD2 induces weight gain and promotes insulin 
resistance whereas activating DRD2 improves insulin sensitivity. Considering 
the impact of DRD2 on metabolism, we hypothesized that dopamine receptors 
might be involved in the beneficial effect of calorie restriction on glucose 
metabolism. We examined this hypothesis in chapter 3. Wt C57Bl6 mice were 
maintained on a high fat diet, either with ad libitum or restricted access. Half 
of the calorie restricted mice also received continuous haloperidol treatment 
to inhibit DRD2 activation. Mice with restricted access to the high fat diet were 
glucose tolerant and insulin sensitive compared to mice with ad libitum access 
to the diet. Haloperidol slightly increased the body weight of calorie restricted 
mice. Also, the drug completely abolished the beneficial impact of calorie 
restriction on glucose tolerance and partly reduced the insulin sensitivity 
observed in calorie restricted mice. The metabolic differences between ad 
libitum fed and calorie restricted mice were not accompanied by alterations 
in hypothalamic DRD2 binding. So, calorie restriction offers protection against 
the deleterious impact of high fat feeding, and blocking DRD2 curtails these 
metabolic benefits. Although this suggests that dopamine receptors are part 
of the mechanism underlying the beneficial effect of calorie restriction, the 
unchanged hypothalamic DRD2 binding in response to restricted access to high 
fat food argues against this suggestion. 
Although in general high fat feeding promotes obesity and insulin resistance 
in rodents, there is a great diversity in the response of individual animals from 
a single strain to such challenge. Based on the body weight gain after several 
weeks of high fat feeding, rodents can be divided into Diet Induced Obese (DIO) 
and Diet Resistant (DR). Interestingly, dopaminergic neurotransmission differs 
in DIO and DR rodents, even before the onset of high fat diet induced weight 
gain. Specifically, DRD2 expression and dopamine turnover are decreased in 
DIO compared to DR rodents. This led us to believe that inherited alterations in 
dopaminergic transmission might mediate the differential corollaries of high fat 
feeding in these animals. We examined this in chapter 4. Based on the weight 
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gain of individual wt C57Bl6 mice on a high fat diet, these mice were classified 
as DIO or DR. Subsequently, half of the DIO mice were given bromocriptine 
to stimulate DRD2 activation and half of the DR mice were given haloperidol 
to inhibit DRD2 activation. Compared to DR mice, DIO mice were heavier, 
had elevated plasma insulin levels and were insulin resistant. Haloperidol 
treatment increased plasma glucose levels and impaired insulin sensitivity 
in DR mice. Furthermore, haloperidol decreased physical activity and energy 
expenditure in these mice. Conversely, bromocriptine tended to reduce body 
weight and physical activity and improve insulin sensitivity in DIO mice. In 
conclusion, blocking DRD2 induces a deleterious metabolic profile in mice that 
are resistant to the impact of a high fat diet, whereas activating DRD2 tends 
to restore a beneficial metabolic profile in mice are that highly susceptible to 
high fat diet induced corollaries. This suggests that dopaminergic transmission 
might indeed be involved in the control of metabolic phenotype.
Antipsychotic drugs are associated with the development of insulin resistance 
in humans and animals. Most reports though have been complicated by weight 
gain, making it difficult to determine any direct impact of the drugs on glucose 
and lipid metabolism. Therefore, in chapter 5 we analyzed the short-term 
effects of 2 antipsychotic drugs to determine the mechanism(s) underlying 
deregulation of glucose and lipid metabolism. Healthy, normal weight, 
men received olanzapine or haloperidol treatment for 8 days. Olanzapine 
hampered insulin sensitivity, while haloperidol did not have a significant 
impact. Olanzapine specifically reduced insulin-stimulated glucose disposal, 
while endogenous glucose production was not affected. Also, lipolysis was 
not affected by either drug. Olanzapine, but not haloperidol, decreased fasting 
plasma free fatty acids and hampered the insulin-induced decline of plasma free 
fatty acids and triglyceride concentrations. Neither drug induced body weight 
gain or an increase in adiposity. In conclusion, short-term olanzapine promotes 
deregulation of glucose and lipid metabolism without changes in body weight 
and adiposity.
Long-term bromocriptine treatment improves glucose and insulin metabolism 
in obese and insulin resistant animal models and humans; the mechanism 
underlying the beneficial impact of bromocriptine treatment however is not 
known. Therefore, the aim of chapter 6 was to elucidate this mechanism. 
Bromocriptine acutely induced glucose intolerance in wt C57Bl6 mice. This 
effect was associated with decreased insulin levels. Furthermore, bromocriptine 
reduced both the first- and second phase glucose-stimulated insulin response 
in mice. Also, in INS-1E cells, bromocriptine inhibited glucose-stimulated insulin 
secretion. Mechanistically, neither cellular energy state nor cell membrane 






were significantly reduced. Surprisingly, the DRD2 antagonist domperidone 
was not able to counteract the effect of bromocriptine either in mice or INS-
1E cells; yohimbine, an α2-adrenergic antagonist however, abolished the 
bromocriptine-induced inhibition of insulin secretion in INS-1E cells. In 
conclusion, bromocriptine acutely suppresses insulin secretion by a (mainly) 
DRD2-independent mechanism, involving direct activation of pancreatic α2-
adrenergic receptors. We believe bromocriptine treatment promotes β-cell 
‘rest’, thereby preventing prolonged insulin hypersecretion and subsequent cell 
death. In the long-term, this may improve insulin secretion.
All together, the studies described in this thesis contribute to our understanding 
of the complex interaction between dopaminergic signaling and disturbances 
in glucose metabolism. We showed that altered dopaminergic parameters 
associated with obesity are due to mechanisms other that diet composition. But 
changes in dopaminergic signaling may set the stage for metabolic corollaries 
of high fat feeding and may be involved in the beneficial impact of calorie 
restriction. We also demonstrated that inhibiting DRD2 activation may affect 
glucose homeostasis independent of its impact on body weight. The underlying 
mechanisms include a reduction in physical activity and a direct effect on 
insulin sensitivity. In addition we provided evidence that the mechanism by 
which long term stimulation of DRD2 activation improves glucose metabolism 
is, paradoxically, inhibition of insulin secretion. We believe these findings may 
offer new ideas for strategies to prevent or treat diabetes mellitus type 2 
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Samenvatting
Het dopaminerge systeem is betrokken bij de controle over een heel scala aan 
fysiologische functies, variërend van motorische activiteit tot de productie 
van hormonen en het teweeg brengen van gevoelens van beloning. Recentelijk 
is het dopaminerge systeem ook in verband gebracht met het glucose en 
insuline metabolisme. Glucose niveaus in het bloed worden strikt gereguleerd 
om enerzijds te voorkomen dat organen beschadigd worden door te hoge 
glucose niveaus en anderzijds om te voorkomen dat de niveaus te laag worden 
waardoor organen die van glucose afhankelijk zijn, zoals de hersenen, niet meer 
voldoende brandstof hebben. Insuline is een van de belangrijkste spelers in 
deze regulatie van bloed glucose niveaus; het remt de productie van glucose en 
stimuleert tegelijkertijd de opname van glucose uit het bloed. Het netto effect 
van insuline is daarom een verlaging van het bloed glucose niveau. Diabetes 
mellitus type 2 wordt gekenmerkt door insuline resistentie en een verminderde 
insuline productie. Gedurende de beginfase van de ontwikkeling van diabetes, 
als weefsels al ongevoelig zijn voor de werking van insuline, is de productie 
van dit hormoon, door β-cellen in de pancreas, verhoogd om te zorgen dat het 
effect van insuline gehandhaafd blijft ondanks de resistentie van de weefsels. 
Als β-cellen echter niet langer in staat zijn om voldoende insuline te produceren 
om het effect van de resistentie op te heffen, zullen de bloed glucose niveaus 
stijgen en is diabetes een feit. Dit zal, als het onbehandeld blijft, leiden tot 
velerlei complicaties en mogelijk zelfs de dood.
Een grote hoeveelheid literatuur laat zien dat er een verband is tussen het 
dopaminerge systeem, en dan met name de dopamine receptor D2 (DRD2), en 
insuline resistentie en diabetes. Zo zijn genetische variaties in het DRD2 gen 
geassocieerd met veranderingen in het energie en voedingsstoffen metabolisme. 
Verder leidt blokkering van DRD2 activatie tot gewichtstoename en diabetes, 
terwijl stimulering van de DRD2 activatie de glucose en insuline stofwisseling 
verbetert. Daarnaast is ook de dopaminerge transmissie in dikke en insuline 
resistente mensen en diermodellen veranderd. Ondanks alles wat al bekend 
is, blijven veel aspecten van de functionele relatie tussen diabetes en het 
dopaminerge systeem onduidelijk. In dit proefschrift hebben wij geprobeerd 
de wederzijdse beïnvloeding van dopamine D2 receptoren en het glucose 
metabolisme te ontrafelen en de onderliggende mechanismen te begrijpen.
Bij onze studies hebben wij gebruik gemaakt van wild type C57Bl6 
muizen. Als deze muizen een aantal weken hoog vet voer te eten krijgen, 
ontwikkelen zij overgewicht, insuline resistentie en een fenotype dat erg veel 
lijkt op diabetestype 2 bij mensen. Daarom is deze muizen stam een waardevol 
diermodel om de ontwikkeling van diabetes in te bestuderen. We hebben ook 
gebruik gemaakt van de INS-1E cellijn die voort gekomen is uit een insuline 






zijn in deze cellijn bewaard gebleven, wat dit tot een waardevol model maakt 
om de insuline secretie te bestuderen in vitro.
Hoog vet voeding bevordert het ontstaan van overgewicht en insuline 
resistentie. Omdat overgewicht geassocieerd is met een verminderde DRD2 
expressie en een verhoogde dopamine productie en blokkering van DRD2 
activatie leidt tot overgewicht, speculeerden wij dat hoog vet voeding de 
dopaminerge transmissie zou kunnen veranderen en via deze route overgewicht 
en een verstoring van het glucose metabolisme zou kunnen induceren. Om dit te 
onderzoeken, hebben we in hoofdstuk 2 de rol van het dopaminerge systeem 
bij het ontstaan van hoog vet dieet geïnduceerde gewichtstoename en insuline 
resistentie bestudeerd. Wild type C57Bl6 muizen kregen hiervoor gedurende 
4 weken een hoog vet dieet. Dit dieet leidde tot een gewichtstoename in deze 
muizen en een afname van de insuline gevoeligheid. Ondanks het effect op 
het metabole profiel, veroorzaakte het hoog vet dieet geen veranderingen in 
de dopamine productie in de hypothalamus van, gevoede of gevaste, muizen. 
Ook de genexpressie van de dopamine receptor D1 en D2, de dopamine 
transporter en tyrosine hydroxylase in de hypothalamus was niet beïnvloed 
door de hoog vet voeding. Hoog vet dieet geïnduceerde metabole veranderingen 
zijn dus onafhankelijk van veranderingen in verschillende parameters 
van het dopaminerge systeem. Daarom hebben wij geconcludeerd dat de 
veranderingen in dopaminerge parameters die gevonden worden in dikke 
mensen en diermodellen, waarschijnlijk een andere oorzaak hebben dan de 
dieet samenstelling.
Beperking van de inname van calorieën is de meest effectieve manier om 
langer en gezonder te leven. Calorische beperking is ook in staat de insuline 
gevoeligheid te verbeteren en het leeftijdsgebonden verlies van DRD2 
receptoren te vertragen. Overgewicht en insuline resistentie zijn geassocieerd 
met een afname van DRD2 expressie. Blokkade van de DRD2 induceert 
gewichtstoename en insuline resistentie, terwijl activatie van de DRD2 insuline 
gevoeligheid stimuleert. Gezien deze invloed van de dopamine receptor D2 
op het metabolisme veronderstelden wij dat dopamine receptoren betrokken 
zouden kunnen zijn bij het gunstige effect van calorische beperking op het 
glucose metabolisme. We hebben deze hypothese onderzocht in hoofdstuk 3. 
Wild type C57Bl6 muizen kregen hiervoor een hoog vet dieet; een deel van de 
muizen kon ongelimiteerd eten, terwijl het andere deel van de muizen slechts 
een  beperkte hoeveelheid van dit voer kreeg. De helft van de calorisch beperkte 
muizen werd ook nog continu behandeld met het antipsychoticum haloperidol 
om de DRD2 activatie te remmen. De calorisch beperkte muizen waren 
gevoelig voor de effecten van zowel glucose als insuline in vergelijking tot de 
muizen die onbeperkt hoog vet voer kregen. Haloperidol leidde tot een kleine 
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gewichtstoename bij de calorisch beperkte muizen. Daarnaast heeft haloperidol 
de positieve invloed van de calorische beperking op de glucose gevoeligheid 
compleet teniet gedaan en de insuline gevoeligheid van de calorisch beperkte 
muizen gedeeltelijk gereduceerd. De metabole verschillen tussen de calorisch 
beperkte of niet-beperkte muizen werden niet vergezeld door veranderingen in 
DRD2 binding in de hypothalamus. Calorische beperking biedt dus bescherming 
tegen de negatieve metabole effecten van hoog vet voeding; gelijktijdige 
blokkade van de DRD2 is echter in staat deze beschermende werking sterk te 
beperken. Hoewel dit suggereert dat dopamine receptoren betrokken zijn bij 
de positieve invloed van calorische beperking op de glucose stofwisseling, pleit 
de onveranderde DRD2 binding na beperkte inname van het hoog vet dieet toch 
tegen deze suggestie.
Hoewel hoog vet voeding over het algemeen overgewicht en insuline resistentie 
veroorzaakt in knaagdieren, kunnen individuele dieren van eenzelfde stam 
toch heel verschillend reageren. Aan de hand van de gewichtstoename na een 
aantal weken hoog vet voeding, kunnen knaagdieren onderverdeeld worden 
in de groepen ‘dieet gevoelig’ (Diet Induced Obese; DIO) en ‘dieet resistent’ 
(Diet Resistent; DR). Heel interessant is dat de dopaminerge neurotransmissie 
verschilt bij deze DIO en DR dieren, zelfs al voordat hoog vet geïnduceerde 
gewichtstoename optreed. In vergelijking tot DR dieren, hebben DIO dieren een 
verlaagde DRD2 expressie en dopamine turnover. Dit suggereert dat aangeboren 
veranderingen in dopaminerge transmissie een rol zouden kunnen spelen bij 
de gevoeligheid van individuele dieren voor de negatieve metabole effecten van 
hoog vet voeding. Wij hebben dit onderzocht in hoofdstuk 4. Uitgaande van 
de gewichtstoename van individuele wild type C57Bl6 muizen op een hoog vet 
dieet, hebben wij deze muizen geclassificeerd als DIO of DR. Vervolgens kreeg 
de helft van de DIO muizen bromocriptine toegediend om DRD2 activatie te 
stimuleren en kreeg de helft van de DR muizen haloperidol om DRD2 activatie 
te remmen. Vergeleken met de DR muizen, waren DIO muizen zwaarder, hadden 
ze een verhoogde insuline concentratie in hun bloed en waren ze insuline 
resistent. De haloperidol behandeling verhoogde de bloed glucose concentratie 
en verminderde de insuline gevoeligheid in DR muizen. Daarnaast verminderde 
haloperidol ook drastisch de fysieke activiteit en het energie verbruik van 
deze dieren. Bromocriptine leek, aan de andere kant, een gewichtsafname te 
veroorzaken en een verbetering van de insuline gevoeligheid in DIO muizen. 
Samenvattend leidt blokkade van DRD2 activatie tot een slecht metabool profiel 
in muizen die van nature ongevoelig zijn voor de effecten van een hoog vet 
dieet, terwijl stimulatie van DRD2 activatie een gunstig metabool profiel lijkt te 
herstellen in muizen die zeer gevoelig zijn voor de consequenties van een hoog 
vet dieet. Dit suggereert dat dopaminerge transmissie inderdaad betrokken is 






Het gebruik van antipsychotische medicijnen, die met name gericht zijn 
op het blokkeren van DRD2 activatie, is geassocieerd met het ontstaan van 
insuline resistentie in mensen en dieren. Omdat de meeste studies echter ook 
gewichtstoename rapporteren, blijft het onduidelijk of deze medicamenten 
een direct invloed hebben op de glucose en vet stofwisseling of dat ze enkel 
een gewichtstoename veroorzaken, wat dan vervolgens leidt tot een verstoring 
van de glucose en vet huishouding. Om hier meer duidelijkheid over te krijgen, 
hebben wij in hoofdstuk 5 de korte termijn effecten van 2 antipsychotische 
medicijnen bestudeerd om zo het mechanisme te ontdekken dat ten grondslag 
ligt aan de verstoring van het voedingsstoffen metabolisme. Gezonde mannen 
met een normaal lichaamsgewicht kregen hiervoor gedurende 8 dagen een 
behandeling met olanzapine of haloperidol. Olanzapine verlaagde de insuline 
gevoeligheid, terwijl haloperidol geen significant effect had. Met name de 
insuline gestimuleerde glucose opname was verlaagd door olanzapine. Zowel 
olanzapine als haloperidol hadden geen invloed op de afbraak van vetten. Maar, 
olanzapine, in tegenstelling tot haloperidol, verlaagde de hoeveelheid vrije 
vetzuren in het bloed tijdens vasten en verstoorde de insuline geïnduceerde 
afname van vrije vetzuur- en triglyceride concentraties in het bloed. Geen 
van de medicamenten resulteerde in gewichtstoename of een toename van 
de vetmassa. Olanzapine is dus in staat om de glucose en vet stofwisseling te 
verstoren zonder dat daar veranderingen in gewicht of vetmassa voor nodig 
zijn.
Langdurige behandeling met bromocriptine (stimuleert DRD2 activatie) 
verbetert het metabole profiel van dikke insuline resistente mensen en 
diermodellen; het onderliggende mechanisme is echter nog onbekend. Het 
doel van hoofdstuk 6 was daarom om meer inzicht in te krijgen in de gunstige 
invloed van dit medicament. Bromocriptine leidde acuut tot glucose intolerantie 
in wild type C57Bl6 muizen. Dit effect ging gepaard met een verlaagde 
insuline concentratie. Verder reduceerde bromocriptine zowel de eerste 
als tweede fase insuline respons na glucose stimulatie. Ook in INS-1E cellen 
remde bromocriptine de glucose-gestimuleerde insuline afgifte. Wat betreft 
het mechanisme was noch de energie status van de cel noch de celmembraan 
depolarisatie aangedaan door bromocriptine, maar de intracellulaire cAMP 
niveaus waren significant lager. Tot onze verrassing was de DRD2 antagonist 
domperidone niet in staat het effect van bromocriptine in zowel muizen als 
INS-1E cellen op te heffen; yohimbine, een α2-adrenerge antagonist, was 
daarentegen wel in staat de bromocriptine geïnduceerde remming van de 
insuline secretie in INS-1E cellen op te heffen. Bromocriptine onderdrukt 
dus acuut de insuline productie door middel van een (voornamelijk) DRD2-
onafhankelijk mechanisme waar directe activatie van α2-adrenerge receptoren 
bij betrokken is. Onze hypothese is dat bromocriptine op deze wijze β-cellen 
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beschermt tegen langdurige insuline ‘overproductie’ en daarmee geassocieerd 
β-cel falen, waardoor op de langere termijn de insuline secretie juist verbeteren 
zal.
Samengenomen dragen de studies, beschreven in dit proefschrift, bij aan ons 
begrip van de complexe interactie tussen dopaminerge activiteit en verstoringen 
van het glucose metabolisme. We hebben laten zien dat veranderingen in 
dopaminerge parameters, geassocieerd met overgewicht, het resultaat zijn van 
andere zaken dan dieet samenstelling. Veranderingen in dopaminerge activiteit 
zouden echter wel ten grondslag kunnen liggen aan de metabole consequenties 
van hoog vet voeding en ze zouden ook betrokken kunnen zijn bij het gunstige 
effect van calorische beperking. We hebben ook laten zien dat remming van 
de DRD2 activatie het glucose metabolisme kan beïnvloeden onafhankelijk 
van veranderingen in het lichaamsgewicht. Onderdeel van het onderliggende 
mechanisme is een afname van de fysieke activiteit en een directe negatieve 
invloed op de insuline gevoeligheid. Daarnaast hebben we ook bewijs geleverd 
dat het mechanisme waardoor langdurige stimulatie van DRD2 activatie leidt 
tot een verbeterd glucose metabolisme, in tegenstelling tot de verwachting, 
een remming van de insuline secretie is. Wij geloven dat deze observaties 
aanknopingspunten bieden voor nieuwe maatregelen en strategieën voor het 







AGRP  Agouti-Gene-Related Protein
AL  Ad Libitum
AMPK  AMP-activated Protein Kinase
AP  Antipsychotic
AR  Adrenergic Receptor
ARC  Nucleus Arcuatus
AUC  Area Under the Curve
BC  Bromocriptine
BMI  Body Mass Index
BW  Body Weight
cAMP  cyclic AMP
CCK  Cholecystokinin
CR  Calorie Restriction
CREB  cAMP Response Element Binding protein
DAT  Dopamine Transporter
DIO  Diet Induced Obese
DMH  Dorsomedial Hypothalamus
DP  Domperidone
DR  Diet Resistant
DRD1  Dopamine Receptor D1
DRD2  Dopamine Receptor D2
EGP  Endogenous Glucose Production
ERK1/2  Extracellular Signal-Regulated Kinases 1/2
FFA  Free Fatty Acids
GIR  Glucose Infusion Rate
GLUT  Glucose Transporter
GSIS  Glucose Stimulated Insulin Secretion
HF  High Fat
HG clamp  Hyperglycemic clamp
HP  Haloperidol




KRBH buffer Krebs-Ringer Bicarbonate HEPES buffer
LHA  Lateral Hypothalamic Area
LF  Low Fat
LPL  Lipoprotein Lipase
MMTT  Mixed Meal Tolerance Test






NEFA  Non-Esterified Fatty Acids
NPY  Neuropeptide Y
NS  Not Significant
P  Placebo
PKA  cAMP dependent Protein Kinase A
POMC  Pro-opiomelanocortin
PVN  Paraventricular Nucleus
PYY  Peptide YY
Ra  Rate of Appearance
Rd  Rate of Disappearance
RQ  Respiratory Quotient
RT-PCR  Real-Time Polymerase Chain Reaction
SD  Standard Deviation
SEM  Standard Error of the Mean
SNP  Single-Nucleotide Polymorphism
TG  Triglyceride
TH  Tyrosine Hydroxylase
VMH  Ventromedial Hypothalamus
WHO  World Health Organization
wt  wild type
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is heerlijk samen te werken met iemand die altijd zijn hoofd koel houdt. Hanna, 
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very grateful for that! Martin, jij was direct enthousiast toen ik je vertelde dat 
ik dopamine wilde meten in de hypothalamus van muizen op een hoog vet dieet. 
Ik ben nog steeds erg dankbaar dat dit in samenwerking met Brains On-Line 
mogelijk is geweest. Karola, jij bent vanuit Groningen helemaal naar Leiden 
gekomen voor de uitvoering van dat experiment, dank je wel! Bruno thanks for 
your willingness to investigate the in vitro impact of bromocriptine. Your input 
has led to a wonderful article!
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plannen van Marcel in de praktijk te brengen, waarvoor dank. Ivo, dank dat je 
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Nitish, dank voor je hulp bij het karakteriseren van de transgene muizen. Jouw 
stage was zeker voor mij, en hopelijk ook voor jou, een leerzame ervaring!
Ook andere mensen van het endo lab die minder direct betrokken zijn geweest 
bij mijn onderzoek, hebben zeker bijgedragen aan de goede tijd die ik gehad 
heb. Chris, ik zou niet weten wat het Endo lab zonder jou zou moeten! Dank 
je wel voor al je hulp bij kapotte apparaten, labspullen die weer eens op 
waren, bestellingen die vandaag nog de deur uit moesten, rare producten (bv 







gelukkig ook altijd tijd voor wat afleiding. Mijn gang collega’s hebben hier zeker 
een grote bijdrage aan geleverd! Willeke, Jitske en Claudia, hartelijk dank voor 
al het gedeelde lief en leed, alle adviezen, quiz-avondjes, etentjes, vissen en nog 
veel meer. Ik kijk met veel plezier terug op de tijd die ik samen met jullie op 
de gang heb doorgebracht. Ook mijn latere collega’s, Ellen, Ebru, Mariette en 
Laura, hebben ervoor gezorgd dat de gang een prettige werkplek bleef. Geertje 
en Hermine, dank voor jullie betrokkenheid en gezelligheid. Ik waardeer het erg 
dat jullie altijd bereid waren ergens mee te helpen of gewoon even een praatje 
te maken. Super dat jullie mijn paranimfen willen zijn! Ook de mensen van het 
endo lab die ik niet bij name heb genoemd; dank voor jullie bijdrage aan de 
goede sfeer en de gezelligheid op het lab!
Gelukkig bestaat het leven van een promovendus niet alleen uit werk. Jefta & 
Esther, Stephan & Annelies en Guillaume & Michelle, ik vind onze vriendschap 
heel waardevol. Ik wil jullie, mijn familie, Esther & Roel, Hanna & Riccardo, 
en schoonfamilie, John, Greet, Carlo & Tina en Marjon, bedanken voor alle 
afleiding die de bezoekjes van, en naar jullie opleverde, en natuurlijk voor alle 
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hebben mij daarnaast ook altijd bijgestaan met woord en daad. Ik ben jullie 
daar heel erg dankbaar voor!
En, tenslotte ‘mijn’ Marcel. Jij hebt mijn hele promotietraject, met alle up’s 
en down’s, van dichtbij meegemaakt. Dank je wel dat jij er altijd bent: bij de 
overwinningen en de teleurstellingen. Ik hou van jou!
Liefs,
Judith
Dankwoord 165
N
ot
es
166
Notes 167
N
ot
es
168
